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Abstract  
 
 
In this thesis, I use clinical assessments and neuroimaging modalities to investigate 
the pathophysiology underlying impulse control disorders (ICDs) and related 
addictive behaviours in Parkinson’s disease (PD). 
 
Using PET with 11C-raclopride, I found that PD patients with a range of ICDs showed 
an increase in dopamine release in their ventral striatum on exposure to reward-related 
visual cues compared to PD controls. Further, the amount of increased dopamine 
release in patients with single ICD was similar to those with comorbid ICDs, 
suggesting the sensitisation of ventral striatum of PD ICD patients, regardless of their 
disease load.  I also found that PD ICD patients with punding, characterised by 
stereotypical behaviours with similarities to obsessive compulsive disorders, had 
lower baseline dopamine D2 receptor binding in the dorsal, but not ventral, striatum at 
rest compared to controls.   
 
In the fMRI imaging study with a block design paradigm, PD patients with 
compulsive sexual behaviours (CSB) showed increase in sexual desire on exposure to 
sexual visual cues compared to controls with a corresponding change in blood oxygen 
level-dependent signal in brain regions corresponding to emotional, cognitive, 
autonomic, visual and motivational processes. When OFF medication, CSB patients 
showed decreases in activation during the presentation of sexual cues relative to rest, 
which was not seen when ON medication.  This provides evidence that passive visual 
cues can act as motivational cues for vulnerable individuals. 
  
!!
3!
 
In the final data chapter, I show that the Internet use habits of PD ICD patients had 
greater interference (increased time spent, obsessive thoughts) with life functioning 
compared to PD and healthy subjects, suggesting that PD ICD patients have an 
increased tendency towards excessive Internet use, which may coexist as an addictive 
behaviour.  
 
These studies show that PD patients on dopaminergic medication have a propensity 
toward impulse control disorders and related behaviours via sensitisation of the dorsal 
and ventral striatum. There is also an increased tendency to excessive Internet use in 
PD ICD subjects.  These findings contribute to our understanding of the mechanisms 
through which a subset of PD patients choose to pursue aberrant rewarding 
behaviours despite negative consequences, with direct implication for clinicians 
managing this patient group.  
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Chapter 1 
Introduction 
 
 
1.1 Parkinson’s disease: A brief overview 
 
Parkinson’s disease (idiopathic Parkinson’s disease; PD) is a neurodegenerative 
disorder, which causes a significant decline in quality of life for both the patients and 
their carers and contributes to substantial economic and health costs. 
 
In the UK, the prevalence of PD ranges from 105 to 178 persons per 100,000, 
adjusted for age, with an estimated total of 150,000 people affected (Parkinson'sUK, 
2009). The incidence of PD rapidly increases with increasing age, with the average 
onset at about 60 years.    In Europe, the prevalence and incidence is similar to that of 
the UK (von Campenhausen et al., 2005). One systematic review of studies published 
from 1965 to 2008 on Asian populations yielded 21 studies, and found a prevalence of 
51.3-176.9 per 100,000, and an incidence rate of 6.7 to 8.7 per 100,000 
(Muangpaisan, Hori, & Brayne, 2009).  Subsequently, the same research group have 
published a systematic review of the worldwide prevalence and incidence of 
Parkinson’s disease, and noted a wide variation between different regions and study 
groups, concluding that the main reasons for such variations are due to differences in 
survival across countries and sampling techniques (Muangpaisan, Mathews, Hori, & 
Seidel, 2011) 
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1.1.1 Clinical features of PD 
 
Clinically, Parkinson’s disease is characterised by the cardinal triad of bradykinesia, 
rigidity and tremor. Bradykinesia (or akinesia in advanced disease) refers to slowness 
(or absence) of movement, which can sometimes be presented by patients as 
micrographia (small handwriting).  Rigidity (stiffness, increased muscle tone) refers 
to an increase in resistance to passive movement around a joint.  The resting tremor is 
usually seen in the upper arms with a frequency of 4-6Hz, which is maximal when the 
limb is at rest and is reduced with voluntary movement.  The tremor is described as a 
pill-rolling motion of the hand and is typically unilateral at onset.  An estimated 30% 
of patients have little or no perceptible tremor, and these cases are described as 
‘akinetic-rigid’ type.  The combination of tremor and rigidity felt by an examiner at 
the wrist of the upper limb is described as ‘cogwheeling’.  Other features noted in PD 
include hypomimia (decreased facial expression), decrease blink rate, and hypophonia 
(soft speech).  Finally, postural instability, usually appearing in advanced PD, denotes 
failure of postural reflexes, which leads to impaired balance and falls (Jankovic, 
2008). 
 
A range of non-motor features have also been observed, which, in the last decade or 
so, have been increasingly recognised. Their clinical presentations are wide-ranging 
and affect almost every aspect of the body.  For example, autonomic failure can be 
presented as orthostatic hypotension and abnormalities of sweating, sphincter control, 
and erectile dysfunctions (Jankovic, 2008).  Cognitive and neurobehavioural 
abnormalities are commonly reported – the Sydney Multicenter Study of PD found 
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that 84% of patients with PD were found to have slow cognitive decline and that 48% 
met the criteria for dementia after 15 years of follow-up (Hely, Morris, Reid, & 
Trafficante, 2005).  Depression affects about 40% of patients before, at, or after 
diagnosis, and has been shown to be the most important factor correlating with 
impaired quality of life.  Other commonly reported non-motor features include late 
onset hypo-osmia, REM sleep behaviour disorder, apathy, anxiety, hallucinations, and 
pain. In some cases, these features have been reported to predate the motor features of 
PD described above. Reported features of PD are summarised in Box 1. 
 
More recently, a group of neuropsychiatric behaviours has been increasingly reported 
in PD patients in association with dopaminergic medication use.  These include 
features of obsessive-compulsive and impulsive disorders, such as craving (especially 
for sweets), binge eating, compulsive foraging, compulsive sexual behaviour, 
pathological gambling, compulsive shopping, dopamine dysregulation syndrome (an 
addiction-like behaviour to dopaminergic medication) and punding (Weintraub et al., 
2006).   These conditions are the focus of the projects in this PhD thesis.   
 
Throughout research literature, ‘Impulse Control Disorders’ have been used 
interchangeably with other terms such as ‘Impulse Control Behaviours’, ‘addictive 
behaviours’, ‘behavioural addictions’, and ‘Reward seeking behaviours’ (to name just 
a few).  Further, subtypes of ICDs have been coined ‘behaviours’ (e.g. compulsive 
sexual behaviour is a type of Impulse Control Disorder), and the same type of 
pathological behaviour have been given different names, e.g. ‘compulsive sexual 
behaviour’ and ‘hypersexuality’.  To minimise confusion, I have used the same terms 
as that of the Diagnostic and Statistical Manual of Psychiatric Disorders 
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(American_Psychiatric_Association, 2000), and used the same term to describe each 
type of pathological behaviour throughout this thesis. 
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Box 1. Motor and non-motor features of Parkinson’s disease. 
 
 
 
 
 
Motor disturbances Resting tremor, bradykinesia, rigidity, postural and 
gait instability 
Autonomic dysfunction Orthostatic hypotension, constipation, urinary and 
sexual dysfunction, weight loss 
Sensory disturbanes Pain and paresthesia, anosmia, visual discrimination 
defects, ageusia 
Mood disturbances Depression, anxiety and panic attacks, apathy 
Sleep disturbances  Sleep fragmentation, excess daytime somnolence, 
vivid dreaming, insomnia, REM behaviour disorder, 
restless leg syndrome and periodic limb movements, 
sleep apnoea 
Neuropsychiatric disorders Impulse control disorders, hallucinations, illusions, 
delusions 
Cognitive disturbances Cognitive impairment, dementia 
Others Seborrhoea, dry eyes, fatigue, diplopia, blurred 
vision, weight loss 
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1.1.2 Neuropathology features of PD 
 
PD has traditionally been defined as a clinico-pathological entity, in which 
progressive levodopa-responsive parkinsonism without atypical features is associated, 
at autopsy, with neuronal loss and the presence of eosinophilic intracytoplasmic Lewy 
bodies in specific central and autonomic nervous structures.  These include the 
pigmented brainstem monaminergic nuclei, the substantia nigra (dopaminergic) and 
locus coeruleus (noradrenergic).  However, the pathology is thought to be much more 
widespread and reported to also involve serotonergic raphe nuclei, dopaminergic 
mesolimbic, mesocortical and tubero-infudibular pathways, the cholinergic nucleus 
basalis of Meynert, the cerebral cortex, the hypothalamus, the dorsal motor nucleus of 
vagus, the olfactory tract and sympathetic ganglia (Quinn et al., 2009).  In 2003, 
Braak and colleagues reported a staging system to classify the neuropathology of 
Parkinson’s disease, in which Lewy bodies first appear in the olfactory bulb, medulla 
oblongata and pontine tegmentum – individuals at this stage being asymptomatic.  As 
the disease progresses, Lewy bodies appear in the substantia nigra and the areas of 
midbrain and forebrain to finally reach the neocortex  (Braak et al., 2003).  However, 
others have argued that although this system reflects the topographical sequence of 
Lewy body distribution, there has not been an attempt to correlate Lewy body and 
neuronal density with loss of neurons and synaptic connections, as well as the lack of 
clinical correlation with clinical severity of PD (Burke, Dauer, & Vonsattel, 2008). 
 
1.1.3 Diagnosis of Parkinson’s disease 
 
Diagnosis of PD is based on clinical criteria as there is yet no definitive investigation.  
The presence of rest tremor, bradykinesia, rigidity and loss of postural reflexes are 
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generally considered the cardinal signs of PD.  Furthermore, clinicians rely on the 
clinical presentation of these features to differentiate PD from other parkinsonism 
disorders (Parkinson’s plus syndromes).  Features that suggest a diagnosis other than 
idiopathic PD include: absence of rest tremor, early occurrence of gait abnormality, 
postural instability, dementia, hallucinations and the presence of dysautonomic, 
ophthalmoparesis, ataxia and other atypical features, in addition to poor or no 
response to levodopa. 
 
Commonly used diagnostic criteria for idiopathic PD include the ‘UK Parkinson’s 
Disease Society Brain Bank’s clinical criteria for diagnosis of probable Parkinson’s 
disease’ (Hughes, Daniel, Kilford, & Lees, 1992) – which is used for the studies in 
this thesis project (see Appendix 1) – and the ‘National Institute of Neurological 
Disorders and Stroke (NINDS) diagnostic criteria for Parkinson’s disease (Gelb, 
Oliver, & Gilman, 1999).  Rapid developments in neuroimaging, such as the use of 
single photon emission computed tomography with the radioligand 123I-FP-CIT to 
assess striatal presynaptic dopamine transporter density have also helped to confirm 
the diagnosis, whilst other neuroimaging techniques have been employed to advance 
research in PD (Piccini & Brooks, 2006). 
 
1.2 Impulse control disorders and addictive 
behaviours in Parkinson’s disease 
 
1.2.1 Introduction 
Impulse Control Disorders (ICDs) are described in the Diagnostic Statistical Manual, 
version 4 (DSM-IV) as a group of psychiatric disorders characterised by a failure to 
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resist an impulse, drive or temptation to perform an act that is harmful to the 
individual or to others (American_Psychiatric_Association, 2000, 2013).  They 
comprise a wide range of neuro-behavioural disorders, including pathological 
gambling (PG), compulsive buying (CB), binge eating (BE), compulsive sexual 
behaviour (CSB), aggression, jealousy and phobias.  As ICDs are a group of 
heterogenous conditions, some (for example, pathological Internet use or Internet 
addiction) have not yet been formally categorised. Conceptually, ICDs have been 
thought of as ‘behavioural addictions’ and lie within a spectrum of disorders with 
ICDs at one end and obsessive-compulsive disorders at the other (Brewer & Potenza, 
2008). 
 
In the last decade, ICDs have become a well-recognised clinical phenomenon with 
their neuro-psychiatric features often being associated with dopaminergic medication. 
This phenomenon has not only been widely reported in patients with PD, but also in 
other conditions, such as restless leg syndrome, for which dopaminergic medications 
is a treatment option (Evans, Lawrence, Potts, Appel, & Lees, 2005; A. D. Lawrence, 
Evans, & Lees, 2003; Voon et al., 2007; Weintraub et al., 2006) . The four most 
common ICDs reported in PD patients include binge eating (Molina et al., 2000), 
pathological gambling (the most recent edition of DSM-V has renamed this as 
Gambling Disorder)  (Gschwandtner, Aston, Renaud, & Fuhr, 2001; Molina et al., 
2000), compulsive buying (also known as compulsive shopping) (Dodd et al., 2005) 
and compulsive sexual behaviour (also known as Hypersexuality) (Wingo, Evatt, 
Scott, Freeman, & Stacy, 2009). A study of over 3,000 PD patients reported an 
increased risk of CSB and PG in males, and of BE and CB in females. PD patients 
with ICDs were generally younger than those without ICDs and there is a higher 
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prevalence of ICDs in younger PD patients, even when taking into account the higher 
use of dopamine agonists (DA) in these patients (Weintraub, Koester, et al., 2010). 
 
1.2.2 Clinical phenomenology of Impulse Control Disorders in Parkinson’s 
disease 
The reported prevalence of ICDs in PD varies from 5.9% to 13.7% (Voon et al., 
2006). Such a wide disparity between results from different studies is thought to be 
due to variation in clinical practice and assessment criteria.  Recently, a large cross-
sectional study on 3,090 PD patients from 46 movement disorder centres in North 
America (The DOMINION study) provided a more definitive insight into the clinical 
facets of four commonly occurring ICDs in PD. Subject recruitment was standardised, 
where inclusion criteria required subjects to be between the age of 30 and 75, to have 
the diagnosis of idiopathic PD and dopaminergic agent treatment for at least one year 
with no dosage changes for six months. This study identified an overall prevalence of 
ICDs in 13.6% of its PD cohort treated with dopaminergic medication (Weintraub, 
Koester, et al., 2010). It also found that ICDs were more common in patients treated 
with a dopamine agonist than in those not taking a dopamine agonist (17.1% vs. 
6.9%). The frequency of ICDs was similar for pramipexole (a partial DA receptor 
agonist) and ropinirole (mainly D2 DA receptors but also has affinities for D3 and D4 
DA receptors).  In another multicentred study involving 1233 medicated PD patients, 
it was found that oral DA treatment (pramipexole and ropinirole) was associated with 
higher risk of ICDs compared with transdermal DA (rotigotine): 42% patients treated 
with oral DA developed ICD, versus 19% patients treated with rotigotine. In 
univariate analysis, a younger age, treatment with rasagiline, and especially treatment 
with an oral DA (pramipexole or ropinirole) were significantly associated with ICD.  
The researchers concluded that since pramipexole, ropinirole and rotigotine are non-
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ergolinic DAs with very similar pharmacodynamic profiles, it is likely that other 
factors including route of administration (transdermal vs oral) explain the difference 
in risk of ICD development (Garcia-Ruiz et al., 2014).  However, a review of case 
reports and cohort studies on the published literature has not found an increase in 
incidence of ICDs in patients receiving intrajejunal levodopa or subcutaneous 
apomorphine compared to oral dopaminergic medications (Todorova & Ray 
Chaudhuri, 2013). 
 
Although recent research evidence indicates that dopaminergic medications are 
thought to influence the development of ICDs in PD, it is notable that a study of a 
drug-naïve cohort using the Minnesota Impulsive Disorders Interview (MIDI) – a 
screening tool for a range of ICDs – found that 17.5% of their 103 consecutive PD 
patients screened positive for at least one impulse control disorder, with CSB most 
commonly recorded at 10.7%. However, in a clinical interview based on DSM-IV 
diagnostic criteria, none of these patients satisfied clinical diagnostic criteria for an 
impulse control disorder.  In addition, the PD cohort as a whole had similar frequency 
of impulse control disorders compared to a group of healthy non-PD subjects, where 
20% reported at least one abnormal behaviour in the MIDI screening tool (Antonini et 
al., 2011). The results of this study suggest that subclinical behavioural abnormalities 
are common in PD even before initiation of dopamine replacement therapy (DRT), 
and that these patients may be more prone to developing a clinically apparent ICD 
after initiation of DRT.  
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1.2.3 Pathological gambling  
Pathological gambling is characterised by: (i) a preoccupation with gambling, (ii) 
betting increasing amounts of money, (iii) persistence of these behaviours despite 
negative outcomes and (iv) unsuccessful attempts to stop this behaviour. Clinically, 
the diagnosis of pathological gambling as a behavioural disorder benefits from a well-
defined criteria in the Diagnostic and Statistical Manual of Mental Disorders (DSM).  
Version IV of the DSM list a set of 10 criteria to aid diagnosis of pathological 
gambling: When an individual satisfies three out of 10 criteria, it is suggestive of 
problem gambling, whilst satisfying five out of the 10 criteria suggests a diagnosis of 
PG (American_Psychiatric_Association, 2000).   In the most recent, Version V of the 
DSM, published in 2013, pathological gambling has been renamed Gambling 
Disorder (American_Psychiatric_Association, 2013). However, as the studies carried 
out in this thesis project were conducted between 2008 and 2011, the DSM-IV criteria 
for pathological gambling were used (see Appendix 2). 
 
The lifetime prevalence of PG in patients with PD ranges from 3% to 8%, in contrast 
to a lower prevalence estimates of 0.42% to 2.5% for the general North American 
population (Lu, Bharmal, & Suchowersky, 2006; Petry, Stinson, & Grant, 2005; Voon 
et al., 2007; Weintraub et al., 2006).  One study reports a prevalence of 8% for 
patients on DA agonists (Grosset et al., 2007).  In addition, it seems that cultural 
differences and reporting criteria have an impact. For example, in a Chinese cohort of 
400 patients, PG was reported to have a prevalence of 0.32% and problem gambling 
up to 1.7% (Fan, Ding, Ma, & Chan, 2009). It was speculated that this relatively 
lower rate might be due to the collection of responses through self-reported 
questionnaires and telephone interviews, as well the limited availability of DA 
agonists in China since 2007, leading to lower usage of DA agonists such as 
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pramipexole (46%) compared to Western countries (50–68%) (Pontone, Williams, 
Bassett, & Marsh, 2006; Weintraub et al., 2006).  In a study conducted on 225 non-
PD subjects with PG, 44 (19.6%) had co-occurring compulsive sexual behaviour (J. 
Grant & steinberg, 2005). Other psychiatric disorders such as depression and alcohol 
abuse have also been reported (J. Y. Lee et al., 2010; Shaffer, Hall, & Vander Bilt, 
1999; Voon, Sohr, et al., 2011). 
 
1.2.4 Compulsive sexual behaviour  
Sexual content in the media has become more explicit and accessible to the general 
public, and such material is readily and freely available on the Internet.  Compulsive 
sexual behaviour is a cause of significant morbidity for patients with Parkinson’s 
disease receiving dopamine replacement therapies (Voon & Fox, 2007; Weintraub et 
al., 2006).  However, little is known about its underlying neurobiology in PD, or how 
visual sexual stimuli, similar to the portrayals of sexuality in the mainstream mass 
media, affect the brain and behaviour in such vulnerable individuals.   
 
Reports of CSB in Parkinson’s subjects include excessive request for sex from a 
spouse or partner, increased pornographic interest, compulsive masturbation and 
sexual promiscuity (Voon et al., 2006). Individuals may resort to Internet-based 
pornographic sites as an outlet for their maladaptive behaviour (Wu et al., 2014).  
Although the prevalence of CSB in PD was estimated to be 3.5% in a large study of 
patients receiving dopamine agonist therapy, with men being more likely than women 
to have a diagnosis of CSB (Weintraub, Koester, et al., 2010), a newer but smaller 
study gives an estimated prevalence of 7%, with a link to levodopa therapy (Hassan et 
al., 2011).  
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It has been shown that continuous exposure to sexual material can stimulate excessive 
and socially unacceptable preoccupations with sex in some constitutionally vulnerable 
individuals (Rees & Noyes, 2007).  Dopamine agonists have been highlighted as the 
culprit in causing CSB in several studies on PD patients (Weintraub, Koester, et al., 
2010), although other studies have linked CSB with levodopa therapy (Ballivet, 
Marin, & Gisselmann, 1973; Hassan et al., 2011; Uitti et al., 1989). Studies in 
monkeys indicate that a synergistic interaction between dopamine drugs and sexual 
cues markedly enhances excessive sexual activity (Pomerantz, 1990). The importance 
of cues being highly associated with reward is consistent with incentive salience 
theory, where ‘wanting’ is produced by a synergistic interaction between the current 
state of the mesolimbic dopamine system and the presence of rewards or their cues 
(Berridge, 2012; Zhang, Berridge, Tindell, Smith, & Aldridge, 2009). 
 
The criteria used for diagnosis of compulsive sexual behaviour for the studies in this 
thesis are detailed in Appendix 3. 
 
1.2.5 Binge eating  
Binge eating is defined as recurring episodes of eating significantly more food in a 
short period of time than most people would eat under similar circumstances, with 
episodes marked by feelings of lack of control.  The foods consumed tend to be 
carbohydrates, fat-rich foods or sugar-rich foods such as chocolate and candies.  
Patients tend to eat much more quickly during binging episodes than when they are 
taking their normal meals and continue to do so when not really hungry. They may 
experience rapid weight gain. The person may feel guilty, embarrassed or disgusted 
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by their behaviour and may binge alone to hide their behaviour.  BE differs from the 
common phenomenon of overeating.  While overeating may be a challenge for many 
people, binge eating episodes are much less common, far more severe and are 
associated with marked stress and negatively impact on the sufferer’s quality of life 
(American_Psychiatric_Association, 2013).  BE was reported in 4.3% of PD patients 
in the DOMINION study (Weintraub, Koester, et al., 2010) . 
 
The studies in this thesis project used the DSM-IV criteria for binge eating (see 
Appendix 4) where it was classifed as an ‘eating disorder not otherwise specified’.  In 
DSM-V, BE has been classified as a distinct entity althought the definitions have not 
changed. 
 
1.2.6 Compulsive buying  
CB is defined as an uncontrollable and excessive buying of goods that can lead to 
psychological distress and substantial debt. In patients with PD who manifest this 
behaviour, purchases tend to be very narrow and focused, such as buying one sort of 
item (e.g. gold fish tanks, laptop computers) repetitively and far in excess of their 
needs. It is not currently listed as a specific disorder in the current DSM-V, but 
researchers have proposed that CB lies within a spectrum of impulsive-compulsive 
disorders (Weintraub & Potenza, 2006)  The DOMINION study estimates the 
prevalence to be 5.7% (Weintraub, Koester, et al., 2010), and in other studies it has 
been reported to range from 0.4% to 5.7%, with the overall prevalence being 7.2% for 
patients on dopamine agonists (Weintraub et al., 2006). 
 
The diagnostic criteria used for CB are detailed in Appendix 5. 
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1.2.7 Other impulsive-compulsive behaviours in Parkinson’s disease patients 
1.2.7.1 Dopamine dysregulation syndrome  
Dopamine dysregulation syndrome (DDS) is defined as the co-occurrence of ICDs 
and PD in the context of compulsive medication use (Evans et al., 2004; Giovannoni, 
O'Sullivan, Turner, Manson, & Lees, 2000).  Patients develop an addictive pattern of 
dopaminergic medication use where they request larger doses of dopaminergic 
medication inappropriate for the severity of PD symptoms or self-escalate these 
medications against their physician’s advice.  They tend to hoard more medication 
than required. Patients may also describe a perceived ineffectiveness of medications 
and typically exhibit avoidance of the Parkinsonian OFF periods. As treatment 
continues, severe drug-induced dyskinesias occur along with socially harmful 
behaviours. Patients with DDS devote a great deal of time to maintaining a complex 
and frequent drug regime, and any attempt by the physician to reduce the overall 
antiparkinsonian medication dose is met with resistance. The pattern of inappropriate 
dopaminergic medication use in patients with ICDs often resembles that of addiction 
to psychostimulants. Patients may develop a range of psychiatric syndromes, such as 
mood disorders, hypomania and manic or cyclothymic affective syndromes in relation 
to DRT. When the level of DRT is reduced, they may develop a withdrawal state 
characterised by dysphoria, depression, irritability and anxiety. These symptoms must 
persist for at least six months to satisfy the criteria of DDS (Appendix 6). The 
prevalence of DDS in patients attending specialist PD centres is about 3–4% (Evans et 
al., 2004). Patients with ICDs in the context of compulsive medication use are 
observed to be taking greater levodopa equivalent daily doses (LEDDs) of 
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dopaminergic medications compared to their counterparts who do not have DDS 
(Evans et al., 2004).   
 
1.2.7.2 Punding 
Punding is a peculiar stereotyped behaviour characterised by an intense fascination 
with complex, excessive, non-goal-oriented, repetitive activities such as manipulation 
of technical equipment like televisions, computers etc.; handling, examining or 
sorting through common objects; grooming; tidying; aimless wandering/driving; 
artistic occupations such as drawing, painting, carpentry, singling, writing or playing 
an instrument; or engagement in extended monologues devoid of content (Evans et 
al., 2004).  Punding seems to entail activities that the person is used to or likes to do. 
If interrupted, individuals with punding feel uneasy and irritated and want to go back 
to the same task.  There appears to be a gender-related component, with men typically 
tinkering with, for example, electronics and women more often grooming.  Punders 
often dedicate many hours at a time to their chosen activities, even in the face of 
negative consequences (for example polishing nails to the point of bleeding).  As 
such, these behaviour become very troublesome and lead to profound social 
withdrawal.  Most patients describe punding as a meaningless activity in which they 
get stuck or ‘hung-up’ in and cannot give up (A. J. Lawrence et al., 2007).  
 
Punding was first described in cocaine and amphetamine addicts (Rylander, 1972), 
and later reported with the use of levodopa in Parkinson’s disease (Friedman, 1994). 
The prevalence of punding in Parkinson’s patients on dopaminergic medication has 
been estimated to vary from 1.4% (Miyasaki, Al Hassan, Lang, & Voon, 2007) to 
14% (Evans et al., 2004), with such disparity due to different treatment options and 
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sampling methods. Little is known about its underlying pathophysiology, but earlier 
studies by Rylander highlighted similarities of punding behaviours to some of the 
features seen in obsessive-compulsive disorder (OCD) such as the repetitive and 
restricted nature of the behaviours (Rylander, 1972).   However, punding also clearly 
differs from OCD by the lack of obsessive thoughts and punding being associated 
with feelings of calmness and intense curiosity, rather than negative affect.  
 
1.2.7.3 Pathological Internet use 
The popularity of the Internet has grown immensely over the last decade, so much so 
that it has become an important tool in our daily lives. Its benefits have given people 
with limited mobility, such as those with Parkinson’s disease (PD), greater 
independence and better quality of life (Houlihan et al., 2003). 
 
More recently, there has been mounting interest in the concept of Problematic Internet 
Use (PIU), also known as Internet addiction disorder, or pathological computer use. 
PIU is conceptually thought of as a behavioural addiction, similar to gambling 
disorder (K. Young, 1996, 2004) .  Its commonly used working diagnostic criteria 
have been adapted from the Diagnostic and Statistical Manual – version IV (DSM-IV) 
criteria for PG (K. Young, 1996). The prevalence of PIU in the general population in 
North America and Europe has been estimated as 1.5% to 8.2%, with such a variance 
due to different populations and assessment tools used (Weinstein & Lejoyeux, 2010). 
 
Similar to PG, people with PIU spend excessive amounts of time on the Internet at the 
expense of and to the detriment of other aspects of their lives. The behaviour tends to 
target particular activities, for example online gambling, multi-user gaming, cybersex 
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or viewing online pornography. Anyone with Internet access can become dependent 
upon it regardless of gender and age, but most research conducted on it in the general 
population targets young people and college students. In the ICD population, 
pathological gambling and compulsive sexual behaviour have been mostly linked to 
PIU, compared to other types of ICDs, such as compulsive buying or binge eating 
(Cash, Rae, Steel, & Winkler, 2012).  
 
PIU in Parkinson’s disease has not been systematically studied.  To date in the 
literature, there are only a handful of reported cases of compulsive Internet use, and 
mainly in association with PG.  Fan and colleagues reported one case of compulsive 
Internet browsing in a group of 400 Chinese PD patients (Fan et al., 2009); Larner 
reported another of using the Internet for gambling purposes (Larner, 2006)  and a 
case series of eight patients with PG, four of whom were reported to use the Internet 
as a medium to propagate their aberrant behaviour (Wong, Cowen, Allen, & Newman, 
2007).  A further case documented a patient who compulsively spends time on his 
computer building word games as a form of punding behaviour (Fasano, Elia, Soleti, 
Guidubaldi, & Bentivoglio, 2006).  These cases are all associated with dopaminergic 
medication use and suggest that compulsive Internet or computer use is a form of 
addictive behaviour in PD.  Currently there is no study specifically comparing 
Internet use in PD with ICDs to a PD control group, nor to the general population. 
 
1.2.8 Clinical factors associated with Impulse Control Disorders in PD  
The occurrence of ICDs in only a subset of PD patients suggests that specific groups 
of individuals with PD are susceptible to developing ICDs during the course of 
disease, particularly during treatment with a dopamine agonist. As such, identifying 
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clinical factors associated with development of ICDs in PD patients may allow us to 
distinguish patients at increased risk, prompting specific screening and monitoring of 
at-risk individuals.  
 
Evidence from case series and larger studies has pointed towards several common 
clinico-psychiatric traits associated with ICDs in PD patients. These include a 
younger age, being unmarried, having a current cigarette smoking habit and having a 
family history of gambling problems. The personality traits of novelty seeking and 
disinhibition have been associated with increased rate of ICDs in PD patients on DRT. 
Furthermore, dopamine agonist treatment in PD is associated with a 2–3.5 fold 
increase in the odds of having an ICD. This represents a drug class relationship across 
ICDs (Weintraub, Koester, et al., 2010). Early PD onset was correlated with a higher 
rate of ICDs, and the association persisted after adjusting for confounders. No 
significant association has been found between severity of PD and ICDs.  
 
A case-control study using a subset of patients from the DOMINION trial also found 
that ICD patients with PD tend to have a higher L-Dopa intake compared to PD 
patients without ICDs, but no difference in dopamine agonist dose (Voon, Sohr, et al., 
2011). PD ICD patients had reduced motivation, higher depression scores (15-item 
Geriatric Depression Scale), state and trait anxieties (State-trait anxiety inventory) and 
OCD behaviours (Obsessive-compulsive inventory). Also, PD ICD patients differed 
from PD patients without ICDs in having higher novelty seeking and impulsivity. In 
addition, PD ICD patients were more likely to be current or ex-smokers, but did not 
differ in their alcohol intake from PD patients without ICDs (Voon, Sohr, et al., 
2011).   
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These individual factors will be explored in turn below. 
 
1.2.8.1 Dopaminergic medication 
Early case reports and case series noted the onset of ICD behaviours co-occurring 
with onset or dose increase of dopamine agonists and a remission of symptoms with 
reduction or cessation of dopaminergic medication (Gschwandtner et al., 2001; 
Molina et al., 2000). However, these earlier studies did not take into account the 
differences in prescribing practice, such as dosing and alternative types of DRT 
(levodopa vs. dopamine agonists). More recently, this observation has been confirmed 
by larger cross-sectional, multi-centre studies that systematically assessed the 
association of medication with ICDs in PD patients. It was shown that PG, CSB and 
CB were strongly associated with the use of dopamine agonists as a class, but not with 
any specific agonists (Voon et al., 2006; Voon, Sohr, et al., 2011; Weintraub, Koester, 
et al., 2010; Weintraub et al., 2006).  In addition, PD patients with ICDs were shown 
to take larger amounts of total LEDDs (calculated for dopamine agonists and 
levodopa) compared to patients without ICDs. However, this trend was not seen when 
different types of ICDs were analysed individually, and an increased total LEDD dose 
has not been shown to predict the presence of an ICD (Weintraub et al., 2006).  
 
ICDs have also been reported in other patient groups where dopamine agonists are 
employed as treatment options – for example, in Parkinsonian-plus disorders such as 
multi-systems atrophy (MSA) and progressive supranuclear palsy (PSP), where use of 
pramipexole or ropinirole have been associated with the onset of compulsive 
gambling, increased sexual behaviour, CB or BE (Klos, Bower, Josephs, Matsumoto, 
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& Ahlskog, 2005; McKeon et al., 2007; O'Sullivan et al., 2010). Similar behaviours 
have been reported for fibromyalgia (Holman, 2009) and restless leg syndrome 
(Evans & Butzkueven, 2007; Quickfall & Suchowersky, 2007; Tippmann-Peikert, 
Park, Boeve, Shepard, & Silber, 2007). For example, a survey of 70 patients with 
idiopathic restless legs syndrome treated with one or more dopaminergic medications 
found that 7% of patients noted a change in gambling behaviour, and 6% reported an 
increased urge and time spent in gambling after the use of dopaminergic medication 
(Driver-Dunckley et al., 2007). These findings suggest that it is the medication, rather 
than the pathogenesis of PD, that causes the development of ICDs. Furthermore, these 
behaviours are not limited to an oral mode of administration as rotigotine, a dopamine 
agonist with transdermal preparation, was also shown to be connected with PG and 
CSB in three PD patients (Wingo et al., 2009).  
 
The use of dopaminergic medications may contribute to the development of ICDs via 
several mechanisms. Firstly, they may interfere with the endogenous physiological 
pattern of dopamine release and cause excessive stimulation of dopamine receptors, 
resulting in aberrant activity in the implicated neuroanatomical regions. Secondly, 
exogenous dopaminergic stimulation may enhance the shift from goal-directed 
behaviours to stimulus response or habit formation, and chronic stimulation may 
result in neuronal sensitisation of ventral or dorsal striatal areas, leading to 
behavioural sensitisation. 
 
In addition, specific dopamine receptor subtypes may be implicated. Dopamine D3 
receptors (D3) are predominantly expressed in ventral areas of the striatum involved 
in reward, emotional and cognitive processes (Benninger & Banasikowski, 2008; 
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Gurevich & Joyce, 1999). The relative binding affinities of D3 to D1 or D2 receptors 
differ between dopamine agonists, and interaction between anti-Parkinsonian 
medication and dopamine receptors may lead to the development of ICDs in PD 
patients (Pontone et al., 2006). This finding was replicated in an animal study where 
related levodopa administration resulted in ectopic induction of Dopamine D3 
Receptors in dorsal striatum, a process that could be responsible for development of 
behavioural sensitisation (Bordet et al., 1997). Moreover, pramipexole and ropinirole 
are two non-ergot dopamine agonists widely used in PD patients and which have 
tropism for D3 receptors found in the nucleus accumbens and the olfactory tubercle 
(Gerlach et al., 2003). Their affinities for D3 receptors are at least 100-fold greater 
than for D2 receptors; neither pramipexole nor ropinirole has any affinity for D1 
receptors. A diagram with distribution of dopamine D1-D5 receptors in normal brain 
is illustrated in Figure 1.  PG and compulsive behaviours are associated with 
dysfunction of these frontal subcortical regions, suggesting a link between specific 
dopamine receptors and development of aberrant behaviours (Singh, Kandimala, 
Dewey, & O'Suilleabhain, 2007). However, the observation of withdrawal symptoms 
when stopping levodopa treatment in non-parkinsonian patients, such as those who 
received the wrong diagnosis, further supports the view that it is the drug rather than 
the underlying dopaminergic state that leads to the symptoms of ICDs (Merims, 
Galili-Mosberg, & Melamed, 2000). Conversely, the fact that withdrawing from D3-
preferring agonists results in a resolution or reduction of the aberrant behaviour 
suggests that they are related. A minority of affected PD patients, however, 
experience withdrawal symptoms when reducing the dose of dopamine agonists, with 
symptoms such as panic, dysphoria, depression, agitation and autonomic symptoms. 
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Figure 1. Distrubution of dopamine D1-D5 receptors in normal brain. 
!!(Reproduced!from!www.cnsforum.com/educationalresources/imagebank/dopaminergic/hrl_rcpt_sys_da_dist)!!
 
There is less evidence for the possible association between monoamine oxidase 
inhibitors type B (MAO-B) and the development of ICD.  Rasagiline is a second 
generation MAO-B inhibitor, inducing moderate symptomatic and possibly disease 
modifying benefits with apparently good tolerability and safety profile in PD patients.   
However there has been single case reports of PD patients developing ICDs when 
treated de novo with MAO-B inhibitors (Reyes, Kurako, & Galvez-Jimenez, 2014) 
(Vitale et al., 2013). 
 
Interestingly, a recent study has also linked amantadine with the presence of ICDs. 
The mode of action of amantadine has yet to be elucidated, but it is a medication 
commonly used to treat dyskineisas in patients with PD, and is believed to have both 
glutamatergic and pro-dopaminergic properties. Amantadine was shown to be 
associated with the presence of one or more ICDs, and after controlling for 
confounding clinical variables, it was found to be specifically associated with PG, 
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CSB and CB (Weintraub, Koester, et al., 2010). However, in this large-scale study, 
amantadine patients were also found to be on higher levodopa dosages (since 
amantadine is typically used to treat dyskinesias associated with high levodopa 
dosages), and higher levodopa dosages were also associated with ICDs, suggesting a 
possible confounding issue. In contrast, in a smaller study (n=17), amantadine use 
was reported to be efficacious for treatment of PG in patients with PD (Thomas, 
Bonanni, Gambi, Di Iorio, & Onofrj, 2010). The authors hypothesised that the 
antiglutamatergic properties of amantadine may have caused such an effect, and this 
is supported by another positive study of N-acetylcsyteine (NAC), an amino acid that 
modulates glutamatergic activity in the treatment of PG in the general population (J. 
E. Grant, Kim, & Odlaug, 2007).  It may also be that the properties of amantadine are 
twofold and not fully understood at present. The authors state that chronic 
dopaminergic stimulation has been linked with both ICDs and dyskinesias but 
hypothesise that amantadine appears to have dyskinetic effects, which may be related 
to its antiglutamatergic properties. Thus the pro-dopaminergic activity of amantadine 
may contribute to ICD development in at-risk PD patients, whilst its antiglutamatergic 
properties may have beneficial effects when introduced in patients already suffering 
from ICDs. A prospective randomised and blinded study would be of use in 
elucidating the precise link between amantadine and the onset of ICD. 
 
1.2.8.2 Personality traits 
Novelty-seeking personality traits are characterised by exploratory approach 
behaviours, excitement with novel situations, impulsivity and rapid decision-making, 
and a number of these have been associated with development of ICDs in patients 
with PD. However, PD patients generally have lower measures of novelty seeking 
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compared to healthy volunteers, and it has been suggested that this reflects underlying 
mesolimbic dopaminergic neurodegeneration in PD patients (Menza, 2000).  
Interestingly, the lower frequency of smoking and caffeine use in PD patients has 
been associated with lower measures of sensation-seeking traits (Allam, Campbell, 
Hofman, Del Castillo, & Fernandez-Crehuet Navajas, 2004; Evans et al., 2006). This 
is in contrast to patients who take dopaminergic medication, as illustrated in two 
separate case-control studies where PD patients with PG, CSB and/or compulsive 
medication use were found to have higher measures of novelty seeking compared to 
matched healthy controls and PD control patients (Evans et al., 2005; Voon et al., 
2007). In addition, novelty-seeking personality traits were found to be significant 
predictors for the development of DDS (Evans et al., 2005) and for the development 
of PG in PD patients (Voon et al., 2007).  
 
PD patients with CB have been found to prefer smaller immediate rewards to larger 
delayed ones (Voon et al., 2010). They make more impulsive choices relative to PD 
controls. However, the range of ICD behaviours are heterogenous – for example, 
patients with CB are more likely to choose small short-term gains compared to larger 
longer-term rewards (Eagle & Baunez, 2010; Voon et al., 2010). Furthermore, in PD 
populations with ICDs, it has been observed that their motivation is focused on the 
particular ICD(s), rather than general motivation being increased (Voon, Sohr, et al., 
2011).  
 
It has also been observed that CSB has a male predominance whereas CB and BE 
have a female predominance; in the case of PG, however, there was no difference in 
gender although in the non-PD general population PG has a male predominance 
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(Voon, Sohr, et al., 2011). These features suggest a potential role for biological or 
social influences in the development of particular ICDs. In addition, subjects with PG 
and CS have more overlapping features when compared to those with CSB and BE, 
specifically in terms of greater anxiety, obsessive-compulsive features and novelty 
seeking. Compulsive shoppers, in particular, received higher levodopa doses and had 
greater exploratory excitability and impulsive choice measures relative to matched 
controls (Voon, Sohr, et al., 2011). These variations may reflect differences in the 
type of reward, such as consumable (e.g. food or sex) and non-consumable (e.g. 
monetary, gambling or shopping) rewards, degree of social interaction, or the level of 
arousal associated with these behaviours.  
 
1.2.8.3 Comorbid psychiatric history 
PD patients with a history of psychiatric disorders are thought to be more susceptible 
to the development of ICDs, especially in the context of DRT. This is supported by a 
study of PD patients with ICDs where the rates of comorbid psychiatric diagnosis 
were found to be higher in the ICD group (Pontone et al., 2006) and also by the 
observation that higher rates of psychiatric comorbidity and depression are to be 
found in individuals with PG in non-PD populations (Dell'Osso, Allen, & Hollander, 
2005). Anxiety disorders and PG frequently coexist, and treatments approved for 
anxiety disorders appear to target both anxiety and gambling measures (J. E. Grant, 
Potenza, et al., 2006). Compared to PD patients without an ICD, those with an ICD 
scored higher on measures of depression, anxiety, obsessive-compulsive features, 
novelty seeking, impulsivity and current and former smoking habits. The greater 
association between ICDs and psychiatric rather than neurological features raises the 
possibility that psychiatric comorbidity may contribute to the development of ICDs in 
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PD. In comparison to the non-PD general population, depression occurs as a frequent 
comorbidity with gambling, and genetic factors also contribute substantially (Potenza, 
Xian, Shah, Scherrer, & Eisen, 2005).   
 
In addition, both PD patients and non-PD individuals with ICDs have higher Geriatric 
Depression Scale values, although the precise relationship to the occurrence of 
abnormal behaviour is still unclear. Furthermore, antidepressants are frequently used 
in the treatment of ICDs, and there is increasing evidence that impulsivity and 
depression may be associated with low serotonin (5-HT) function, resulting in an 
imbalance between dopamine and 5-HT neurotransmission. Although no clinical 
studies have shown that antidepressants are effective treatment options for this group 
of patients (Frankle et al., 2005), subtle symptoms of depressed mood, appetite 
changes, irritability and disinhibition are more likely to be present in the group of 
patients with ICDs (Pontone et al., 2006).  
 
There is a further suggestion that a family history of psychiatric illness may also be 
associated with the development of ICDs in patients with PD. This is illustrated by a 
study of PG and medication association in PD which found that three out of 10 PD 
patients with ICDs had a psychiatric history in their first-degree relatives, compared 
to 286 PD patients without PG where none of them had this feature (Voon et al., 
2006). However, data on clinical features has come from case series and case-control 
studies with small numbers of patients, and more objective methods are necessary to 
determine a precise relationship between the development of ICDs and a comorbid 
psychiatric history in PD patients.  
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1.2.8.4 Early onset PD 
Patients who develop PD at a younger age are more likely to develop ICDs, 
particularly if they are treated with a dopamine agonist (Voon et al., 2006; Weintraub, 
Koester, et al., 2010). PD patients who developed PG were found to be nine years 
younger at the onset of their parkinsonian symptoms (49 years old on average) 
compared with the mean age of 58 years at onset observed in a group of 286 patients 
without PG (Evans et al., 2005). 
 
1.2.8.5 History of alcoholism or substance use 
Compulsive medication use in PD and PG has been associated with a personal or 
immediate family history of alcohol use, which was found to be an independent 
predictive factor for the development of PG with dopamine agonists (Dodd et al., 
2005; Stamey & Jankovic, 2008). However, observational studies on adult twins (in 
the non-PD population) suggested that there may be some common genetic ground 
between PG and alcohol dependence, as it was observed that up to 42% of gamblers 
also manifest symptoms of alcohol dependence (Lobo & Kennedy, 2006; Slutske et 
al., 2001), but the precise relationship between alcohol use and the development of 
PG has not been fully elucidated. 
 
1.2.8.6 Deep brain stimulation (DBS) 
Whilst electrical stimulation to the subthalamic nucleus has been shown to markedly 
improve the motor symptoms of PD, its relationship to the development of ICDs in 
PD patients is unclear. ICDs have been reported to occur following DBS (Lim, Evans, 
& Miyasaki, 2008; Volkmann, Daniels, & Witt, 2010) although it has been argued 
that this may be due to a reduction of dopaminergic medication use associated with 
successful surgery (Ardouin et al., 2006; Bandini, Primavera, Pizzorno, & Cocito, 
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2007; Witjas et al., 2005). Another study found that following DBS of the 
subthalamic nucleus there was no association between the use of dopamine agonists 
and impulsivity in DBS patients, though ICDs were observed in three of the 16 
patients (Halbig et al., 2009). 
 
It has been suggested that the use of electrical stimulation may block the direct 
pathway of the basal ganglia and in turn produce another type of impulsivity (Frank, 
Samanta, Moustafa, & Sherman, 2007). In a cohort of 96 PD patients, it was found 
that more PD patients with BE had a history of DBS (44% vs. 14%) and that a history 
of DBS was the only independent predictor of overeating (Zahodne et al., 2011). 
 
1.2.8.7 Dyskinesias 
The recent observation that dyskinesias are associated with multiple ICDs, but not 
single ICDs, suggests potential overlapping mechanisms across a range of excessive, 
repetitive motoric behaviours, perhaps linked to dopaminergic modulation. Relative to 
controls, PD patients with multiple ICDs had higher dyskinesia measures (Voon et al., 
2009; Weintraub, Sohr, et al., 2010). Overall, ICD patients had greater functional 
impairment in routine daily activities compared with PD controls, despite exhibiting a 
similar severity in motor signs. This may be due to an increased severity of depression 
or other psychiatric symptoms adversely impacting on functional abilities. Given the 
association of ICDs with higher levodopa use, these effects may be mediated by 
levodopa rather than dopamine agonists per se. Further supporting evidence for this 
comes from local electric field potentials from deep brain stimulation of PD patients 
who either have ICDs or dyskinesias. It was found that both these groups have greater 
subthalamic nucleus activity in the theta-alpha band, with different corticosubthalamic 
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coherence suggestive of associative-limbic and motor corticostriatal activity, 
compared to post-DBS patients with neither dyskinesias nor ICDs (Rodriguez-Oroz et 
al., 2011). This suggests a potential similar underlying pathophysiology between 
behavioural and motor symptoms that may implicate specific dopamine receptor 
subtypes, or serotonergic, glutamatergic or sensitisation mechanisms, although further 
studies are warranted. 
 
1.2.8.8 Genetic influences 
Studies in genetic influences on the development of ICDs in patients with PD are 
limited. However, in the non-PD population, observational studies have supported 
genetic influences on the development of ICD, particularly for PG. For example, the 
Vietnam Era Twin (Registry) reports that genetic factors account for 34–54% of 
predisposition to PG (Eisen et al., 1998). This degree of heritability is similar to those 
of other psychiatric disorders, such as drug addiction (Tsuang et al., 1996).  
 
One of the few studies on PD patients focusing on genetic traits was conducted by 
Lee and colleagues (2009), who found an association of ICDs with patients carrying 
the AA genotype of a dopamine receptor D3 variant (DRD3 p.S9G) and the CC 
genotype of the GRIN2B (c.366C>G) in 404 PD patients. Of this cohort, 14.4% of 
subjects had impulse control-related behaviours, and the study suggested that carrying 
either of these genotypes was an independent risk factor for the development of 
impulse control and related behaviours.   
 
As dopamine plays a key role in reward mechanisms, it follows that genetic 
polymorphisms which affect dopamine neurotransmission may influence an 
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individual’s response in anticipation of reward. Genetic polymorphisms to key 
enzymes in the degradation of dopamine will cause a flux in the intrasynaptic 
availability of dopamine. For example, healthy subjects who possess the dopamine D2 
receptor A1 allelic gene have reduced dopamine function and were less effective at 
gaining money in an anticipation paradigm compared to their A2 counterparts 
(Jonsson et al., 1999; Kirsch et al., 2006). Interestingly, the presence of the D2 
receptor A1 allele was twice as high in PG subjects compared to controls (Comings et 
al., 1996). Evidence also supports its predilection in alcohol dependence (Ritchie & 
Noble, 2003), compulsive eating and smoking (Blum et al., 1995; Haile, Kosten, & 
Kosten, 2007).  
 
Other genetic polymorphisms include the exon 3 variable number of tandem repeats 
(VNTR) polymorphism for the dopamine D4 receptor, where the 7 repeat 
polymorphism results in a reduced or suboptimal response to dopamine (Swanson et 
al., 2000). Adults with the L allelic variant have increased cravings for food, 
cigarettes, alcohol and heroin in response to cues (Hutchison, LaChance, Niaura, 
Bryan, & Smolen, 2002; Hutchison, McGeary, Smolen, Bryan, & Swift, 2002; Shao 
et al., 2006; Sobik, Hutchison, & Craighead, 2005). Similarly, the dopamine 
transporter is responsible for removing dopamine from the extracellular space, so 
variations to its function as a result of allelic differences will have an influence on the 
available dopamine level in the synapse (Bannon, Michelhaugh, Wang, & Sacchetti, 
2001). A functional VNTR polymorphism in the 3' untranslated region of the DAT 
gene has been found, where the 10/10 repeat geneotype has excessive amounts of the 
transporter and therefore low extracellular dopamine levels. 
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Catechol-O-methyltransferase (COMT) is an enzyme abundant in the frontal cortices 
responsible for the breakdown of dopamine due to the lack of dopamine transporter 
(DAT) in this region. The functional polymorphism val158met leads to reduced 
function of the met/met alleles, with reduced breakdown of dopamine, and therefore 
higher levels in the frontal regions is thought to influence reward responsivity and 
decision-making (Marco-Pallares et al., 2009; Roussos, Giakoumaki, Pavlakis, & 
Bitsios, 2008; van den Bos, Homberg, Gijsbers, den Heijer, & Cuppen, 2009). Other 
genetic variants involving MAO-A (Ibanez, Perez de Castro, Fernandez-Piqueras, 
Blanco, & Saiz-Ruiz, 2000), serotonin transporter and dopamine receptors D1, D2, and 
D3 (Comings et al., 1996; Perez de Castro, Ibanez, Saiz-Ruiz, & Fernandez-Piqueras, 
1999; Swanson et al., 2000) have also been studied in the healthy population, but few 
studies have focused on PD subgroups of patients. 
 
1.3 The role of functional neuroimaging in 
understanding the neurobiology of ICDs 
1.3.1 Studies investigating impulsivity personality traits  
It has been postulated that behavioural addictions, such as gambling, are caused by 
dysregulation of the dopaminergic pathways, much like that for drug addiction.  These 
changes, as manifested by neurochemical fluxes, may exist in addicted individuals 
even before they begin taking drugs (i.e. individual susceptibility).  Using a reversible 
D2/3 receptor binding ligand 11C-raclopride, Volkow and colleagues found that 
differences in dopamine D2 and D3 receptors binding in the striatum of healthy 
invididuals without previous drug exposure predicted the degree of ‘liking’ of a single 
dose of methylphenidate (Volkow, Fowler, Wang, Ding, & Gatley, 2002).  Those with 
low binding indicating higher engdogenous DA levels or low D2/3 receptor 
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availability were more likely to report the drug as pleasurable than those with high 
binding.  In addicted individuals, low binding of 11C-raclopride in the striatum 
correlated with reduced glucose metabolism in the orbitofrontal and anterior cingulate 
cortex, areas associated with reward processing an inhibitory control (Volkow et al., 
2001).    
 
In healthy, non-PD, individuals without addiction, a PET study with 18F-fallypride (a 
a radioligand that binds to extrastriatal D2/D3 receptors) has found that amphetamine-
induced DA release was greater in those with greater impulsivity traits (Buckholtz et 
al., 2010).   The prefrontal cortex has also been implicated in contributing to the 
propensity for individuals’ impulsive behaviours.  i.e. poor inhibitory control 
mediated by frontal under-activity may represent a risk factor for addiction.  In the 
motor domain, impulsivity is measured using response inhibition paradigms in which 
a subject is required to inhibit a well-practised or automatic action (e.g. stop-signal 
and go/no-go tasks).  Chemical addictions have been associated with poor 
performance on these tasks, and mixed results have been found in behavioural 
addictions (N. S. Lawrence, Jollant, O'Daly, Zelaya, & Phillips, 2009).  Using a 
Stroop task in which an automatic spoken response must be limited, Potenza and 
colleagues found hypoactivation of the left ventromedial prefrontal cortex for those 
trials requiring inhibition in pathological gamblers compared with controls, but 
similar performance was observed in both groups (Potenza et al., 2003).  These 
studies suggest that impulsivity in chemical addictions reflects hypoactivation of 
frontal brain areas sub-serving response inhibition in the healthy brain.   
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1.3.2 Studies investigated the role of dopamine agonist in altering learning from 
reward and punishment 
In the non-PD population, it has been shown that DA agonists trigger behavioural 
changes and that these changes are associated with DA agonist-dependent changes in 
the frontstriatal activity measured with fMRI (Cools, Lewis, Clark, Barker, & 
Robbins, 2007).  This corroborates with a study showing that those PD 
individuals with high trait impulsivity that are on dopaminergic medications are more 
susceptible to development of ICDs (Voon et al 2011), suggesting that dopaminergic 
medications are implicated in the development of ICDs in PD.    Given the 
involvement of ventral striatum in drug and behavioural addictions, it might be 
predicted that excessive limbic dopaminergic stimulation via dopamine agonists 
might increase addictive behaviours.  Thus PD patients with preserved ventral striatal 
DA projects at the time of initial treatment maybe particularly susceptible of 
developing ICDs.  Tonic occupation of postsynaptic receptors may also impair ability 
to learn from reward and/or punishment.  Van Eimeren and colleagues have shown 
that, in PD patients without ICDs, both dopamine agonist and L-Dopa diminished 
ventral striatal reward processing.  Further, dopamine agonist, but not L-dopa, 
increased activity in the orbitofrontal cortex during the receipt of the reward (van 
Eimeren et al., 2009). In a different study on patients with restless legs treated with 
dopamine agonists, Abler and colleagues showed that fMRI activation of the ventral 
striatum in response to reward expectation only occurred when subjects were on 
dopamine agonists (Abler, Hahlbrock, Unrath, Gron, & Kassubek, 2009).  Upon 
receipt or omission of rewards, agonists were associated with abnormal processing of 
errors.  On the other hand, Voon et al observed greater learning from positive 
feedback in a group of PD patients with ICDs compared with control PD patients 
when on DA agonists, associated with greater ventral striatal activity (Voon, Gao, et 
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al., 2011).  Thus, in patients without ICDs, DA agonists led to markedly changed 
neural processing of negative consequences, and that positive reinforcement may be 
augmented by agonists due to tonic occupation of postsynaptic receptors during 
positive feedback that may signal that a response gave greater than expected reward, 
and therefore, should be repeated. 
 
Further, the idea that intact impulse control may protect patients from development of 
ICDs during agonist exposure is supported by a recent 15H2O PET study where PD 
patients were scanned before and after administration of DA agonists to measure 
changes in regional cerebral blood flow during a card selection game with feedback 
(van Eimeren et al., 2010).  The authors observed that DA agonists increased activity 
in brain areas associated with impulse control in patients without pathological 
gambling.  The PD gamblers however showed a significant DA agonist induced 
reduction of activity.  These findings indicate that DA agonists may interact with 
underlying differences in dopaminergic modulation of prefrontal cortex to induce 
ICDs in susceptible individuals, potentially linked with poor inhibitory control and 
therefore increased impulsivity. 
 
1.3.3 Studies investigating different mechanism through which dopaminergic 
medication promotes pathological impulsive behaviour !
1.3.3.1 Increased response to rewards due to sensitization of ventral striatum 
An early PET study with 11C-raclopride by colleagues from my research group found 
that PD patients with DDS showed an enhanced dopamine release in the ventral 
striatum in response to levodopa.  Further, such change correlated with increased 
motivation to take the drug (Evans et al., 2006). These findings corroborated with 
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those of drug addiction in the general population where individuals with drug 
addictions show enhanced ventral striatal dopamine release. On this front, Volkow 
and colleagues have shown that chronic drug abuse in substance-addicted individuals 
causes ventral striatal dopaminergic abnormalities (Volkow et al., 2001; Volkow et 
al., 1993).   The results support the incentive sensitisation theory, which posits that 
compulsive drug use arises from the excessive attribution of incentive salience or 
‘wanting’ for drug rewards and their cues due to progressive neuroadaptation in 
striatal neurocircuitry (Robinson & Berridge, 1993).   Applied to behavioural 
addictions, it is therefore feasible that compulsive reward-seeking behaviours arise 
from excessive attribution of incentive salience for rewards and their associated cues 
(Berridge, 2012).  In a study of PD individuals with PG, using 11C-raclopride with 
PET, following dopamine agonists, patients with pathological gambling demonstrated 
greater decreases in binding potential in the ventral striatum during gambling than 
control patients, likely reflecting greater dopaminergic release (Steeves et al., 2009).   
 
Results from studies on compulsive sexual behaviour in animal models and non-PD 
individuals have also supported that excessive dopaminergic stimulation increases 
addictive behaviours.  In animals, sexual-related cues enhance sexual motivation and 
pursuit in the dopaminergic neural circuits involving the VS, hypothalamus, amygdala 
and the medial prefrontal cortex (PFC) (Pfaus et al., 2010; Stolzenberg & Numan, 
2011).  Further, sensitisation by dopaminergic drugs has been shown to enhance the 
pursuit of natural rewards (including sexual incentives) as a result of excessive 
incentive salience attribution to reward-related cues (Afonso, Mueller, Stewart, & 
Pfaus, 2009; Fiorino & Phillips, 1999b; Nocjar & Panksepp, 2002).  Moreover, 
dopaminergic drugs and sexual behaviours have been shown to co-activate a 
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population of neurons in the VS, amygdala, hypothalamus and anterior cingulate 
cortex (ACC), identifying potential sites where drugs can influence sexual behaviour 
(Frohmader, Wiskerke, Wise, Lehman, & Coolen, 2010; Holder et al., 2010). In line 
with the incentive sensitisation theory, CSB in patients with PD could be associated 
with increased processing in brain regions linked to sexual motivation and cue 
reactivity and that these activations could be potentiated by dopaminergic medication. 
 
In the general population, it has been shown that visual cues related to different 
rewards elicit increased dopamine release in the striatum (Koepp et al., 1998; 
Sescousse, Redoute, & Dreher, 2010) - this has not been investigated in patients with 
Parkinson’s disease.  Reward-related visual cues are particularly pertinent in today’s 
society where we are bombarded with visual imageries from advertising campaigns 
centred on food (supermarket adverts), gambling activities (lotteries, online gambling 
sites), store promotions and portrayals of sexuality in everyday media.  The effects of 
these on vulnerable individuals, such as patients with ICDs, are not known.   
 
1.3.3.2. Reduced ventral striatal D2 receptor availability related to reward 
deficiency syndrome 
The reward deficiency syndrome, first coined by Blum et al refers to an insufficiency 
of ‘usual feelings of satisfaction’, as a result of dysfunction in the brain reward 
cascade caused by reduced striatal D2 receptor availability (Blum et al., 1996).    It 
has been found that individuals with alcohol dependence and other drug addictions 
have reduced basal striatal dopamine levels.    
 
In this regard, Steeves et al observed reduced binding in 11C-raclopride during a 
control task involving no reward in PD individuals, and the authors concluded that 
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this indicated lower D2/3 receptor availability.  Further, they showed an increased 
release of DA in the ventral striatum during a gambling task involving real monetary 
reward, indicating abnormalities in DA binding in patients with pathological 
gambling similar to those reported for chemical and behavioural addictions in the 
general population, implying that PD patients who develop an ICD may represent a 
susceptible group of individuals whose ICDs has been unmasked via the application 
of agonists.   
 
1.3.3.3. Downregulation of midbrain dopamine autoreceptor function 
A lack of homeostatic control over striatal dopamine release causes increased 
sensitivity to rewards and propensity for impulsive action.   This is demonstrated in a 
PET study by Ray and colleagues, who found that, changes in 11C FLB-457 (a PET 
radiotracer with high affinity for extrastriatal DA D2/3 receptors) binding potential 
during gambling was reduced in PD patients with pathological gambling in the 
midbrain (Ray et al., 2012). The degree of occupation of the DA D2/3 receptors 
during gambling was also correlated with impulsivity.  
 
In summary, neuroimaging studies have provided insight into the link between ICDs 
and chemical addictions, showing similar changes in fronto-striatal brain activity and 
neurotransmitter release.  In PD, dopamine agonists may induce changes in brain 
function that impair patients’ ability to learn from both reward and punishment.  
Recent studies have also suggested that increased susceptibility for ICD and addiction 
associated with impulsive personality trait may be dependent on normal variations in 
brain function that, in PD, exposure to dopamine agonist may lead to pathological 
behaviours.   However, it should be noted that the latter studies have employed 
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hypothetical experimental design paradigms that simulate, but do not represent, real-
life circumstances.  
 
1.4  Comorbidity of impulse control disorders in 
Parkinson’s disease patients 
Impulse control disorders (ICDs) on the whole occur in about 14% of patients with 
Parkinson’s disease treated with dopaminergic medication (Weintraub, Koester, et al., 
2010), but over a quarter (28%) of these patients have been shown to have co-morbid 
ICDs (i.e. more than one ICD) (Weintraub, Koester, et al., 2010).   
 
Evidence from epidemiology studies in the general population have also shown that 
23% of pathological gamblers report a comorbid impulse control disorder, most 
commonly compulsive sexual behaviour and compulsive buying (J. E. Grant & Kim, 
2003), and 61% of pathological gamblers satisfy diagnostic criteria for personality 
disorders and have increased frequency of other ICDs (Kruedelbach et al., 2006).    
 
A clinical case-control study noted that PD patients with comorbid ICDs had greater 
functional impairment in activities of daily living compared to those without, despite 
having similar severity of motor signs (Voon, Sohr, et al., 2011).  These findings 
reverberate evidence from the general (non-PD) population, where comorbidity of 
diseases has been linked to worse clinical severity, more functional impairment, 
poorer prognosis and more resistance to treatment compared with uncomplicated 
symptom presentations (i.e. those with a single diagnosis), (Krueger & Bezdjian, 
2009; Krueger, Caspi, Moffitt, Silva, & McGee, 1996; Verhulst & van der Ende, 
1993).  
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Furthermore, PD patients with comorbid ICDs have greater functional impairment in 
activities of daily living compared to those with a single ICD, despite having similar 
severity of motor signs (Voon, Sohr, et al., 2011).   The underlying neurobiology in 
PD-ICDs is thought to involve drug-induced neuroplasticity in the dopaminergic 
mesolimbic reward circuitry, such that reward-related stimuli acquire excessive 
salience, triggering impulsive pursuit (‘wanting’) (Robinson & Berridge, 1993). 
Existing neuroimaging studies have supported this by showing increased ventral 
striatal dopamine release to reward-related cues in PD patients with pathological 
gambling compared to PD controls (Joutsa, Johansson, et al., 2012).  In animal 
models, incentive salience ‘wanting’ can be very narrowly focused on a single 
preferred type of reward cue, or more broadly focused such that multiple incentives 
become more ‘wanted’ together (Berridge, 2012).  For example, amphetamine 
sensitisation in rats can amplify the incentive value of drug-associated stimuli (but not 
food or sex) for some individuals, but it can also enhance ‘wanting’ of both food and 
sex rewards (but not drugs) in others (Nocjar & Panksepp, 2002).  Such broad 
motivational ‘wanting’ may underlie the development of comorbid ICDs in PD 
patients, where an individual develops several different ICDs simultaneously.  The 
extent to which the breadth of incentive salience attribution is linked to alterations in 
striatal dopaminergic neurotransmission is unknown (Berridge, 2012). 
 
There are currently no neuroimaging studies on comorbidity of ICDs in PD; however, 
in non-PD subjects, exposure to reward-related cues triggers both the excessive 
‘wanting’ for that particular type of reward (e.g. pathological gambling or cocaine) 
and also enhances the pursuit of other reward types (food and sex) (Fiorino & 
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Phillips, 1999a; Nocjar & Panksepp, 2002). Such a ‘cross-sensitisation’ phenomenon 
may therefore underlie the neurobiology for development of comorbid ICDs in PD 
patients where an individual develops two or more clinically different ICDs. 
1.5 Overview of chapters 
Chapter 2 contains the methodologies used for the studies in this thesis and is divided 
into three subsections.  The first part details patient recruitment and clinical 
assessments relating to PD patients with and without ICDs and matched healthy 
volunteers.  The second part explores the general methodological principles of PET.  
In the last subsection, the methodological basis of functional magnetic imaging is 
discussed.  Specific methodologies related to each study are detailed within the 
respective chapter. 
 
In Chapter 3, using positron emission tomography with 11C-RAC, I investigate 
whether passive viewing of rewarding visual cues has an effect in striatal dopamine 
neurotransmission in PD patients with and without impulse control disorders.   
 
Chapter 4 examines punding behaviour in PD patients, and its associated striatal 
dopamine D2 receptor binding compared to a PD control group using PET with 11C-
RAC.   
 
In Chapter 5, I use functional MRI to explore changes in striatal BOLD signal in PD 
patients with compulsive sexual behaviour compared to a control group and discuss 
their associated clinico-behavioural differences. 
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Chapter 6 examines excessive Internet use in PD patients with ICDs and assesses their 
severity against a group of PD controls and healthy volunteers using the Yale-Brown 
Obsessive Compulsive Scale, adapted for Internet use.   
 
In Chapter 7, I discuss the main findings from my studies and suggest 
recommendations for future research for PD patients with impulse control disorders 
and related addictive behaviours. 
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Chapter 2 
Methodology 
 
 
2.1 Patient recruitment and clinical assessments 
2.1.1 Ethical approval 
All studies received ethical approval from the Hammersmith and Queen Charlotte’s 
and Chelsea Hospitals Research Ethics Committee.  Permission to administer 
radioactive substances was obtained from the Administration of Radioactive 
Substances Advisory Committee (ARSAC) of the Department of Health, UK.  The 
radioactive tracers were fully supplied by Hammersmith Imanet plc, London, UK. 
 
2.1.2 Subject recruitment and clinical assessment of participants with 
Parkinson’s disease 
Participants with PD were recruited from specialist Movement Disorder Clinics at 
Imperial College NHS Healthcare Trust and at the National Hospital for Neurology 
and Neurosurgery, Queen Square.  Healthy volunteers were recruited through 
advertisement in London newspapers, PD society UK, local PD newsletters and 
magazines and publicity posters.  
 
Each potential participant who showed an interest in the research project was invited 
to attend a brief meeting in a clinic room at the Cyclotron Building at Hammersmith 
Hospital.  The purpose of this was to allow for an opportunity to ask questions that 
they may have had after reading about the research project (from the patient 
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information leaflet given previously) and to obtain written consent.   Those who were 
interested in participating in studies involving PET imaging were given a tour of the 
scanning facilities. 
 
All subjects gave informed written consent in accordance with the Declaration of 
Helsinki (International Committee of Medical Journal Editors, 1991).   
 
All participants who consented to participate in the research study were then 
scheduled for a detailed, face-to-face semi-structured interview.  This clinical 
interview lasted approximately one hour and consisted of a review of their history of 
Parkinson’s disease, their medications, a physical examination and the completion of 
a battery of clinico-behavioural questionnaires.  The name and dose of each anti-
parkinsonian medication was recorded and calculated into ‘levodopa equivalent daily 
dose (Evans et al., 2004) (see equation 1). 
 
Patients were also asked if they wanted to have their carer or spouse present during 
these research sessions to help with completion of questionnaires or collateral history.  
I also talked with the carers regarding the confidentiality of these sessions and that 
they may be asked to leave the room at the patient’s request. 
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2.1.3 Diagnosis of Parkinson’s disease 
A full medical history was taken where participants were asked to provide 
chronological details of their symptoms similar to attending a first consultation with a 
neurologist in a clinical setting.  For each symptom related to their Parkinson’s 
disease, they were asked to give further information as appropriate, such as time of 
onset and details related to severity.  Following this, each patient was asked about 
other aspects of his or her medical history such as past medical illnesses, systems 
review, drug history, social history and any other relevant information. 
 
The parkinsonian symptoms reported by the patient were checked to ensure that they 
satisfied the clinical diagnostic criteria given by the UK Parkinson’s Disease Society 
Brain Bank’s clinical criteria (Hughes et al., 1992).   
 
2.1.4 Assessment for evidence of impulse control disorders 
During the face-to-face interview, using open-ended questions, patients were asked if 
they had ever experienced impulse control disorders in their lifetime and particularly 
since they have been diagnosed with PD.   Following this, patients were asked 
specifically about particular impulse control disorders such as gambling, binge eating, 
shopping and compulsive sexual behaviour.  Patients were also asked specific 
questions related to their medication intake, punding behaviour and Internet use.   
Patients were subsequently assessed for ICD and related behaviours using the 
diagnostic criteria detailed in Appendices 2–8. 
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2.1.5 Medication review 
Patients were asked to provide a list of their anti-parkinsonian medication and the 
length of time they had been on that specific medication.  Those who were assessed to 
have evidence of any ICDs and related behaviours were asked to provide details of 
any medications when the behaviour started and any subsequent medication changes.  
Patients were also asked to provide the names and doses of all medications for 
treatment of other medical conditions (if any).  
 
2.1.5.1 Calculation of L-Dopa equivalent daily dose  
Calculation of an L-Dopa equivalent daily dose (LEDD) for each patient was based 
on theoretical equivalence to L-Dopa as described in Evans et al. (2004). 
 
Equation 1. Calculation of L-dopa equivalent daily dose 
LEDD = L-Dopa dose + L-Dopa dose x 1/3 if on entacapone + bromocriptine (mg) x 10 + 
 cabergoline or pramipexole (mg) x 67 + ropinirole (mg) x 20 + pergolide (mg) 
 x100 + apomorphine (mg) x 8.   
 
 
2.1.6 Evaluation of motor symptoms 
Clinical evaluation of motor symptoms severity was performed using the United 
Parkinson’s Disease Rating Scale (UPDRS) – part III (Goetz et al., 2007) and a 
modified version of the Hoehn &Yahr scale (Hoehn & Yahr, 1967).   
 
During the semi-structured interview, subjects were assessed whilst on their own 
medications.  In studies detailed in subsequent chapters, subjects were assessed with 
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UPDRS Part III and H&Y staging in an OFF medication condition and in an ON 
medication condition after administration of L-Dopa 250/carbidopa 25.   
 
2.1.6.1 Unified Parkinson’s Disease Rating Scale (UPDRS)  
The UPDRS is currently the most established scale for assessing disability and 
impairment (Goetz et al., 2007; Ramaker, Marinus, Stiggelbout, & Van Hilten, 2002). 
It was developed in an attempt to combine elements of a number of scales to produce 
an efficient and flexible tool to monitor the impact of PD and the degree of disability 
caused.  The scale has three sections that evaluate the key areas of disability, together 
with a fourth section that evaluates any complications of treatment. Part I assesses 
cognition, behaviour and mood.  Part II is intended for the patient to evaluate their 
ability to carry out activities of daily life and includes tasks such as swallowing, 
handwriting and cutting food.  Part III of the UPDRS is used in the studies of this 
thesis to record the motor function of patients when ON and OFF medication (see 
Appendix 9).  It provides a comprehensive coverage of the cardinal motor symptoms 
in patients with PD (e.g. tremor, rigidity, bradykinesia, postural instability) and 
contains 27 questions (for 14 subitems) for the different body regions, scored from 0 
(normal) to 4 (maximal severity) with a maximum (worst) total score of 108.  Finally, 
Part IV assesses complications of antiparkinsonian therapy, such as dyskinesias, 
dystonia and symptomatic orthostasis. 
 
2.1.6.2 Hoehn and Yahr scale 
The Hoehn and Yahr scale (H&Y) is commonly used in clinical studies to compare 
groups of patients and to provide gross assessment of disease progression (Hoehn & 
Yahr, 1967).  The modified H&Y staging assesses the relative level of disability as 
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follows: stage 0 = no signs of disease; stage 1= unilateral disease; stage 1.5 = 
unilateral plus axial involvement; stage 2= bilateral disease without impairment of 
balance; stage 2.5 = mild bilateral disease with recovery on pull test; stage 3 = mild to 
moderate bilateral disease with some postural instability, but physically independent 
stage 4 = severe disability but still able to walk or stand unassisted and stage 5 = 
wheelchair-bound or bedridden unless aided (Goetz et al., 2004). 
 
2.1.7 Other clinical assessments 
All participants also underwent the following assessments. 
 
2.1.7.1 Mini-mental state examination  
Introduced in 1975 by Folstein and colleagues, the Mini-Mental State Examination 
(MMSE) is a 30-point questionnaire test that is used to screen for cognitive 
impairment (Folstein, Folstein, & McHugh, 1975). It tests for different facets of 
cognition such as orientation in time and place of the test, repeating lists of words, 
arithmetic, language use and comprehension, short-term memory and basic motor 
skills. It can also be used as a guide to evaluate the severity of the impairment.  The 
maximum score is 30; a score greater than or equal to 25 points indicates normal 
cognition.  Attainment of 21 to 24 points indicates mild cognitive impairment, 10 to 
20 points indicates moderate impairment, and any score less than 9 points indicates 
severe impairment. 
 
In the study for this PhD, patients scoring below 26 were excluded because of the 
requirement to complete self-administered questionnaires. 
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2.1.7.2 Beck Depression Inventory version II  
The Beck Depression Inventory-II (BDI-II) created by Dr Aaron T Beck is one of the 
most widely used instruments for measuring the severity of depression.  The revision 
in 1996 (Beck, Steer, Ball, & Ranieri, 1996) made the questionnaire more consistent 
with the Diagnostic and Statistical Manual – IV (DSM-IV) criteria for depression.   
The scale consists of 21 multiple-choice questions, where each statement ranges from 
zero to three with a maximum total score of 63.  Subjects pick one statement in each 
group that best describes the way they have been feeling during the past two weeks 
(including the day of the test).  A score of 0–13 refers to minimal depression, 14–19 
indicates mild depression, 20–28 refers to moderate depression and 29 and above 
denotes severe depression (i.e. the higher the total score, the more severe the 
depressive symptoms). The BDI-II is shown to have a high one-week test-retest 
reliability (Pearson r=0.93), suggesting that it was not overly sensitive to daily 
variations in mood. This self-reporting depression screening tool has been validated in 
patients with PD, with the optimal cut-off for discriminating between depressed and 
non-depressed PD patients set at 16–17 for BDI II (Leetjens et al 2000; Silberman et 
al 2006).  BDI-II was used for all subjects during their semi-structured clinical 
interview for screening of depression.  
 
2.1.7.3 Alcohol Use Disorder Identification Test (AUDIT) 
This questionnaire was developed by WHO and consists of 10 questions to determine 
if an individual’s alcohol consumption may be harmful (Saunders, Aasland, Babor, de 
la Fuente, & Grant, 1993).  Questions 1 to 3 ask about alcohol consumption, 4 to 6 
relate to alcohol dependence and 7 to 10 consider alcohol-related problems.  A score 
of 8 or more in men and 7 or more in women indicates that the individual is likely to 
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be consuming harmful levels of alcohol.  A score of 20 or above suggests alcohol 
dependence (Babor, Higgins-Biddle, Saunders, & Monteiro, 2006). 
 
2.1.7.4 The Fagerstrom Test for Nicotine Dependence (FTND) 
This six-item questionnaire was designed to screen for nicotine dependence 
(Heatherton, Kozlowski, Frecker, & Fagerstrom, 1993).  A score of 1–2 indicates low 
dependence, 3–4 indicates low to moderate dependence, 5–7 moderate dependence 
and 8 or above high dependence. 
 
2.1.8 Clinical assessment of non-PD participants (healthy volunteers) 
Similar to PD participants, healthy volunteers attended an initial brief interview.  The 
purpose of this was to obtain written consent and to allow for an opportunity to ask 
questions that they may have after reading about the research project (from the patient 
information leaflet sent to them previously).  Those that were interested in 
participating in studies involving PET imaging were given a tour of the scanning 
facilities. 
 
They were subsequently scheduled for a face-to-face assessment where a detailed 
medical history and physical examination were performed.  Anyone with major 
psychiatric comorbidity was excluded from the research.  The healthy volunteers also 
underwent self-completed questionnaires to assess for different types of ICDs 
(Appendices 2–8). 
 
All normal controls recruited were in good healthy and did not have any history of 
neurological or psychiatric illnesses, and were not taking any medication. 
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2.1.9 Diagnostic criteria used for evaluating impulsive-compulsive disorders and 
related behaviours 
During the semi-structured interview, I assessed each patient against the diagnostic 
criteria for the four most commonly reported ICDs and related addictive behaviours in 
Parkinson’s disease patients. 
 
2.1.9.1 Gambling  
See Appendix 2. 
  
2.1.9.2 Compulsive sexual behaviour 
See Appendix 3. 
 
2.1.9.3 Compulsive buying 
See Appendix 4. 
 
2.1.9.4 Binge eating 
See Appendix 5. 
 
2.1.9.5 Dopamine Dysregulation Syndrome (DDS) 
See Appendix 6. 
 
2.1.9.6 Punding 
See Appendix 7. 
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2.1.10 Questionnaires used for assessment of impulse control and related 
disorders 
2.1.10.1 Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease 
(QUIP) 
The questionnaire was designed and validated as a screening instrument and consists 
of three sections: Section 1 assesses for four commonly occurring ICDs (compulsive 
gambling, sexual, buying and eating behaviours) and consists of five questions 
including an introductory question that defines and gives examples of problem 
behaviours; section 2 assesses for other compulsive behaviours (punding, hobbyism, 
and walkabout) through three distinct introductory questions and two common 
additional questions; and section 3 assesses for compulsive medication use using five 
questions.  The QUIP was tested on a sample of 157 patients with idiopathic PD.  The 
ICD section of the QUIP has at least 80% sensitivity and specificity for each of the 
four ICDs.  The sensitivity and specificity for the hobbyism subsection was >90% 
(Weintraub et al., 2009).   
 
This questionnaire acted as a screening test, taken at the beginning of the semi-
structured interview, and any positive answer was followed up to verify whether the 
patient had a clinically significant ICD or other compulsive behaviour.  
 
2.1.10.2 Brief Sensation Seeking Scale (BSSS-4) 
Sensation seeking is a personality trait with a biological basis defined by the ‘seeking 
of varied, novel, complex and intense sensations and experiences, and the willingness 
to take physical, social, legal and financial risks for the sake of such experience’ 
(Zuckerman & Neeb, 1979).  Sensation seeking has been associated in a number of 
risky behaviours such as heavy drinking and drug abuse.  High sensation seekers tend 
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to go for activities that provide greater arousal.  Various sensation seeking scales exist 
to test for personality traits of thrill and adventure seeking, experience seeking, 
disinhibition and boredom susceptibility.  These characteristics have been found to be 
potential endophenotypes for ICDs.   The four-item index (BSSS-4) has been shown 
to perform similarly to longer measures (Stephenson, Hoyle, Palmgreen, & Slater, 
2003). 
 
2.1.10.3 Yale-Brown Obsessive Compulsive Scale, adapted for Internet 
The original Yale-Brown Obsessive Compulsive Scale (Y-BOCS) is a 10-item 
questionnaire which measures obsessive and compulsive elements separately 
(Goodman, Price, Rasmussen, Mazure, Fleischmann, et al., 1989). This questionnaire 
has been widely used and adapted for screening and evaluation of various impulsive-
compulsive behaviours, such as gambling (J. E. Grant et al., 2003), compulsive sexual 
behaviour (Coleman et al., 2010), and compulsive shopping (Monahan, Black, & 
Gabel, 1996).   The Y-BOCS has been widely used in the general population among 
those with OCD and/or ICD with good validity and reliability (Deacon & 
Abramowitz, 2005; Goodman, Price, Rasmussen, Mazure, Delgado, et al., 1989; J. E. 
Grant, Mancebo, Eisen, & Rasmussen, 2010) (J. E. Grant, Mancebo, Pinto, Eisen, & 
Rasmussen, 2006)  (Stengler-Wenzke, Kroll, Riedel-Heller, Matschinger, & 
Angermeyer, 2007).  The questionnaire has an equal number of questions on 
obsessions and compulsions without giving bias to either component. It has also been 
successfully adapted for use on ICDs, showing good reliability and validity for 
pathological gambling (J. E. Grant et al., 2003; Pallanti, DeCaria, Grant, Urpe, & 
Hollander, 2005) and compulsive shopping (Black, Gabel, Hansen, & Schlosser, 
2000; Monahan et al., 1996; Mueller et al., 2008).    
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The Y-BOCS has been adapted for Internet use (Appendix 8) and applied in the study 
of pathological Internet use in Parkinson’s disease patients (Chapter 6).  Only non-
essential Internet usage (non-business or non-academic use) was evaluated, in line 
with recommendations for assessing PIU (K. Young, 2004). Participants were advised 
that ‘Internet use’ denotes access to the Internet via an electronic medium, to include 
laptop and desktop computers, tablet computers, smartphones and any other media 
through which Internet can be accessed. 
 
2.1.11 Statistics 
For the studies included in this thesis, SPSS (SPSS version 20 statistical software for 
Mac, SPSS Inc., IL, USA) software packages were used. 
 
For between-group comparisons regarding the clinical data, one-way ANOVA 
assumptions were tested with the Bartlett and Kolmogorov and Smirnov methods.  
Where a successful normality test was obtained and SDs were not different among 
groups tested, one-way ANOVA was used and multiple comparisons were checked 
with the Bonferroni post hoc test.  Where normality tests failed and SDs were 
different among groups tested, the nonparametric Kruskal-Wallis test was used and 
multiple comparisons were checked with Dunn’s test. The significance (alpha level) 
was set at p<0.05 corrected, and all significance levels reported in two-group 
comparisons in this thesis are two-tailed. 
 
Additional statistical studies employed in each study are documented in the methods 
section of each chapter. 
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2.2 Positron Emission Tomography (PET) 
methodology  
2.2.1 Introduction on Positron Emission Tomography  
Positron Emission Tomography (PET) is a nuclear medicine imaging technique that 
measures biological processes of a given tissue by mapping the functional activity 
through short-lived radionuclides (A. Paans & van Waarde, 2002).  The PET 
technique is unique in that it detects metabolism within living tissue (in vivo), where 
as other types of nuclear medicine detects the amount of radioactive substance 
collected in a body tissue at a certain location.  Positrons were first discovered in the 
1930s. They are particles of equal mass but have an opposite charge to electrons and 
are their anti-matter equivalent.  When emitted from an unstable nucleus, a positron 
travels one to three millimetres before colliding with an electron in the outer shell of 
an atom.  This results in annihilation, and the energy is emitted as two 511keV 
gamma rays, released at 180 degrees to each other.  The first positron imaging device 
was used in the early 1950s at Massachusetts General Hospital in Boston to detect 
brain tumours and other brain diseases.  The development of reconstruction 
algorithms associated with Computed Tomography (CT) imaging induced a 
widespread interest in PET technology.  Since the mid 1980s, PET has become a tool 
for medical diagnosis, dynamic studies of human metabolism and studies of brain 
activation (A. M. Paans, van Waarde, Elsinga, Willemsen, & Vaalburg, 2002). 
Subsequently, one of its major applications has been in furthering our understanding 
of complex neurological disorders like PD. 
 
PET imaging starts with the injection of an active tracer (for example, raclopride or 
flurodopa), a biological molecule which carries a positron emitting isotope such as 
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carbon-11 (half life, t1/2=20 minutes) and fluorine 18 (t1/2=110 minutes). The half life, 
t1/2, for radioisotopes is the amount of time it takes for half of the label to decay; the 
faster the decay, the less time between injection and scanning. 
 
Within minutes, the molecule accumulates in an area of the body for which it has an 
affinity. These positrons collide with free electrons, usually no farther away than 1mm 
from point of emission.  The collision results in a conversion from matter to energy 
and emits two high-energy gamma rays in opposite directions (Figure 2).  These, after 
administration, can be recorded simultaneously by a pair of detectors and the 
annihilation processed that occurred along the line connecting the detectors.  The 
exact position of the annihilation can be computed by measuring the time difference 
between the arrivals of the two rays.  The information is recorded in real time to 
obtain structural and kinetic information, such as the distribution of receptors in the 
brain or areas of increased blood flow stimulation.   
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Figure 2. Principle of PET imaging - the collision of a positron with an electron results 
in two gamma rays emitted in opposite directions 
 
 
 (Reproduced from  
http://www.cs.uni-magdeburg.de/~nroeber/english/intern/node15.html#122) 
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2.2.1.1 Advantages of PET imaging 
PET has high sensitivity and provides good spatial and temporal resolution by 
accurately determining the activity concentration of the radiotracer within a volume.  
The resolution of images from a PET scan is two to three fold higer than Single 
Photon Emission Computerised Tomography (SPECT), another imaging technique 
that also uses gamma rays - commonly used to help with the clinical diagnosis of PD 
[also known as a DaT (dopamine transporter) scan].  The unique advantage of PET 
over other modalities is its ability to determine tissue metabolism in vivo by 
measuring the activity concentration of a radiotracer within a volume.  Using different 
radiotracers, it is possible to measure blood flow, oxygen concentration and glucose 
metabolism.  In a research context, this allows for measurement of different 
compounds to further our understanding of the underlying biology of different tissue 
states.  Applied clinically, PET is useful for diagnosis of different conditions and is 
excellent at differentiating between benign and malignant tissue; as such, it is also 
useful to monitor for response to treatment (e.g. chemotherapy).   
 
2.2.1.2 Disadvantages of PET imaging 
PET is limited by the high costs involved in producing the radioisotopes and the 
specialised on-site chemical synthesis apparatus. In addition, it involves exposure to 
ionising radiation.  The total dose of radiation is small, however – usually around 
7mSv.  This can be compared to 2.2mSv average background radiation in the UK, 
0.02mSv for a chest x-ray, up to 8mSv for a CT scan of the chest and 2-6mSv per 
annum for aircrews. 
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2.2.2 The cyclotron 
The process of isotope production begins with the production of negatively charged 
hydrogen ions in a particle accelerator called a cyclotron.  The particle is usually 
produced from an ion source, either a proton or deuteron.  These particles are injected 
into the cyclotron through a beam. The cyclotron accelerates charged particle beams 
using a high frequency alternating voltage applied between two ‘D’-shaped electrodes 
(the ‘dees’).  An additional static magnetic field is applied in a perpendicular direction 
to the electrode plane, enabling particles to re-encounter the accelerating voltage 
many times at the same phase (Figure 3).  These negatively charged hydrogen ions are 
converted into positively charged protons.  The interaction of protons with the stable 
forms of elements such as oxygen, nitrogen or carbon converts them to a radioactive 
condition.  The radioactive condition is largely unstable because it possesses too 
many protons and is called radioisotope. 
 
As the particle gains energy, it follows a spiral path from the centre of the cyclotron 
as a maximum radius from where it is then focused by an electrostatic deflecting 
beam to bombard a target.  Through computer software, the radioisotopes are then 
made to attach to the synthetic molecule of interest, such as raclopride, DASB or 
flurodopa in a biosynthesiser unit called a hot cell. 
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Figure 3. Principles of the cyclotron. 
 
 
 
The accelerating electric field reverses just at the time the electrons finish their half circle so that it 
accelerates them across the gap.  With a higher speed, they move in a larger semicircle.  After repeating 
this process several times, they come out the exit port at a high speed.  
(Reproduced from http://hyperphysics.phy-astr.gsu.edu/hbase/magnetic/cyclot.html) 
!!
82!
2.2.3 Coincidence detection 
The radionuclide in the radiotracer decays, and the resulting positrons subsequently 
annihilate on contact with electrons after travelling a short distance of several 
millimetres within the body.  Each annihilation produces two gamma rays (511 keV 
photons) travelling in opposite directions (Figure 4).  The gamma rays can be detected 
by a detector made from a scintillation bismuth germanate crystal connected to a 
photomultiplier tube.  The detector electronics are linked so that two detection events 
unambiguously occurring within a certain time window (a coincident) is determined 
to have come from the same annihilation.  The scintillation crystal emits low-energy 
photons (visible light) after interaction with high-energy photons (gamma rays).  The 
photomuliplier tube then converts the scintillation events into electrical pulses (Figure 
5). 
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Figure 4. Positron annihilation to produce two gamma rays (511keV) 
 
(Reproduced from http://depts.washington.edu/nucmed/IRL/pet_intro/intro_src/section2.html) 
 
 
 
Figure 5. Coincident detection. 
 
(Reproduced from http://depts.washington.edu/nucmed/IRL/pet_intro/intro_src/section2.html) 
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The size of the crystal detection system is a major factor in the resolution of the PET 
camera, and the maximal physical image resolution is approximately 1.1 to 1.2 times 
greater than the width of the individual detector crystals.  In current PET scanners, the 
detector is made of multiple rings stacked on top of each other to detect volumetric 
data from a wide field of view (FOV).  In two-dimensional scanning, the coincidences 
within the same ring define an intra-ring image, and coincidences between adjacent 
rings form independent inter-ring images (cross-planes).  In a three-dimensional 
scanning, coincidence detected between all rings are counted, which results in a six-
fold increase in signal but also an increase in count due to scatter (Cherry, Woods, 
Hoffman, & Mazziotta, 1993).  When scattered events are subtracted, the efficiency of 
coincidence detection at the centre of the FOV increases by a factor of 4.8 (Spinks et 
al., 1992). The advantage of 3D acquisition over 2D is that scans of comparable 
quality can be obtained by using four times less radiation.  
 
2.2.3.1 Types of coincidence events 
PET radiotracers emit positrons.  The PET tracers produce positively charged 
positrons that travel a short distance in the brain before colliding with a negatively 
charged electron.  The positron and the electron annihilate each other and, in the 
process, emit two gamma ray photons (511 KeV) at 180 degrees to each other.  The 
photons are detected as ‘pairs in coincidence’ by a series of specialised detectors 
arranged in a ring around the subject.   A coincidence event is assigned to a line of 
response (LOR) joining the two relevant detectors, which gives positional information 
on the detected radiation.   
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‘True’ coincidences occur when both photons from an annihilation event are detected 
by detectors in coincidence, neither photon undergoes any form of interaction prior to 
detection and no other event is detected within the coincidence time-window. 
 
‘Random’ coincidences occur when two photons from separate annihilation events are 
detected simultaneously at opposing detectors.  These are identified by introducing a 
delay into one side of the coincidence detection circuit by 48nsecs, and coincidences 
resulting from a single annihilation event are not detected under these circumstances.  
 
Annihilation events in which one of the photons is deflected (‘scattered’) but in which 
the two photons are nevertheless detected simultaneously at opposing detectors can 
still constitute a proportion of the true rate.  However, scattered photons tend to have 
lower energy, and so the scatter fraction may be minimised by energy windowing.  
Scattered coincidences can add statistical noise to the signal.   
 
‘Multiple’ coincidences occur when more than two photons are detected in different 
detectors within the coincidence resolving time.  In this situation, it is not possible to 
determine the LOR to which the event should be assigned, and the event is rejected. 
 
2.2.4 Image reconstruction and attenuation correction 
True coincidence events detected are recorded in real time as a series of histograms by 
a computer system and sorted into sinograms.  The computer then generates 3-
dimensional images through the application of a ‘filtered back projection’ 
reconstruction algorithm similar to that used in computed tomography (CT) (Phelps, 
1977).  The algorithm consists of the projection of a series of radiation profiles 
!!
86!
(sinograms) recorded at different angles to produce a cross-sectional image of the 
original distribution of radioactivity.  The sinograms used in image reconstruction in 
PET represent the distribution of activity in the scanned tissue, reduced by tissue 
attenuation.  It is, therefore, necessary to correct for this attenuation in order to allow 
for true quantitative reconstruction. 
 
The tissue attenuation is measured by performing transmission and blank emission 
scans.  A 5- to 10-minute transmission scan is performed prior to injection of the 
tracer to correct for tissue attenuation of gamma radiation.  The radioisotopes (known 
as PET tracers) are injected as IV bolus in the bloodstream where they migrate to the 
regions of interest (ROI).  The injection is followed by a phase called ‘time lag’, 
where the scanner records the concentration and distribution of the tracer. 
 
In a transmission scan, the tissue attenuation of 511keV photons along all coincidence 
lines is calculated by exposing the subject to be imaged to an external ring or rotating 
point positron source emitting 511keV gamma radiation, usually 68Ge-68Ga.  The 
blank emission scan is performed with no tissue between the detector rings to detect 
levels of background radiation.  The ratio of the blank and transmission scan data 
provides attenuation coefficients for 511keV gamma rays on a voxel basis for the 
object to be studied. 
 
2.2.5 PET scanner 
PET scans for the studies in this PhD thesis were performed with a CTI/Siemens 962 
ECAT HR+ (Siemens; Munich, Germany) 3D PET camera with a total axial field of 
view (FOV) of 15.5 cm.  This camera has a mean image trans-axial resolution (3D 
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mode) over a 10 cm radius FOV (from the centre) of 6.0±0.5 mm and an axial 
resolution of 5.0±0.8 mm (Brix et al., 1997). 
 
2.2.6 PET Radioligand: 11C-raclopride 
The radioisotope 11C-raclopride (RAC) was used for the studies in this thesis project   
RAC is a synthetic compound of the salicylamide series that has been used over the 
last two decades in PET imaging as a marker for dopamine D2 and D3 receptor 
binding by acting as a reversible antagonist (Farde, Hall, Ehrin, & Sedvall, 1986).  
This has allowed scientists to directly assess the availability of D2 receptors and, 
indirectly, the levels of pre-synaptic dopamine release and has been used in a number 
of studies on PD (Antonini, Schwarz, Oertel, Pogarell, & Leenders, 1997; Rinne et al., 
1993). 
 
Several pharmacological aspects of RAC make it a suitable radioligand for PET.  It 
has a low nanomolar affinity for D2 and D3 receptors and a low lipophilicity such that 
the tracer reaches equilibrium between brain and plasma after IV administration 
within the time course of a PET scan (Farde et al., 1986).  Being a reversible 
antagonist of D2 receptors, its uptake in the brain is influenced by endogenous 
dopamine and competes for D2 receptor binding with endogenous dopamine.  Early 
studies reported a rapid uptake of ligand by the brain, with striatal radioactivity 
reaching a peak at 25 minutes post IV injection and then slowly declining as 
dissociation from binding sites occurred.  Cerebellar activity peaked rapidly and then 
declined throughout the time course of the scan (Farde et al., 1986). 
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RAC also has a good safety and tolerability profile, with the majority of the tracer 
being rapidly excreted through the renal system (Ribeiro et al., 2005).  The mean 
effective dose of RAC for normal adults was estimated to be 6.7 +/- 0.4µSv/MBq 
(mean +/- SD).   It was also shown that by using 222 MBq for each injection, subjects 
may be able to undergo two to three PET scans per year for adequate cerebral D2 
receptor imaging and for the evaluation of neuroprotective drugs (Ribeiro et al., 
2005).  The authors of another study have also found that the doses of RAC 
commonly used in PET research (270-555MBq) were much lower than the acceptable 
maximum single radiation dose under the USA federal regulations for studies 
performed under the Radiation Drug Research Committee (Slifstein et al., 2006). 
 
2.2.6.1 Displacement studies 
Neurotransmitter fluxes can be indirectly measured with PET imaging in the living 
human brain. When endogenous dopamine binds to D2 receptors, it competes with the 
reversible antagonists Raclopride (Figure 6).  This phenomenon allows synaptic 
dopamine levels to be estimated indirectly from changes in the tracer’s D2 receptor 
binding (Laruelle, 2000; Ross & Jackson, 1989). 
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Figure 6. Classic occupancy model of 11C-raclopride binding to dopamine D2 receptors 
 
 
Schematic representation of the Classic Occupancy Model adopted to explain the increase and decrease 
of 11C -raclopride binding following depletion or stimulation, respectively, of dopamine concentration 
in the vicinity of D2 receptors by dopamine.  At a tracer dose, 11C-raclopride occupies a fraction of the 
available receptors.  As such, the effective binding of 11C-raclopride is related to its binding potential, 
which in turn is affected by the presence of dopamine in a complex manner since dopamine affects 
both the number and affinity of the available sites.  Reproduced from Laruelle (2000). 
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Typically D2 binding of RAC is computed from regional brain Time Activity Curves 
(TACs) using the Simple Reference Tissue Model (SRTM), which assumes that the 
cerebellum is devoid of dopamine receptors, and so its TAC reflects non-specific 
binding levels in other brain regions.  Following challenges that increase synaptic 
dopamine concentrations, reductions in radiotracer BPND are assumed to directly 
reflect changes in the availability of D2 receptors due to occupancy by endogenous 
dopamine (Laruelle, 2000). 
 
In reality, this theory is probably more complex as binding of dopamine leads to 
internalisation of D2 receptors (Ginovart, 2005).  However this does not invalidate the 
Classic Occupancy Model as RAC can only bind to D2 receptors on the cell surface 
due to its low lipophilicity, preventing diffusion through plasma membranes into the 
cell cytoplasm (Laruelle, 2000).  Increase in dopamine synaptic concentrations can be 
achieved in vivo by administering inhibitors of the Dopamine Transporter (DAT) such 
as methylphenidate (Volkow et al., 1994) and cocaine (Schlaepfer, Pearlson, Wong, 
Marenco, & Dannals, 1997) or with dopamine releasers such as amphetamines 
(Ginovart, Farde, Halldin, & Swahn, 1999; Laruelle, 2000).  
 
2.2.7 PET scanning procedures 
A schematic diagram of the PET scanning procedure is illustrated in Figure 7.  
 
 
 
 
 
!!
91!
Figure 7. Overview schematic flow chart of the PET imaging process. 
 
Figure legend: ON scan denotes PET scan following 250 mg levodopa challenge taken 60 minutes 
prior to start of scan. 
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All participants underwent RAC scans on a weekday morning (1100–1300) after a 12-
hour withdrawal of their medications for PD. Patients were instructed to fast from 10 
PM the evening before each scan and to avoid alcohol, smoking, and caffeinated 
beverages for at least 12 hours before scanning.    
 
PET scans were performed with a CTI/Siemens 962 ECAT HR+ (Siemens; Munich, 
Germany) 3D PET camera with a total axial field of view (FOV) of 15.5 cm.  This 
camera has a mean image trans-axial resolution (3D mode) over a 10 cm radius FOV 
(from the centre) of 6.0±0.5 mm and an axial resolution of 5.0±0.8 mm (Brix et al., 
1997).  A mean dose of 250 MBq 11C -RAC was administered as an intravenous bolus 
over 10 seconds.  Dynamic data were collected over 60 minutes as 20 time frames.  
The patient’s head movement was minimised using a soft head-strap, and position 
was monitored using a laser system to ensure that the detectors and orbito-meatal line 
were parallel throughout the scan. 
 
2.2.8  Tracer kinetic modelling 
For RAC data analysis, the estimation of binding potential (BP) was performed using 
quantitative tracer kinetic modelling.  Based on in vitro radioligand, BP is defined as 
the ration of Bmax (receptor density) to KD (radioligand equilibrium dissociation 
constant). See Equation 2.  As the affinity of ligand binding is the inverse of KD, BP 
can be equivalently viewed as the product of Bmax and affinity (Mintun, Raichle, 
Kilbourn, Wooten, & Welch, 1984) . 
 
Equation 2. Estimation of binding potential 
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In vivo BP measures target receptors in terms of specific radioligand binding.  
Specific binding is defined as that associated with the target and distinct from 
radioligand which is free in solutions or nonspecifically associated with other 
macromolecular components.  BP quantifies the equilibrium concentration of specific 
binding as a ratio to some other reference concentration (Innis et al., 2007). 
 
BPND refers to the ratio at equilibrium of specifically bound radioligand to that of non-
displacable radioligand in tissue. The BPND measurement compares the concentration 
of radioligand in receptor-rich to receptor-free regions, and forms the basis of 
Simplified Reference Tissue Compartmental Model (SRTM) (Gunn, Lammertsma, 
Hume, & Cunningham, 1997; Lammertsma & Hume, 1996) that uses cerebellum as 
the reference tissue.  The BPND reflects but not typically equals Bmax/KD, which is 
true for in vitro measurements (Mintun et al., 1984).  BPND does not require blood 
sampling, and therefore it is relatively easy to implement.  However, use of BPND as 
an outcome measure relies on the assumption that non-displaceable uptake is 
independent of subject groups or treatment effects. 
 
2.2.9 Region of Interest (ROI) analysis 
The most common way to determine what the local activity concentration is in a PET 
image (or volume) is to define a region of interest (ROI) on an image using an 
analysis software package.  The average voxel value within the region is calculated.  
This value is then converted to an activity concentration in becquerels per millimetre.  
Because PET data sets are usually made up of a stack of images that form a volume, a 
volume of interest (VOI) can be defined by connecting several ROIs defined on 
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multiple contiguous planes into a single VOI.  If a dynamic sequence of images has 
been acquired, the ROI that has been defined can be applied to the same region on all 
images to generate a time activity curve (TAC) that shows the radiotracer 
concentration in a specific region of the body over time.  This time-dependent data set 
can then be used with a compartmental model to determine biologically meaningful 
parameters and to construct parametric images.  
 
Analysis of PET data in this thesis project was performed using a region-of-interest 
(ROI) approach.  Each scan generated 20 frames of dynamic images over 60 minutes.  
The dynamic images were calibrated and then summed to produce an ‘ADD image’.  
This consisted of the integrated total emission data for the whole brain during the 
scan.  The subdivisions and ‘ADD image’ were then normalised to an RAC template 
on Montreal Neurological Institute space using Statistical Parametric Mapping (SPM) 
software (SPM2; Wellcome Department of Cognitive Neurology, London).  The 
normalisation process allowed for the standardisation of the brain position and shape 
and facilitated the tracing of the ROIs, which were drawn manually with guidance 
from a well-established probabilistic brain atlas developed in-house (Duvernoy, 1999; 
Gousias et al., 2008).  The ROIs traced were left and right caudate, putamen and 
ventral striatum (Figure 8).  These striatal regions have an abundance of D2 receptors 
for the binding of the radioligand raclopride.  Each object map was applied to the 
dynamic images to generate time activity curves of brain uptake of 11C -RAC using 
ANALYZE 8.1 software (Mayo Clinic). For each patient, the average left and right 
caudate, putamen and ventral striatum regional binding potential (BPND) was 
calculated for statistical analysis using the SRTM, with the cerebellum as a reference 
region (Gunn et al., 1997; Lammertsma & Hume, 1996). The cerebellum is relatively 
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devoid of D2/3 receptors, and this method has been proven to be superior to kinetic 
modelling using arterial data. 
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Figure 8.  Striatal Region-of-Interests on an MRI T2 image 
Figure 8a. Caudate and Putamen (demonstrated by anatomical areas outlined in red 
and annotated in white letters on an MRI T2 image in the axial plane) 
 
Figure 8b. Ventral striatum (demonstrated by anatomical areas outlined in red and 
annotated in white letters on an MRI T2 image in the coronal plane) 
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2.3 Functional magnetic imaging methodology 
2.3.1 Introduction to functional magnetic imaging 
This section provides a brief account of the general principles of functional magnetic 
resonance imaging (fMRI) and the methodologies used in analysis of fMRI data. 
 
Functional magnetic resonance imaging is one of the most exciting methodologies to 
evolve in the last century and has capitalised on the physical principles discovered 
from nuclear magnetic resonance (NMR) and magnetic resonance imaging (MRI).  
Whereas MRI is used to produce structural images for anatomical and clinical studies, 
the functional component of fMRI allows for an indirect measure of activity of a 
particular tissue by measuring changes in oxygen levels of the blood.  This has proved 
to be invaluable to clinicians and scientists investigating the cognitive and 
behavioural aspects of the nervous system. 
 
2.3.2 Physiological principles of fMRI 
The fMRI method capitalises on magnetic differences between oxygenated and 
deoxygenated blood.  In short, haemoglobin in the blood becomes strongly 
paramagnetic in its deoxygenated state.  Deoxygenated haemoglobin can therefore be 
used as a naturally occurring contrast agent, with highly oxygenated brain regions 
producing a larger magnetic resonance (MR) signal than less oxygenated areas.  Thus, 
during brain activation, localised increases in blood flow will increase blood 
oxygenation and consequently reduce deoxygenated haemoglobin, causing the MR 
signal to increase.  It is assumed that these localised increases in blood oxygenation 
reflect increases in neuronal activity.  This method, blood-oxygenation-level 
dependent (BOLD) imaging, eliminates the need for exogenous contrast agents 
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(Kwong et al., 1992; Ogawa, Lee, Kay, & Tank, 1990; Turner, Le Bihan, & Chesnick, 
1991).   
 
2.3.2.1 Spin and radiofrequency pulse 
Atomic particles possess a property called spin.  In nuclei with an even number of 
protons and neutrons, the pairing of atomic particles leaves a net magnetic moment of 
zero.  In nuclei with an odd number of protons and neutrons, such as the hydrogen 
nucleus (1H), the unpaired particle has a net magnetic field.  They behave like tiny 
rotating magnets. MRI uses signals from nuclei with an odd number of protons or 
neutrons.  The signal from 1H, the most abundant atom in the brain, is the most 
commonly used signal for MRI.  In the presence of a magnetic field, the hydrogen 
atoms, which are present in the water molecules of the brain, align themselves with 
the magnetic field and reach an equilibrium state.  Exchange of energy between two 
systems at a specific frequency is called resonance.  
 
2.3.2.2 BOLD signal 
The BOLD fMRI technique is designed to measure changes in the inhomogeneity of 
the magnetic field that result from changes in blood oxygenation (Roy & Sherrington, 
1890).  However, the exact relationship between the MR signal and physiological 
mechanism underlying this signal is unclear.  The BOLD signal correlates best with 
the local field potential (LFP) rather than neuronal firing rates based on studies of 
simultaneous electrophysiological and fMRI BOLD recordings in non-human 
primates (Logothetis, Pauls, Augath, Trinath, & Oeltermann, 2001), suggesting that 
the BOLD signal reflects synaptic process rather than axonal spiking.  However, a 
separate study in humans using the same paradigm showed equal correlations between 
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local field potentials and BOLD compared to spike activity (action potential) and 
BOLD (Mukamel et al., 2005).    
 
Current data from the literature supports the theory that the BOLD signal correlates 
better with local field potential (reflecting inputs and intrinsic activity) than neuronal 
firing rates (reflecting outputs).  This is in keeping with the organisation of the 
cerebral cortex.  The vast majority of excitatory and inhibitory neurons terminating on 
a cell in the cerebral cortex originate from neighbouring cells in close vicinity to the 
synapse (Sillito & Jones, 2002).  Given that the BOLD signal likely has a positive 
relationship with both synaptic activity and action potentials, the BOLD signal may 
be interpreted as reflecting increased activation in that region for a specific 
experimental condition.  It is worthy to note that the BOLD signal does not 
distinguish between inhibitory or excitatory synaptic activity.  Local field potentials 
can be excitatory (70–80% of cortex) or inhibitory (20% of cortex).  However, in 
theory, since the BOLD signal reflects both synaptic activity and action potentials, 
inhibitory synaptic activity may decrease BOLD signals by reducing net spiking 
potential. 
 
To date, most studies have relied on the phasic changes in the BOLD signal to 
indicate neural activations.  These changes occur over several seconds.  Following the 
presentation of a stimulus, the fMRI signal begins to increase after a few seconds and 
does not peak until approximately 5 to 6 seconds after the stimulus.  Subsequently, 
when the stimulus is turned off, or activity ends, the signal takes approximately 10 to 
12 seconds to return to baseline (Figure 8).  However, rather than settling directly 
back to baseline, the BOLD signal decreases below baseline for a short period; this is 
!!
100!
referred to as the post-undershoot (Buxton, Wong, & Frank, 1998), and is called the 
Haemodynamic Response Function (HRF).  This relatively long haemodynamic 
response was originally considered as a limitation for the temporal resolution of fMRI 
studies.  However, this has been overcome by the development of event-related 
designs and selective trial averaging so that it is now possible to measure activation 
over events just two seconds apart (Dale & Buckner, 1997).  
  
The HRF profile shows some variability both between subjects and between different 
brain regions.  When repetitive transient neural activations occur in close temporal 
succession, the resulting HRFs sum non-linearly (Glover, 1999).   Furthermore, this 
non-linear summation also varies between cortical regions.  To limit the effects of 
closely temporally related stimuli, the following measures were employed for the 
fMRI study conducted in Chapter 5: the experiment was a block-design paradigm, 
with each block of stimuli lasting 14.7s.  Within each block, seven images were 
displayed consecutively, each pictorial image was displayed for 2100ms and each 
thematic block was followed by a 4000ms rating slide, followed by 1000ms 
interstimulus interval of a fixation cross.  In addition stimulus times were staggered 
relative to scan times by ensuring that trials and TR were non-integer multiples of one 
another to ensure a higher effective sampling rate. 
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Figure 9. The haemodynamic response function of fMRI (reproduced from Heeger and 
Rees, 2002). 
 
 
There are several characteristics of the BOLD fMRI signal that affect the design of 
imaging studies and the interpretation of their results.  These include stimulus 
characteristics such as duration, presentation rate and stimulus intensity.  Most 
importantly, these effects vary as a function of the stimulus type (e.g. visual vs. 
affective) and brain region of interest (e.g. visual cortex vs. amygdala). 
 
2.3.3 Block vs. event-related designs 
Two types of fMRI study designs are commonly employed: block design and event-
related design.  Block design is an epoch-based design using blocks of stimulation and 
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event-related design is where data are recorded to monitor the BOLD response 
following a marked (pre-determined) event such as a single stimulus or task. 
 
Block design experiments (Bandettini, Wong, Jesmanowicz, Hinks, & Hyde, 1994) 
are used to average across many trials to obtain sufficient signal-to-ratios to generate 
functional activation images.   
 
The disadvantages of Block designs are that they do not allow separate trials within 
the task blocks to be distinguished.  Block designs are not feasible if we want to 
consider trials that depend on a subject’s performance (e.g. correct or wrong; 
choosing among different alternatives) or need to present trials in a non-blocked 
fashion (e.g. the oddball paradigm).  In contrast, Dale and Buckner (1997) 
demonstrated the possibility of using fMRI for selective averaging of rapidly 
presented individual trial events – a technique that was used in event-related potential 
(ERP) studies such as EEG/MEG.  It is shown that the haemodynamic response is 
delayed and lasts for several seconds even for brief stimulations.  As the 
haemodynamic response to individual trials extends temporally, the responses to 
successive trials may overlap.  Hence, the inter-trial interval between successive trials 
needs to last for about 15 seconds.  However, this severely limits the number of trials, 
which can be averaged per unit time, thus limiting the achievable signal-to-noise ratio.  
Dale and Buckner (1997) demonstrated that the haemodynamic response to successive 
events summates in an approximately linear fashion even at relatively short inter-trial 
intervals (2 and 5 seconds), and hence selective averaging of rapidly presented 
individual trials is feasible.  These finding support the Linear Time Invariant Model 
for the haemodynamic response function (Boynton, Engel, Glover, & Heeger, 1996).  
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Dale has shown that the statistical efficiency of rapid event-related designs when the 
inter-trial interval is appropriately jittered can be up to 10 times greater than fixed 
inter-trial interval designs (Dale, 1999).  Further, random intermixing of trial types 
eliminates strategy effects that might otherwise confound the results in blocked task 
paradigms.   
 
2.3.4 fMRI data pre-processing 
Pre-processing is a necessary step to transform raw fMRI data into a format that is 
suitable to be statistically analysed.  This process involves correcting the slice time, 
spatial realignment to the first volume to account for movement, and then spatially 
normalisation.  The image analysis for the fMRI study (Chapter 5) was conducted 
using Statistical Parametric Mapping, SPM 5 (Wellcome Department of Imaging 
Neuroscience, UCL, UK). 
 
2.3.4.1 Spatial and temporal realignment 
Despite the liberal use of foam support and head restraints during scanning, subjects 
commonly show several millimetres of displacement and several degrees of rotation 
during a scan, leading to voxel misalignment and additional variance. Spatial 
realignment is crucial given that we use such a small voxel size in fMRI practice 
(3x3x3 mm).  Spatial preprocessing involves a rigid body (6 degrees of freedom) 
transformation to minimise the sum of squared difference of voxel intensity between 
successive scans and a reference scan (T1 structural scan). A rigid body can have a 
linear translational movement or a rotational movement in each of the three directions 
(X, Y and Z). Correspondingly, there are six parameters that need to be estimated (X, 
Y, Z translations, pitch, roll and yaw). For multi-session data, realignment works in 
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two steps. First, the first functional images from each session are realigned to each 
other, taking the first session as reference. Second, the remaining images within each 
session are realigned to the first image. As a consequence, all images are realigned to 
the first image from the first session. The echo planar images are then re-sampled and 
a mean echo planar image volume is generated. 
 
The EPI time series are then normalised and spatially smoothed.  Each individual 
subject’s data were pre-processed independently. 
 
2.3.4.2 Spatial normalisation 
The process of normalisation refers to transformation of fMRI data into a standardised 
anatomical space.  In the fMRI study in this thesis project, all echoplanar data were 
spatially normalised to a standard brain using Montreal Neurological Institute 
standard stereotactic space using parameters from the segmented T1 structural image. 
 
2.3.4.3 Spatial smoothing 
In an fMRI study involving multiple subjects, echo-planar images for each subject are 
smoothed prior to statistical analysis so that corresponding sites of activation can be 
superimposed.  Smoothing has the effect of increasing signal to noise ratio.   The idea 
of smoothing is to replace the intensity value within each voxel with a weighted 
average (as determined by a Gaussian kernel centred on that particular voxel) that 
incorporates the intensity values of the neighbouring voxels.  From the matched filter 
theorem, a filter that is matched to the signal should be employed to achieve optimum 
resolution of signal from noise, and since haemodynamic responses are modelled to 
have a Gaussian shape, a Gaussian kernel of the size of at least twice the voxel size 
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should be used for smoothing of the functional images (Full Width Half Maximum 
[FWHM] of 6 to 8 mm).  In the study in Chapter 5, a FWHM of 8 mm was used.   
Smoothing is performed to compensate for residual between-subject variability after 
normalisation.  Smoothing also permits the application of Gaussian random field 
theory at the statistics inference stage. 
 
The resultant advantages of spatial smoothing are therefore several fold: smoothing 
will make errors more normally distributed and ensure that subsequent parametric 
statistics are valid, and spatial smoothing can accommodate inter-subject differences 
in anatomical variability at homologous brain regions. 
 
2.3.5 Basic principles of fMRI analysis  
Functional specialisation and integration are important principles central to the 
science of neuroimaging.  Function specialisation refers to the anatomically distinct 
neural areas specialised to perform specific cognitive or motor function.  This is in 
contrast to functional integration, which relates to the interaction between these 
functionally segregated areas.  fMRI uses the haemodynamic responses 
accompanying mental processes to investigate the localisation and integration of these 
functions in the brain, for which one of the most common methods is statistic 
parametric mapping (SPM), which uses mass univariate statistical tests (one of each 
voxel in the image volume).    
 
SPM links the measured BOLD response and task components using a design matrix 
allowing incorporation of a wide range of task-related and task-unrelated factors 
within the same model.  The General Linear Model (GLM) is a statistical model 
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which provides a framework for parameter estimation for each factor at each image 
voxel.  This results in statistical parameters which form an image – the statistical 
parametric map (SPM). 
 
The design matrix is separated into effects of interest and confounders, such as 
residual variance associated with head movement and error.  The main effects of 
different psychological inputs can then be modelled as stick functions or blocks of 
stimulation in separate columns of the design matrix.  To approximate the 
haemodynamic response, each stick function, block of activity, parametric modulator 
and confound is convolved with a canonical HRF (Friston, 2004).  Session effects, 
covariates, and low frequency drift of the magnetic field are treated as confounds.  
The GLM is applied with the null hypothesis of no significant activation between 
event trials and baseline.  The design matrix is applied independently to all voxels and 
allows perturbing inputs (trial events) to be connected to all regions while discounting 
interactions between regions.  However, as the neuronal response of neighbouring 
voxels is often related and not truly dependent, correction for multiple corrections is 
applied, the most conservative of which is the Bonferroni corrector or Family-Wise 
error. 
 
One of the most commonly used tools to localise neural activities is the technique of 
cognitive subtraction.  If two or more closely related factors differ by only a single 
construct, calculating the net activity difference between the two tasks will identify 
neuronal activity specifically related to that factor.  Alternatively, two or more 
orthogonal factors can be modulated, and the interaction between these factors can be 
identified. 
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In fMRI analyses, because of short range serial temporal correlation, data rarely 
conform to the assumptions of independent and identical distribution used in standard 
statistical tests.  To account for the temporal correlation, the error structure is 
modelled with a first-degree auto-regressive process and solved using Restricted 
Maximum Likelihood, producing corrected degrees of freedom.  This technique is 
employed in first-level analysis, together with the application of random field theory, 
to produce a SPM for each subject.  Once completed for each subject for the study, 
second-level random effects analysis is performed to allow for generalisation of 
results to the whole cohort.  Summary statistics for each contrast of interest are 
concatenated across subjects with the associated error terms reflecting between 
subject variability.   
 
A random effects analysis can be carried out to find the areas that are activated in 
much the same way across all subjects, as opposed to a fixed-effects model, which 
gives areas that are activated on the average across the subjects.  The difference 
between fixed and random effects is crucial since a fixed effects analysis may yield 
significant results when one or a couple of subjects has a large activation whilst the 
other subjects do not show much activation.  The random effects analysis incorporates 
both within-subject variance as well as between-subject variance.  This allows 
generalisation of the results to the population from which the subjects were drawn. 
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Chapter 3 
PET imaging of impulse control 
disorders in Parkinson’s disease 
patients 
 
 
3.1 Introduction 
In this study, I use 11C-RAC with PET to investigate dopamine neurotransmission in 
PD patients with and without ICDs in response to reward-related visual cues. 
Exploration of this would be particularly pertinent to (1) elucidate the neurobiology 
underlying this group of patients and (2) to inform clinical management of these 
patients as they are more challenging to treat. 
 
3.2 Aims and hypotheses 
The aims of this study are: 
1. To investigate striatal dopamine neurotransmission across a broad spectrum of 
Parkinson’s disease-associated ICDs in relation to L-Dopa and reward cues.  
2. To compare dopamine neurotransmission between PD patients with comorbid 
ICDs, a single ICD and PD control patients in response to viewing of passive 
reward-related cues and neutral cues. 
3. To explore clinical and neuroimaging correlates between PD ICD patients as a 
group and controls, and to further examine these correlations between those 
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with comorbid ICDs, a single ICD and controls. 
 
I hypothesise that patients with ICDs would demonstrate sensitisation of their 
ventral striatal circuitry in response to reward-related cues compared to PD 
controls.  PD patients with comorbid ICDs will have greater ventral striatal 
dopamine release in response to reward-related cues compared to those with 
single ICDs and to controls.  I also hypothesise that PD patients with comorbid 
ICDs will also have characteristic traits showing greater risk-taking behaviour and 
greater clinical impairment compared to those with a single ICD and controls. 
 
3.3 Methods 
3.3.1 Participants 
A total of 17 patients with ICDs and nine control patients free from any symptoms of 
ICDs or other neurological and psychological comorbidities were studied.  All 
patients satisfied the Queen Square Brain Bank for Neurological Disorders clinical 
criteria for Parkinson’s disease (Hughes et al., 1992).  
3.3.2 Evaluation of clinical and behavioural characteristics 
All participants were assessed as detailed in Chapter 2, section 2.1.  
  
3.3.3 PET scanning procedures 
All participants underwent two 11C-RAC scans on separate weekday mornings after a 
12-hour withdrawal of their medications for PD.  Patients were instructed to fast from 
10 PM the evening before each scan to control for the state of hunger and to avoid 
alcohol, smoking and caffeinated beverages for at least 12 hours before scanning. 
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An overview of the procedures on the day of each scan is illustrated in Figure 9, and 
each of the components is described below. 
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3.3.3.1 Medication (Levodopa) challenge 
All participants in this study were given an oral dose of Levodopa (Madopar 
dispersible 50/200) 45 minutes prior to scanning. 
 
Levodopa (L-dopa; L-3,4-dihydroxyphenylalanine) is a natural chemical synthesised 
from the amino acid L-tyrosine.  L-Dopa is the precursor to the neurotransmitter 
dopamine, norepinephrine and epinephrine.  As a drug, it has a half life of 0.7 to 1.5 
hours and is excreted through the renal system. 
 
L-Dopa 200/Benserazide base 50 mg (Madopar Dispersible 250®) is a combination 
of levodopa and the peripheral decarboxylase inhibitor benserazide for the treatment 
of PD.  Current evidence shows that symptoms of PD are related to depletion of 
dopamine in the corpus striatum.  Administration of dopamine is ineffective in the 
treatment of PD as it does not cross the blood-brain barrier (BBB).  However, L-
Dopa, the metabolic precursor of dopamine, does cross the BBB and presumably is 
converted to dopamine in the brain.  This is thought to be the mechanism whereby L-
Dopa relieves symptoms of PD.   
 
When L-Dopa is administered orally, it is rapidly decarboxylated to dopamine in 
extracerebral tissues so that only a small portion of a given dose is transported 
unchanged to the central nervous system (CNS).  For this reason, large doses of L-
Dopa are required for adequate therapeutic effect, and these may often be 
accompanied by nausea and other adverse reactions, some of which are attributed to 
dopamine formed in extracerebral tissue.  Since L-Dopa competes with certain amino 
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acids for transport across the gut wall, the absorption of L-Dopa may be impaired in 
some patients on a high protein diet.  Benserazide inhibits decarboxylation of 
peripheral L-Dopa.  It does not cross the BBB and does not affect the metabolism of 
L-Dopa within the CNS. Since its decarboxylase-inhibiting activity is limited to 
extracerebral tissues, administration of benserazide with L-Dopa makes more L-Dopa 
available for transport to the brain.  In a clinical study, the latency to ‘ON’ was 
significantly faster with Madopar 250 dispersible compared to standard (non-
dispersible) forms of L-Dopa preparation (Sinemet 200/50), with an equal amount of 
duration of ‘ON’ (Steiger, Stocchi, Bramante, Ruggieri, & Quinn, 1992).  As such, 
using Madopar dispersible can reduce the total time involved per scanning procedure. 
 
3.3.3.2 Assessments before and after each PET scan  
Each patient arrives at the research centre in an OFF medication state on the morning 
of a scanning session (after withdrawal of their usual anti-parkinsonian medication 
from 10 PM the evening before).   I then assess them on the motor score of the 
UPDRS (Part III).  Following this the patient is given a single dose of Madopar 250-
mg dispersible 45 minutes before the injection of 11C-RAC.  
 
Immediately prior to the patient entering the scanner, I re-examined the patients on 
the motor score of UPDRS (Part III) to ensure that they were in an ON medication 
state (Stebbins & Goetz, 1998), and asked to completed the Positive and Negative 
Affect Schedule (PANAS).  PANAS is composed of two 10-item mood scales that 
reliably measure positive and negative affect (Watson, Clark, & Tellegen, 1988); 
(Crawford & Henry, 2004). 
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3.3.3.3 Visual task during PET scan 
During one scan, patients were asked to view neutral cues throughout the scanning 
period (the neutral scan).  During the other scan, patients were shown a series of 
reward-related visual cues (the reward scan).  These images of similar resolution 
consisted in equal proportion of pictures of appetising foods, pictures with sexual 
themes, and depictions of gambling/money or shopping-related activities.  A sample 
of neutral and reward-related visual cues is illustrated in Figure 10.  Most of these 
pictures were obtained from the International Affective Picture System (IAPS) (Lang, 
Bradley, & Cuthbert, 2008).   The order of scanning conditions was randomised for 
each patient.  
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I decided to use passive visual cues as they require minimal motor demands.  
Furthermore, excessive reward pursuit following drug-induced sensitisation is thought 
to result from excessive incentive salience attribution to reward cues (Wyvell & 
Berridge, 2001).  In addition, heightened cue reactivity has been reported in drug 
addiction (Carter & Tiffany, 1999) and in a number of ICDs in the non-PD 
population, including pathological gambling (Sodano & Wulfert, 2010), compulsive 
shopping (Starcke, Schlereth, Domass, Scholer, & Brand, 2012) and binge eating 
(Sobik et al., 2005).   
 
The images were presented as a PowerPoint TM (Microsoft; Redmond, WA, USA) 
presentation on a computer screen placed in front of the patient’s full field of view 
while the patient was prone in the scanner. The picture presentation started two 
minutes prior to a bolus injection of 11C-RAC and ran continuously until the end of 
the scan.  Each image was shown for 10 seconds, and patients were exposed to 360 
images in total for the duration of each scan without repetition.  
 
Please refer to section 2.2.7 (PET scanning procedures) for details of PET scanner and 
PET radiochemistry. 
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3.3.4 Positron Emission Tomography data analysis 
Please refer to section 2.2.9 (Region of Interest analysis) for PET data analysis.  
 
For each patient, RAC BPND values of the striatal regions during the reward scan 
were compared to the RAC BPND during the neutral scan and expressed as a 
percentage change.  This is calculated using equation 3. 
 
Equation 3. Calculation of percentage change in RAC BPND comparing reward scan to 
neutral scan. 
 
 
3.3.5 Statistical analysis 
Please see Chapter 2, section 2.1.11. 
 
Group comparisons for differences in percentage change in 11C-RAC BPND in the 
striatal regions (caudate, putamen and ventral striatum) between different groups were 
tested with one-way analysis of variance (ANOVA) and Fisher’s Least significant 
difference.  Univariate correlations between percentage change in RAC BPND and 
variables such as percentage change in PANAS scores or craving scores were made 
using Spearman’s rho correlation tests separately on each group.  The alpha level was 
set at p<0.05, corrected for multiple comparisons. 
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3.4 Results 
3.4.1 Comparison of PD ICD group vs. PD control group 
3.4.1.1 Clinical data 
Patients were matched for sex, age, PD duration and medication intake (Table 1). 
Patients with PD and ICD behaviours as a group had higher UPDRS (III) motor 
scores when OFF medication (p=0.0392), higher depression scores from BDI (II) 
(p=0.0288) and higher Brief Sensation Seeking Score (p=0.0357) compared to non-
ICD controls. 
!!
119!
 
Table 1. Clinical and psychological data of PD ICD group and PD control group (for 
PET study of PD ICD subjects) 
 PD ICD 
patients 
Non-ICD 
patients 
Mean difference p 
Sample size 17 (14M: 3F) 9 (7M: 2F)   
Age (yrs) 59.8 (2.3) 60.2 (3.2) -0.40 [-8.67 to 7.87] 0.9199 
Age at PD onset (yrs) 47.1 (2.7) 50.3 (3.4) -3.28 [-12.37 to 5.82] 0.4580 
Disease duration 
(yrs) 
12.8 (2.2) 9.9 (2.1) 2.88 [-3.41 to 9.17] 0.3532 
UPDRS (III) OFF 
medication 
41.47 (2.50) 32.78 (3.00) 8.693 [0.48 to 16.91] 0.0392** 
LEU DA (mg/day) 244.11 (37.74) 165.56 (48.85) 78.56 [-51.68 to 208.8] 0.2203 
Percentage of 
patients on DA (%) 
16 (94.1%) 7 (77.8%)  0.2677& 
L-Dopa (mg/day) 515.65 (59.00) 666.33 
(129.00) 
-150.7 [-462.8 to 161.4] 0.3108 
Total LEDD 
(mg/day) 
748.00 (66.10) 831.89 
(119.20) 
-83.89 [-342.1 to 174.3] 0.5089 
MMSE 29.29 (0.27) 29.56 (0.24)  0.7501a 
BDI (II) 16.41 (1.90) 10.44 (1.70) 5.967 [0.679 to 11.260] 0.0288** 
BSS 7.47 (0.89) 4.78 (0.81) 2.693 [0.197 to 5.189] 0.0357** 
Alcohol Use Disorder 
Identification Test: 
self-report version 
2.12 (0.50) 1.44 (0.72)  0.2680a 
Fagerstrom Test for 
Nicotine Addiction 
0 (0) 0 (0)  1.0000 
All values are given as mean (SEM).    LEU DA, L-Dopa and total LEDD reported as at time of 
recruitment.  Mean difference reported with [95% confidence interval].  Abbreviations: LEU DA = 
Levodopa Equivalent Units of Dopamine Agonists; LEDD = L-Dopa Equivalent Daily Dose; MMSE = 
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Mini Mental State Examination; BDI(II) = Beck Depression Inventory, version II; BSS = Brief 
Sensation Seeking.  Statistical analysis conducted using two-sampled t test with Welch’s correction 
where statistical significance is considered as alpha<0.05. ** denotes statistical significance; a Mann 
Whitney U test; & Fisher’s exact test. 
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Details of individual patients with PD and their ICDs are listed in Table 2. Seven 
patients reported single ‘pure’ ICDs; of these, four patients had compulsive sexual 
behaviour (57.1%) and three had pathological gambling (42.9%).  Ten patients 
reported more than one ICD—one had four ICDs (10%), two patients had three ICDs 
(20%), and the remaining seven patients had two ICDs (70%).  Notably, all patients 
with single ICDs were male; binge eating and especially compulsive buying only 
occurred in conjunction with other ICDs and were never present as isolated, ‘pure’ 
conditions.
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3.4.1.2 PET data: Comparison of ICD vs. PD controls  
Using the a priori defined striatal regions of interest, I found no significant differences 
at baseline in RAC BPND between the two groups during the PET scan showing 
neutral images .  However, on comparing RAC BPND percentage differences between 
the reward and neutral scans, I found increased ventral striatal dopamine release to 
reward cues in the ICD group compared to PD controls as demonstrated by a 
reduction in 11C-raclopride BPND (p=0.0018) (Table 3; Figures 11 and 12). 
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Table&3.&Percentage&reduction&in&regional&RAC&BPND&comparing&reward&scan&to&neutral&scan&in&PD&
ICD&and&PD&control&groups 
Regions-of-
interest 
PD ICD group 
(n=17) 
PD controls 
(n=9) 
Mean difference 
[95% Confidence 
Interval] 
P value  
Caudate 6.701 (2.641) 3.827 (2.687) 2.874 [-7.267 to 
13.01] 
0.4541 
Putamen 8.125 (2.606) 4.247 (1.877) 3.878 [-6.23 to 
14.02] 
0.2395 
Ventral Striatum 18.00 (3.053) 5.647 (1.669) 12.35 [2.211 to 
2.49] 
0.0018** 
Values given are % change (SEM) in BPND values comparing scan with reward cues to scan with 
neutral cues. Comparisons made with one-way ANOVA corrected with Fisher’s Least Significant 
Difference. Statistical analysis conducted using two-sampled t test with Welch’s correction where 
statistical significance is considered as alpha<0.05. ** denotes statistical significance.  
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Figure 12. Percentage change in regional RAC BPND values comparing reward scan to 
neutral scan in PD ICD and PD control groups  
 
Figure legend: ** denotes statistical significance, where alpha level is set at <0.05. 
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Figure 13. Representative PET scan images of PD ICD and PD control groups during 
scans with neutral and reward-related visual cues.   
The top two scans represent PET images from the neutral scans. The lower two scans 
represent PET images from the scans showing reward-related images.   
 
 
Figure legend: PD ICD patient has reduced RAC BPND binding most marked in the ventral striatum as 
demonstrated by reduced colour intensity on the reward-related scan compared to the neutral scan.  The 
difference is much less prominent in the PD control patient. 
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Results of the PANAS showed that during the neutral scan, there was no difference in 
percentage change in the positive or negative score in both PD ICD and non-ICD 
control groups (Table 4).  However, during the reward scan, there was a significant 
increase (p=0.0187) in the positive score in the PD ICD group compared to the 
control group.  
 
Table 4. PANAS scores for PD ICD and PD control groups 
 
  PD ICD 
group 
PD controls Mean 
difference 
P =  
Percentage 
change in 
PANAS 
positive score  
4.62 
(5.538) 
-21.58 
(13.48) 
26.20 [6.260 to 
58.660] 
0.1023 Neutral cues 
scan: 
Percentage 
change in 
PANAS 
negative score 
-15.94 
(9.196) 
-32.01 
(16.90) 
16.07 [-25.85 to 
58.00] 
0.4199 
Percentage 
change in 
PANAS 
positive score  
17.80 
(3.576) 
-27.20 
(14.87) 
45.00 [9.73 to 
80.20] 
0.0187** Reward cues 
scan:  
Percentage 
change in 
PANAS 
negative score 
-30.41 
(8.878) 
-41.84 
(15.65) 
11.44 [=22.90 to 
45.77] 
0.4984 
Values given are % change (SEM).   Comparisons made with t test (two-tailed, unequal variance), ** 
denotes statistical significance, where alpha level is set at p<0.05. 
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3.4.1.3 Clinical correlations 
I did not find any correlations between sensation seeking measures and the percentage 
change in RAC BPND of the three-striatal regions in the PD ICD group nor in the PD 
control group. 
 
3.4.2 Comparison of PD patients with comorbid ICDs, single ICD and PD control 
groups 
3.4.2.1 Clinical and psychological data 
Patients were matched for sex, age, PD duration and medication intake (Table 5).  
Levels of depression, as evidenced by BDI (II) scores were significantly higher in the 
ICD groups compared to controls, and greatest in the comorbid ICD group.  Scores 
for BSS were also higher for patients with ICDs, particularly the comorbid cases, but 
the overall group effect failed to reach statistical significance (p=0.097, table 5). 
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3.4.2.2 PET data  
The RAC BPND raw values for the scan with neutral cues were similar for all three 
groups of patients for each striatal region (Figures 13 a, b and c). 
 
By contrast, the percentage reduction in ventral striatal (but not caudate or putamen) 
regional RAC BPND during reward vs. neutral scans were significantly different 
between groups, and was significantly larger in both of the ICD groups compared to 
control patients, indicating a significantly elevated endogenous ventral striatal 
dopamine release in response to reward-related visual cues in both ICD groups 
relative to controls (figures 13d, e, and f).  The levels of reward-related ventral striatal 
dopamine release were, however, comparable in both the single and comorbid ICD 
cases.  (Table 6). 
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Table 6. Percentage reduction in regional RAC BPND values comparing reward scan to 
neutral scan in comorbid ICDs, single ICD and PD control groups 
 
Regions-of-
interest 
Comorbid 
ICD 
group 
(n=10) 
Single ICD 
group 
 (n=7) 
Non-ICD 
controls 
(n=9) 
F (2, 23) p value  
Caudate 7.88 (2.74)bc 4.03 (4.85)ac 5.96 (3.37)ab 0.285 0.754 
a0.716 
b0.692 
c0.460 
 
 
Putamen 5.97 (2.86) bc 10.47 (4.75) ac 5.77 (2.44) ab 0.590 0.563 
a0.340 
b0.965 
c0.350 
Ventral 
Striatum 
17.51 (2.77)bc 17.19 (6.82)ac 6.74 (2.15)ab 3.306 0.050** 
a0.051 
b0.028** 
c0.920 
 
Omnibus comparisons made with one-way ANOVA. Values given are % change (SEM) in 
BPND values comparing scan with reward cues to scan with neutral cues.  aPost-hoc 
comparison (Least Significant Difference) between controls and single ICD groups. bPost-hoc 
comparison between controls and >1 ICD group.  cPost-hoc comparison between single and 
>1ICD group. ** denotes statistical significance. 
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3.4.2.3 Subjective cue reactivity 
Subjective cue-reactivity (as measured by pre-post scan change in PA and NA on the 
PANAS) did not differ between groups in the neutral condition (data available on 
request).  In contrast, in the reward cue condition, there was significant change in PA, 
but not NA between groups (Table 7), with both ICD groups showing relative 
increases in PA compared to controls (who reported a decrease in PA over time).  The 
two ICD groups showed comparable increase in PA. 
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3.4.2.4 Relationship between ventral striatal dopamine release and behavioural data 
I did not find any significant correlations between changes in ventral striatal 
dopamine neurotransmission during reward vs. neutral cue scans and trait sensation 
seeking, depression severity or subjective cue-reactivity (PA) in the ICD or control 
groups (all p>0.05). 
 
3.5 Summary of findings 
In this PET study, I investigated dopamine neurotransmission in PD patients with a 
range of ICDs (PD ICD group) and PD controls.  I exposed subjects to a range of 
visual cues during two 11C-RAC PET scans, where during one scan I showed them 
reward-related passive visual cues; and during the other I showed them neutral visual 
cues.  On the whole, I observed a greater reduction in RAC BPND in the ventral 
striatum of subjects with ICDs compared to controls following exposure to reward-
related visual cues. These changes indicate an increase in dopamine release in the PD 
ICD group in response to viewing of reward-related cues.   
 
I then performed a secondary analysis where I divided the PD ICD group into those 
with comorbid ICDs and those with a single ‘pure’ ICD and compared their dopamine 
release to the PD control group.  I found that both comorbid and single ICD groups 
showed greater dopamine release in the ventral striatum to heterogenous reward-
related images compared to the control group, but dopamine release was comparable 
between those with comorbid and those with a single ICD.   
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This study explored the range of chosen activities pursued for each impulse control 
disorder.  Nine out of ten patients with compulsive sexual behaviour have admitted to 
watching pornography, whilst four reportedly pestered their partner or friend for sex.  
Patients with binge eating have a predilection for sugary foods such as chocolate, 
sweets and ice cream, and foods rich in carbohydrates (cakes and biscuits), which 
invariably led to marked weight gain.  Those with pathological gambling preferred 
slot machines, horse and sports betting and bingo.  Three of seven patients pursued 
their gambling in betting shops, two used online gambling sites, whilst one patient 
used both mediums to gamble and one did not disclose location.   Females with 
compulsive buying prefer to buy fashion items such as clothes, bags and shoes, whilst 
males tend to go for electronic items as well as clothing.  The precise motivational 
mechanisms underpinning the various behavioural symptoms manifested in ICDs are 
important topics for future investigation. It was notable that binge eating and 
compulsive shopping, unlike pathological gambling and compulsive sexual behaviour, 
never occurred in isolation. 
 
Subjects with ICDs had higher levels of depression (a finding that extended itself 
when the group was dissected into those with comorbid ICDs and single ICD).  Those 
with comorbid ICDs also had marginally increased sensation seeking scores compared 
to subjects with a single ICD and control group, despite having similar disease 
duration and motor disability.  
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Chapter 4 
PET imaging of punding 
behaviour in Parkinson’s disease 
patients 
 
 
 
4.1 Introduction 
 
In this chapter, I investigate resting baseline dopamine level in PD patients with 
punding behaviour (PD punders) compared to PD control patients.  I also explore 
whether PD punders display characteristic traits similar to that observed in subjects 
with OCD. 
 
4.2 Aims and hypotheses 
The aims of this study are: 
1. To invesetigate baseline resting dopamine state in PD patients with and without 
punding behaviour.   
2. To compare clinico-behavioural characteristics in these two patient groups, 
including obsessive compulsive traits using the Padua Inventory for obsessive 
compulsive traits. 
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I hypothesise that Parkinson’s disease patients with punding will have lower D2/3 
binding in the dorsal striatum compare to controls, similar to that found in non-PD 
OCD subjects, and that they will also demonstrate a higher level of obsessive-
compulsive characteristics as measured using the Padua Inventory. 
 
4.3 Methods 
4.3.1 Participants 
Thirteen PD patients with punding behaviours and 15 participants with PD who were 
free from symptoms of punding, ICD or DDS were studied. All patients satisfied the 
Queen Square Brain Bank for Neurological Disorders clinical criteria for Parkinson’s 
disease (Hughes et al., 1992).  
 
4.3.2 Evaluation of clinical and behavioural characteristics 
All participants were assessed as detailed in Chapter 2, section 2.1.   In addition, they 
were also asked to complete PADUA Inventory – Washington State University 
Revision (PI-WSUR):  a self-reporting measure to assess symptoms of OCD (Burns, 
1996).  It consists of five subscales: contamination obsessions and washing 
compulsion, dressing / grooming compulsions, checking compulsions, obsessional 
thoughts of harm and obsessional impulses to harm.  Punding is thought to share 
similarities with OCD as the repetitive and complex behaviours in punding may be 
considered a form of compulsion.  
4.3.3 PET scanning procedures 
All participants for this study underwent one 11C-RAC scan in an OFF medication 
state on a weekday morning as per protocol detailed in section 2.2.7. 
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4.3.4 Positron Emission Tomography data analysis 
Please refer to section 2.2.9 (Region of Interest analysis) for PET data analysis.  
 
4.3.5 Statistical analysis 
Statistical analysis was carried out as detailed in Chpater 2, section 2.11. Group 
comparisons for differences in 11C-RAC BPND in the striatal regions (caudate, 
putamen and ventral striatum) between the two different patient groups were tested 
with independent t test.  The alpha level was set at p<0.05. 
 
4.4 Results 
4.4.1 Demographics and clinical behaviour 
Punders and control subjects were matched for age, disease duration and disease 
severity (Table 8).  Total daily Levodopa equivalent units and amount of dopamine 
agonist were similar in both groups (punders: 727.54 ± 421.58; controls: 686.57± 
283.97; p=0.840).  Seven patients from each group were on dopamine agonists: 
ropinirole (punders n=3; controls n= 2), ropinirole XL (punders n=1; controls n= 2), 
pramipexole (punders n=3; controls n=1); rotigotine (punders n=1; controls n= 2). 
Regarding rescue medications, one punder and one control participant were 
prescribed fast-acting dispersible levodopa, whilst another punder was prescribed 
apomorphine bolus injections. Punders scored marginally higher on the Beck 
Depression Inventory (II) and the Padua Inventory although differences between the 
two groups were not significant on either of these measures [BDI(II): PD punders 
15.16 (8.17); PD controls 12.77 (6.00); p=0.41,  Padua Inventory total score: PD 
punders 12.69 (16.56); PD controls 12.77 (6.00); p=0.27].   However, I observed a 
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significantly higher score for the dressing/grooming subscale in the PD punders 
compared to controls [PD punders 2.62 (2.69); PD controls 0.73 (1.67); p=0.042]. 
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Table 8.Clinical and behavioural characteristics of PD punders and PD control groups.  
 Punders Controls p value 
Number of participants 13 15  
Gender  11M: 2F 10M:5F  
Age in years  61.15 (10.72) 66.55 (7.29) 0.23 
Disease duration 10.04 (4.01) 8.68 (4.80) 0.43 
H&Y score 2.66 (0.88) 2.39 (0.65) 0.39 
UPDRS III (OFF medication) 41.17 (14.38) 39.29 (9.98) 0.71 
Dyskinesias 7 4 0.25§ 
Total LEDD in mg/d 727.54 (421.58) 686.57 (283.97) 0.84 
Dopamine agonist (LEDD) in mg/d 160.67 (161.15) 170.00 (175.89) 0.89 
No. on dopamine agonist 7 7 0.70§ 
BDI (II) 15.16 (8.17) 12.77 (6.00) 0.41 
Padua Inventory 12.69 (16.56) 7.06 (6.12) 0.27 
Contamination obsession and 
washing compulsions subscale 
5.38 (7.70) 3.06 (3.59) 0.33 
Dressing / grooming compulsions 
subscale 
2.62 (2.69) 0.73 (1.67) 0.042 ** 
Checking compulsions subscale 2.85 (4.91) 2.26 (2.58) 0.71 
Obsessional thoughts of harm to 
self/others subscale 
1.46 (2.99) 0.73 (1.10)  0.42 
Obsessional impulses to harm 
self/others subscale 
0.38 (1.39) 0.20 (0.56) 0.66 
Abbreviations: H&Y: Hohn & Yhar; UPDRS: United Parkinson’s Disease Rating Scale; LEDD: 
Levodopa Equivalent Daily Dose; BDI: Beck’s Depression Inventory. § Chi-square test.  **denotes 
statistical significance, two tailed student t test. 
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The stereotyped behaviours reported are detailed in Table 9.  Behaviours were often 
influenced by their previous occupation, whilst others were related to their hobbies.   
Three patients satisfied criteria for dopamine dysregulation syndrome.  Other 
concomitant impulse control disorders reported were CSB (n=8), PG (n=2), CB (n=5), 
and BE (n=2). 
 
Table 9. Punding behaviours of PD participants diagnosed with punding. 
Age (yrs), 
gender 
Previous 
occupation 
Punding behaviour Concomittant 
ICD, DDS  
66M Academic Intense writing of monologues with no real 
content 
CSB  
54M Builder Sorting tools, dismantling computers and 
reassembling without success 
CSB, PG 
41M Banker Obsession with sorting and organising 
media collection (CDs/DVDs) 
DDS, CSB 
63M Banker Walking with no intended goal, often at 
night and for several hours at a time, 
despite medication wearing off and freezing 
DDS 
69M Labourer Repetitively sorting and resorting 
household objects 
PG, CB 
72M Self-employed 
Businessman 
Sorting and re-sorting receipts, papers.  CSB 
56F Housewife Jewellery making but disassembling and 
reassembling >5 hours/day, pointless 
driving, arranging kitchen cupboards 
CB 
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69F Housewife Sorting and rearranging items in kitchen 
cupboard, household objects 
BE, CB 
47M Engineer Dismantling and reassembling electrical 
items, old computers, laptops 
CSB, BE 
62M Engineer Dismantling and reassembling machinery CB 
78M Self-employed 
businessman 
Repetitive actions of sorting, examining, 
arranging and resorting objects, obsession 
with sorting meds into dosset boxes 
CSB, DDS 
66M Self-employed 
businessman 
Writing blogs with no specific content, 
repetitively sorting emails and files on 
computer 
CSB 
51M Academic Repetitive editing of video clips, labelling 
media files 
CSB, CB 
Abbreviations: ICD: Impulse Control Disorder; DDS: Dopamine Dysregulation Syndrome; CSB: 
compulsive sexual behaviour; PG: pathological gambling; CB: compulsive buying; BE: binge eating. 
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4.4.2 PET with 11C-RAC (punders vs controls) 
Compared to controls, punders had lower RAC BPND levels in caudate (punders: 
1.718 ± 0.2033; controls: 2.067 ± 0.2661; p=0.0006) (Figure 14a), indicating higher 
resting endogenous dopamine level in this group.  RAC BPND values for putamen 
were also lower in punder compared to control but this was not statistically significant 
(punders: 2.548 ± 0.3763; controls: 2.824 ± 0.3765; p=0.0641). RAC BPND values  in 
the ventral striatum were similar between the two groups (punders: 1.342 ± 0.248; 
controls: 1.348 ± 0.268; p=0.9499) (Figures 14b and c).   
 
4.4.3 Correlations 
I did not find any significant correlation between caudate RAC BPND and depression 
score (p=0.6320), nor to the Padua Inventory (p=0.475) or its subscales. 
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Figure 15. Scatterplots showing RAC BPND values (y-axis) for the three striatal regions 
for PD punders and PD control groups  
Figure 14a. Caudate 
 
 
Figure 14b. Putamen 
 
 
Figure 14c. Ventral striatum 
!
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4.5 Summary of findings 
I studied dopamine D2 binding in PD participants with punding and compared them 
to PD control participants using positron emission tomography with 11C-RAC.  I 
observed lower values of RAC BPND) in the caudate of punders compared to controls 
when participants were scanned under resting condition in an OFF medication state. 
 
In looking at the clinical aspects between the punding and control groups, I did not 
find any discernable pattern to the dopamine receptor stimulation profile of the 
medications used by the punders compared with the nonpunders.  More punders 
reported dyskinesias (n=7) than controls (n=4) but the difference was not statistically 
significant.  Punders scored higher in the Padua inventory but the scores remain 
within the non-OCD range and did not differ significantly from PD controls, 
suggesting that punding behaviour does not have the characteristics, nor is it driven by 
the anxiety of obsessions.   
 
I also observed a higher percentage (100%) of comorbid ICDs in the punding group 
than previously reported (59%) (Fasano & Petrovic, 2010).   Similar to other reports 
of punding, I did not find any difference in depression scores between punders and 
controls (Fasano et al), suggesting that punding does not correlate with mood or 
anxiety disorders. 
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Chapter 5 
Neural response to visual sexual 
cues in Parkinson’s disease 
patients with compulsive sexual 
behaviour: A study using fMRI 
 
 
 
5.1 Introduction 
Very little is known about the underlying neurobiology of CSB, or how visual sexual 
stimuli, similar to the portrayals of sexuality in the mainstream mass media, may 
affect the brain and behaviour in such vulnerable individuals. In this study, I employ 
fMRI to investigate the neural response of PD patients with and without CSB on 
exposure of sexual-related stimuli.  !
5.2. Aims and hypotheses 
The aims of this study are: 
1. to investigate blood-oxygen-level depdendence (BOLD) signal alterations in PD 
subjects with CSB (PD-CSB) and PD controls in response to passive sexual-related 
vs neutral visual cues. 
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2. to correlate the above imaging results with behavioural assessments of sexual 
motivation. 
 
I hypothesise that PD patients with CSB would show aberrant sexual cue-related 
activity in regions linked to sexual motivation, which would be modulated by 
dopaminergic medication, and linked to enhanced sexual motivation. 
 
5.3 Methods 
5.3.1 Participants 
Twenty-four non-demented patients with idiopathic Parkinson’s disease were studied.  
Twelve of these patients fulfilled the proposed operational diagnostic criteria for CSB 
(Voon et al., 2006).  The other 12 patients had no history of CSB or other ICDs and 
served as a control group.  
5.3.2 Clinical and behavioural assessments 
All patients attended a semi-structured interview with the author (KW) to complete an 
assessment battery as detailed in Chapter 2, section 2.1. 
 
5.3.3 fMRI scanning procedures  
 
Participants were scanned on two separate mornings (between 11:00 and 13:00) seven 
days apart in a cross-over randomised design after skipping breakfast and stopping 
medication at least 12 hours prior to scanning.  
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5.3.3.1 Medication (Levodopa) challenge 
Participants were scanned in the practically defined OFF medication condition in one 
scan and in ON medication condition after receiving an oral dose of levodopa 
(Madopar dispersible 50/200) 45 minutes prior to the scan starting (see section 3.3.3.1 
for biochemistry of levodopa). The use of L-Dopa was chosen because all Parkinson’s 
disease patients were previously taking this, whereas not all were on the same 
dopamine agonist. Moreover, L-Dopa can increase sexual motivation in PD, and CSB 
has been observed in combination with concurrent L-Dopa treatment, not just 
dopamine agonist treatment (Ballivet et al., 1973; Hassan et al., 2011). 
 
5.3.3.2 Assessments before and after each fMRI scan 
Motor performance was assessed with the UPDRS motor scores at baseline and 
immediately before scanning to ensure patient has responded to the medication 
(defined as > 25% improvements in UPDRS-III motor scores).  
 
Before and after scanning, participants were asked to rate their libido and sexual 
desire on a visual analogue scale (10 cm), anchored between ‘the lowest ever’ (0 cm = 
0 points) and ‘the most ever’ (10 cm = 10 points). Both scales were self-reported and 
related to how the participants felt within the past hour only. Single-item desire scales 
have been shown to be as reliable as longer multi-item questionnaires (West & 
Ussher, 2010). Since most of the Parkinson’s disease patients with CSB had 
additional ICDs, similar self-reported desire scales for gambling, drugs and food were 
also administered. 
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5.3.3.3 Scanning procedures 
Participants were placed in the scanner with headphones and padding round the head, 
the shoulders and arms to ensure as little area for movement as possible.  Movements 
were monitored throughout the scans and, in case of excessive movements, the scan 
was either restarted or the relevant volumes were removed from the analysis (5.2% of 
runs were restarted due to tremor or dyskinesias).  Imaging acquisition was conducted 
on a 3T Philips Intera whole-body scanner.  Whole-brain data were acquired with 199 
volumes of T2*-weighted gradient-echo-planar imaging in ascending order with an 
automated higher-order shim procedure [slice thickness 3.25mm; repetition time (TR) 
3000ms; echo (TE) 30ms; 90° flip angle; field of view (FOV) 190 x 219; matrix 112 x 
112].  The slice acquisition angle was set at -30° from the anterior-posterior (AC-PC) 
line to reduce frontal lobe signal dropout due to the air sinuses, with a z-shim gradient 
correction to compensate for through-plane susceptibility gradients (Deichmann, 
Gottfried, Hutton, & Turner, 2003; Goldstone et al., 2009).  One high-resolution T1-
weighted turbo field echo structural scan was also collected (TE 4.6ms; TR 9.7ms, 8° 
flip angle; FOV 240 mm). 
 
5.3.4 fMRI paradigm 
During the fMRI scan, five types of colour images were presented in a block design: 
(i) dopaminergic drugs cues, (ii) appetising food cues, (iii) money and gambling cues, 
(iv) sexual cues and (v) neutral cues. The vast majority of reward-related and neutral 
visual cues were obtained from the International Affective Picture System (IAPS) 
(Lang et al., 2008) and were supplemented by freely available images obtained from 
websites. A visual sexual cue was defined as including depictions of intimate 
touching, passionate kissing, physical flirting, and provocative images of women or 
men (gender based: men saw women and women saw men) with their bodies partly 
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clothed. Neutral visual cues included landscapes and nature scenes, household 
objects, and random patterns. The IAPS sexual visual stimuli has been previously 
validated and have been shown to induce significant levels of sexual arousal in 
previous fMRI / psychophysiological studies (Bradley, Codispoti, Sabatinelli, & 
Lang, 2001; Walter et al., 2008). 
 
Images of similar resolution were presented in 14.7s blocks in two runs lasting 9 min 
56s each.  Each block contained seven different images from the same category, with 
a total of six blocks of each type shown in a pseudorandom block order with a 
randomised image order in each block.  Run order was counterbalanced across 
participants and visits.  Each image was displayed for 2,100 ms and each thematic 
block was followed by a 4,000 ms rating slide whereby the participant had to rate 
from one to five how much they liked the block of images they saw (with one being ‘I 
hated it’ and five being ‘I loved it’).  These ratings were made by voice and they were 
recorded in a computer.  The rating slide was followed by a 1,000 ms inter-stimulus 
interval of a fixation cross.  Images were viewed via a mirror mounted above an eight-
channel RF head coil, which displayed images from a projector using the IFIS-SA 
image presentation system (In Vivo, Wurzburg, Germany) and E-Prime software 
(Psychology Software Tools Inc., Pittsburgh, PA, USA). 
 
5.3.5 fMRI data analysis 
Imaging data were analysed using Statistical Parametric Mapping version 5 (SPM5, 
Wellcome Department of Imaging Neuroscience, UCL, UK). The first five volumes 
of each fMRI run were discarded to allow for equilibrium effects, and all functional 
scans were realigned to the first scan of the run and then again to the mean of all of 
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the volumes for motion and slice-timing correction. All scans included in the final 
analysis consisted of less than 2 mm of movement in each direction. I explored the 
data for residual artifacts using the TSDiffAna utility implemented in SPM5, which 
produces mean and variance images for each functional volume (http://imaging.mrc-
cbu.cam.ac.uk/imaging/DataDiagnostics). An artifact is defined as the co-occurrence 
of a variance spike and a mean intensity drop uncorrelated with experimental design. I 
did not detect any artifacts that needed more detailed inspection. The mean functional 
image was co-registered to the T1 structural image. The echo-planar images were then 
normalised into Montreal Neurological Institute (MNI) standard stereotactic space 
using parameters from the segmented T1 structural image and smoothed using an 8 
mm full-width at half-maximum (FWHM) Gaussian filter. 
 
5.3.5.1 First-level analysis 
First-level analysis was performed at the single participant level where individual 
contrasts were created in a general linear model for each reward condition minus 
baseline (neutral pictures) and for sex minus other rewards (sex vs. other rewards). 
The general linear model included six motion and nuisance parameters, accounting for 
movement and other nuisance artifacts occurring in three directions of translation 
(displacement) and three axes of rotation (x, y, z translation and x, y, z rotation) for 
each run. Contrasts of interest produced as this stage (e.g. sex vs. neutral) were used 
in the second-level, group random effects analysis. A statistical threshold of p < 0.001 
uncorrected and cluster extent over 10 voxels (2 x 2 x 2 mm) was used for activation 
using whole-brain analysis with correction for multiple comparisons using the false 
discovery rate (FDR) at p < 0.05 (Genovese et al., 2002). Coordinates of peak voxel 
activation within the brain were determined at the group level for ON and OFF scans 
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in Parkinson’s disease patients with and without CSB. I also performed an additional 
between-group (Parkinson’s disease controls vs. Parkinson’s disease CSB) and 
between-condition (OFF vs. ON medication) analysis in order to investigate whether 
motion parameters were larger in one patient group or condition group than the other 
and found that movement did not vary between groups and conditions (p > 0.1 in both 
cases).  
 
5.3.5.2 Second-level analysis 
Since a regional a priori hypothesis existed, additional second-level random effects 
analyses (sex vs. neutral and sex vs. other rewards contrasts in ON and OFF 
medication conditions) were carried out for specific regions-of-interest (ROIs) using 
MarsBar (Brett et al., 2002) using the same statistical threshold (FDR at p < 0.05). 
These regions were OFC, ACC, posterior cingulate cortex (PCC), amygdala, VS and 
the hypothalamus. The models of OFC, ACC, PCC and amygdala were taken from the 
‘Automated Anatomic Labeling’ (AAL) library that accompanies MarsBar. The VS 
and hypothalamus object maps were constructed by drawing these ROIs in 
ANALYZE medical imaging software (version 8.1, Mayo Foundation). These object 
maps were then used to mask out the rest of the brain, allowing comparisons within 
specific volumes (1850 mm3 in each hemisphere for VS and 1380 mm3 in each 
hemisphere for the hypothalamus). Individual participants’ contrast (e.g. sex vs. 
neutral) values of each ROI for both ON and OFF medication scans were extracted for 
correlation with the behavioural data.  
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5.3.6 Statistical analysis 
Statistical analyses were performed as detailed in Chapter 2, section 2.2.9. 
Comparisons within groups (e.g. Parkinson’s disease CSB OFF scan sex vs. neutral) 
were performed using paired t tests and comparisons between groups (e.g. 
Parkinson’s disease CSB OFF sexual vs. neutral – vs. – Parkinson’s disease controls 
sexual vs. neutral) were performed using two sample t tests. For the clinical and 
behavioural analysis, variance homogeneity and Gaussianity were tested with Bartlett 
and Kolmogorov-Smirnov tests. Parametric and non-parametric tests were used 
appropriately. Pearson correlation coefficient r and Spearman’s rho (ρ) (when 
variables were not normally distributed) were used to examine the relationship 
between individual sexual desire scores after exposure to sexual visual cues and 
individual bilateral BOLD ROI contrast values for sexual vs. neutral contrast in the 
ON and OFF medication states. The Bonferroni correction was used to counteract the 
problem of multiple comparisons.  
 
 
 
5.4 Results 
5.4.1 Participants’ clinical and behavioural characteristics 
PD-CSB subjects were taking significantly more dopamine agonists and significantly 
less L-Dopa compared to controls. The two groups did not statistically differ in any of 
the other clinical characteristics (age, sex, disease duration, UPDRS part III OFF, ON 
and response after L-Dopa, MMSE, and daily LEDTOTAL).  Eight out of 12 PD-CSB 
patients exhibited at least one additional ICD (Tables 10 and 11). 
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Table 10. Clinical characteristics of participants (in fMRI study of PD patients with 
CSB)  
 PD CSB PD controls p value 
Number of subjects 12 12 - 
Age (years ± SD) 55.2 ± 9.2 62.3 ± 9.7 0.077b 
Sex 11M/1F 10M/2F - 
Disease duration (years ± SD) 9.6 ± 5.2 10.1 ± 6.4 0.85b 
UPDRS OFF motor (Part III) 
score (mean ± SD)a 
40.2 ± 10.1 34.9 ± 9.9 0.21b 
UPDRS ON motor (Part III) score 
and % improvement (mean ± 
SD)a 
23.1 ± 8.2 (43.8 ± 9.7%) 20.0 ± 5.5 (41.4 ± 11.7%) 0.29 (0.59)b 
MMSE (mean ± SD) 29.8 ± 0.4 28.9 ± 2.2 0.30c 
Daily LEDTOTAL (mg ± SD) 600 ± 327 778 ± 278 0.17b 
Daily LEDL-DOPA (mg ± SD) 288 ± 326 646 ± 264 < 0.05c 
Daily LEDDA (mg ± SD) 311 ± 183 132 ± 143 < 0.01c 
a The average of five evaluations on five different days; b Unpaired t test; c Mann-Whitney test; PD 
CSB: Parkinson’s disease patients with compulsive sexual behaviour; PD controls: Parkinson’s disease 
patients without compulsive sexual behaviour or other impulsive-compulsive behaviours; M=male; 
F=female; SD=standard deviation; UPDRS=Unified Parkinson’s Disease Rating Scale; 
LED=Levodopa Equivalent – the dose is calculated similarly to a previous report (Politis et al., 2010) 
LED (mg) = (1 X Levodopa) + (0.77 X Levodopa CR) + (1.43 X Levodopa + Entacapone) + (1.11 X 
Levodopa CR + Entacapone) + (20 X Ropinirole) + (20 X Ropinirole ER) + (100 X Pramipexole) + 
(30 X Rotigotine) + (10 X Bromocriptine) + (8 X Apomorphine) + (100 X Pergolide) + (67 X 
Cabergoline); LED formula, In Levodopa/Carbidopa or Benserazide hydrochloride: Only Levodopa is 
calculated; MMSE=Mini-Mental State Examination.  
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Before the OFF and the ON scans, PD-CSB and PD control patients did not differ on 
sexual desire scores (Table 12).  After the OFF and the ON scans where participants 
had been exposed to sexual cues, PD–CSB patients showed a significant increase in 
their sexual desire compared to their rating before scan and also showed a significant 
increase compared to the sexual desire of the PD controls, the latter remaining 
relatively stable pre and post scan. PD CSB patients had higher increases in their 
sexual desire in the ON compared to the OFF scan (Table 12). The PD-CSB and PD 
control groups did not show any within or between group differences in food, 
gambling and drug desire before and after the ON and OFF scans. 
 
Table 12. Sex cravings before and after exposure to common sexual visual stimuli. 
OFF scan Before sexual visual stimuli After sexual visual stimuli P value 
PD controls (mean ± SE) 1.98 ± 0.59 2.25 ± 0.45 0.31a 
PD CSB (mean ± SE) 2.67 ± 0.56 3.70 ± 0.50 < 0.01a 
P value 0.40b < 0.05b  
ON scan Before sexual visual stimuli After sexual visual stimuli P value 
PD controls (mean ± SE) 1.32 ± 0.28 2.12 ± 0.60 0.18d 
PD CSB (mean ± SE) 2.01 ± 0.39 5.24 ± 0.41 < 0.001a  
P value 0.15c < 0.001b  
a Paired t test; b Unpaired t test; c Mann-Whitney test; d Wilcoxon matched pairs test 
 
 
PD-CSB patients liked the sexual visual cues presented during the fMRI significantly 
more than controls (quality of data = 85.2%; 3.4 ± 1.2 vs. 2.1 ± 0.6, mean ± SD; P < 
0.05, unpaired t test with Welch correction) but there was no difference in their 
ratings for reward cues related to drugs, money and gambling or food (p > 0.1 in all 
cases, unpaired t test with Welch corrections). No differences were found between 
ON and OFF scans. 
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5.4.2 Region-of-interest fMRI analysis 
The ROI analysis showed that the PD-CSB patients had stronger activity (increased 
BOLD signal) than the PD controls during exposure to sexual vs. neutral visual cues 
in the OFF medication states in the following regions: OFC (L: p < 0.001, R: p < 
0.005), ACC (L: p < 0.005, R: P < 0.001), PCC (L: p < 0.001, R: p < 0.001), left 
amygdala (p < 0.05), VS (L: p < 0.05, R: p < 0.05), and hypothalamus (L: p < 0.005, 
R: p < 0.01) (Figures 15C–H). For the same contrast in the ON medication state, a 
similar set of regional brain activations was observed, and there were no significant 
differences in activations between ON and OFF scans. When I compared the effect of 
OFF vs. ON medication state just in the group of PD-CSB patients, I found no 
differences in activation. 
 
The ROI analysis showed that the PD-CSB patients had stronger activity during 
exposure to sexual compared to other rewards visual cues in the OFF medication 
states in the following regions: OFC (L: p < 0.001, R: p < 0.001), ACC (L: p < 0.001, 
R: p < 0.001), PCC (L: p < 0.001, R: p < 0.001), VS (L: p < 0.001, R: p < 0.001), and 
hypothalamus (L: p < 0.001, R: p < 0.001). Similar activations were observed during 
the ON medication state, and there were no significant differences in activations 
between OFF and ON scans. 
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Figure 16. Projections of statistical parametric maps showing significant BOLD signal 
increases associated with exposure to common sexual visual cues (compared to neutral 
visual cues) in PD control participants and PD-CSB participants..  
PD control patients (Figures A and B) and PD-CSB patients (Figures C–H). Sagittal (left) and 
axial (right) views showing activation in anterior prefrontal cortex (aPFC) (BA 10), anterior 
cingulate cortex (ACC) (BA 24), superior parietal lobule (SPL) (BA 5), posterior cingulate 
cortex (PCC) (BA 23 and 31), left and right middle temporal gyrus (MTG) and middle 
occipital gyrus (MOG). Bilateral activation in MTG and MOG is also present in the PD 
control group. The colour bar indicates T-values.  
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5.4.3 Whole-brain fMRI analysis 
5.4.3.1 Common brain activity between Parkinson’s disease compulsive sexual 
behaviour and Parkinson’s disease controls patients 
PD-CSB and PD controls showed similar significant BOLD signal increases during 
exposure to sexual vs. neutral visual cues in both ON and OFF medication states 
bilaterally in middle temporal gyrus (MTG) and middle occipital gyrus (MOG) 
(Figures 15A and 15B; Tables 13 and 14). For the same contrast in the OFF state, PD-
CSB and PD controls showed similar significant BOLD signal decreases bilaterally in 
isthmus of cingulate gyrus (ICG) (BA 29 and 30), parahippocampal gyrus (PHG), and 
cuneus (BA 17) (Figures 16A and 16B; Tables 13 and 14). 
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Figure 17. Projections of statistical parametric maps showing significant BOLD signal 
decreases associated with exposure to common sexual visual cues compared to neutral 
visual cues in PD control and PD CSB participants during OFF medication state.  
PD controls (Figures A and B) and PD-CSB patients (PD CSB, Figures C and D) during OFF 
medication state. Axial views (left and right) showing bilateral deactivation in parahippocampal gyrus 
(PHG), cuneus (BA 17), isthmus of cingulate gyrus (ICG) (BA 30), insula and right claustrum. 
Deactivation in insula and claustrum are only specific to the group of PD-CSB patients compared to 
controls. The colour bar indicates T-values.  
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5.4.3.2 Brain activity specific to Parkinson’s disease compulsive sexual behaviour 
patients 
Whole-brain analysis confirmed the ROI results and showed additional significant 
BOLD signal increases in the group of PD-CSB compared to PD controls during 
exposure to sexual vs. neutral visual cues in the OFF and ON medication states in the 
following regions: bilateral anterior PFC (aPFC) (BA 10) and superior parietal lobule 
(SPL) (BA 5 and 7), and right lateralised activation in the inferior parietal lobule 
(IPL) (BA 40) (Figures 15C–H; Tables 13, 14). For the same contrast in the OFF 
state, PD-CSB compared to PD controls showed significant BOLD signal decreases 
bilaterally in insula and right claustrum (Figures 16C and 16D; Tables 13 and 14). 
There were no different BOLD signal increases during exposure to sexual vs. neutral 
visual cues in PD-CSB patients between the OFF and ON medication states. 
 
Whole-brain analysis also confirmed the ROI results in PD-CSB patients when 
compared sexual vs. other rewards visual cues and showed additional significant 
BOLD signal increases in the OFF and ON medication states in bilateral dorsolateral 
PFC (BA 9) and right lateralised activation in aPFC (BA 10) and PHG. 
 
5.4.4 Effect of L-Dopa medication in brain activity in Parkinson’s disease 
compulsive sexual behaviour patients 
In the group of PD-CSB patients in ON medication state, the decreases observed in 
the OFF state and in the OFF and ON states in PD controls (reduced BOLD signal 
during exposure to sexual vs. neutral visual cues in ICG, PHG, cuneus, insula and 
claustrum) were eliminated (Tables 13 and 14). 
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5.4.5 Brain activity related to other reward visual cues in Parkinson’s disease 
compulsive sexual behaviour patients 
I found no significant differences within or between PD-CSB and PD controls in any 
other reward condition minus baseline (neutral pictures) (e.g. dopaminergic drugs vs. 
neutral) in either ON or OFF scans.  
 
5.4.6 Correlations 
In the group of PD-CSB patients, sexual desire post-exposure to sexual visual cues 
correlated in OFF medication state with the activity contrast (sex vs. neutral) in PCC 
(r = 0.78, p < 0.01) and VS (r = 0.80, p < 0.01) (Figures 17A and 16B), and in ON 
medication state with the activity in ACC (r = 0.87, p < 0.001) and medial OFC (r = 
0.65, p < 0.05) (Figures 17C and 17D). No correlations were found in the PD-CSB 
group between ‘liking’ the sexual cues and brain activity during exposure to sexual 
vs. neutral visual cues in both ON and OFF medication states. No correlations were 
found between desire scores and activity contrasts in the PD control group in both ON 
and OFF medication states (p > 0.1 in all cases).  
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Figure 18. In PD-CSB individuals, sex cravings post-exposure to erotic visual cues 
correlate with increases in PCC activation during OFF medication (A), with increases in 
ACC (B), medial OFC (C), and acitvation during ON medication. 
 
 
 
5.5 Summary of findings 
This study explored the mechanisms underpinning dopaminergic medication linked 
compulsive sexual behaviours in patients with PD.  By employing behavioural 
assessments of sexual motivation and using an fMRI paradigm with common 
portrayals of sexuality (similar to those projected by mass media) as visual cues, this 
study confirmed that exposure to such cues was sufficient to increase the sexual desire 
of PD CSB patients by activating brain regions linked to sexual motivation. 
 
In agreement with functional imaging studies of visual sexual stimulation in healthy 
individuals (Arnow et al., 2002; Redoute et al., 2000; Walter et al., 2008), exposure to 
visual sexual cues activated parieto-temporal-occipital visual processing regions such 
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as the MOG and MTG in the PD CSB group and PD controls. In PD-CSB patients, 
exposure to sexual visual cues in both ON and OFF medication conditions showed 
increased activation in OFC, ACC, PCC, VS, aPFC, SPL, amygdala and the 
hypothalamus compared to controls. PD-CSB patients showed significantly increased 
sexual desire and liking of the sexual content following exposure to sexual cues. Their 
sexual desire was increased more when they were ON L-Dopa compared to OFF 
medication after exposure to sexual content. The crucial role of ACC, PCC, VS and 
OFC in sexual motivation was highlighted by the fact that increased activation in 
these regions correlated with increased sexual desire.  
 
Since the majority (8/12) of PD CSB patients had at least one additional ICD (e.g. 
pathological gambling, binge eating, etc.), I wanted to test whether the changes in 
behavioural assessments and brain activation following reward cue exposure were 
specific to sex or extended to other rewards. Self-reported desire and liking for 
gambling, drugs and food were not different within or between the groups of PD CSB 
and PD controls before and after the ON and OFF scans. Similarly, there were no 
differences between PD CSB and PD controls in neural response to other rewarding 
visual cues in the fMRI analysis, indicating that the imaging results were also specific 
to CSB. However, I also wanted to explore the specific brain activity related to sexual 
visual cues compared to other rewards. The findings revealed strong activation in both 
ON and OFF state scans in OFC, ACC, PCC, VS, aPFC, dorsolateral PFC, PHG and 
hypothalamus, confirming the specific importance of these regions in sexual 
motivation and desire, at least in the context of CSB. 
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The enhanced brain activity after exposure to sexual cues was not influenced by the 
administration of L-Dopa as suggested by the similar BOLD signal increases in ON 
and OFF medication scans. However, the absence of acute L-Dopa effect does not 
eliminate the effect of synergistic interaction of mesolimbic dopamine state and the 
presence of sexual cues in stimulating enhanced ‘wanting’ for sexual reward in the 
PD CSB group (Berridge, 2012; Oei, Rombouts, Soeter, van Gerven, & Both, 2012).  
 
In the PD-CSB group of patients, after acute L-Dopa challenge, the decreases 
observed when OFF their drugs and in the OFF and ON states in PD controls (reduced 
BOLD signal during exposure to sexual vs. neutral visual cues in ICG, PHG, cuneus, 
insula and claustrum) were eliminated (for a similar effect of dopaminergic drug 
challenge in cocaine addiction, see Volkow et al, 2010).  
 
.  
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Chapter 6 
Problematic Internet use in 
Parkinson’s disease patients 
 
6.1 Introduction 
In this chapter, I examine patients with PD and healthy controls for excessive Internet 
use, and adapt the 10-item Y-BOCS (Goodman, Price, Rasmussen, Mazure, 
Fleischmann, et al., 1989; Shapira et al., 2003) as a tool to explore problematic levels 
of Internet use in PD patients with and without ICDs and healthy controls, adapting 
the questions for Internet use (Appendix 8).  
 
6.2 Aims and hyptheses 
The aims of this study are: 
1. To explore non-essential Internet use in PD ICD patients, PD control patients and 
healthy volunteers to see the range of online activities these three groups engage in. 
2. Using the Y-BOCS, to subjectively explore possible Internet use in these three 
groups of patients. 
 
I hypothesised that the PD–ICD group will spend more time on the Internet, 
particularly accessing websites related to their ICDs (e.g. gambling, pornography) 
relative to both the PD control and healthy volunteer (HV) groups.  
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6.3 Methods 
6.3.1 Participants 
Twenty-nine patients were identified as having problematic Internet use based on 
their report of maladaptive behaviour that causes functional impairment according to 
proposed diagnostic criteria (Shapira, Goldsmith, Keck, Khosla, & McElroy, 2000; 
Shapira et al., 2003).  These patients also satisfied the diagnostic criteria for one of the 
four major ICDs  (CSB, PG, CB and BE) reported in PD using the following: (1) 
DSM-IV diagnostic criteria for pathological gambling 
(American_Psychiatric_Association, 2000); (2) DSM-IV proposed criteria for binge 
eating (American_Psychiatric_Association, 2000); (3) proposed criteria for 
compulsive sexual behaviour (Voon & Fox, 2007); and (4) compulsive buying (Voon 
& Fox, 2007).  Nineteen patients with PD free from any symptoms of ICDs or other 
neurological and psychological comorbidities were recruited as controls. All patients 
with PD satisfied the Queen Square Brain Bank for Neurological Disorders clinical 
criteria (Hughes et al., 1992). None of the participants in this study has been 
diagnosed with PIU prior to the use of PD medication, and none had a diagnosis of 
obsessive-compulsive disorder.  Twenty non-PD healthy volunteers matched for age 
and sex were recruited from individuals who responded to a local newspaper advert 
and acted as a comparison group. All participants endorsed using the Internet for 
‘non-essential’ purposes.  
 
6.3.2 Additional measures 
All participants underwent a semi-structured face-to-face interview with the myself  
as detailed in Chapter 2, section 2.1.  
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In addition, they were asked to complete the Yale-Brown Obsessive Compulsive 
Scale – a 10-item questionnaire which measures obsessions and compulsive elements 
separately (Goodman, Price, Rasmussen, Mazure, Fleischmann, et al., 1989), adapted 
for Internet use (Shapira et al., 2000). The Y-BOCS is a suitable tool for our target 
group as it is used widely in the general population among those with OCD and/or 
ICD with good validity and reliability (J. E. Grant, Mancebo, et al., 2006). The 
questionnaire has an equal number of questions on obsessions and compulsions, 
without giving bias to either component. It has also been successfully adapted for use 
in non-PD cases with PIU (Shapira et al., 2000) as well as for use in ICDs, showing 
good reliability and validity for pathological gambling (J. E. Grant et al., 2003) and 
compulsive shopping (Black et al., 2000).  Only non-essential Internet usage (non-
business or non-academic use) was evaluated, based on recommendations for 
assessing PIU (K. S. Young, 1998). Participants were advised that ‘Internet use’ 
denotes access to the Internet via an electronic medium, including laptop and desktop 
computers, tablet computers, smart phones and any other media through which 
Internet can be accessed. 
 
The scores for Internet-related compulsions and obsessions in the PD–ICD group 
were evaluated for internal consistency with a Cronbach’s Alpha coefficient 
(Cronbach, 1951). 
 
PD ICDs were also asked to document what types of websites they spend most time 
on whilst online.  
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6.3.3 Statistical analysis 
Statistical analysis was performed as detailed in Chapter 2, section 2.2.9.  Group 
comparisons for groups of PD–ICD, PD controls and non-PD controls were tested 
with one-way analysis of variance (ANOVA) with Bonferroni post hoc test or its non-
parametric equivalent: the Kruskal-Wallis test with Dunn’s post hoc test. The alpha 
level was set at p<0.05 and corrected in instances for which multiple comparisons 
were indicated. 
 
6.4 Results 
6.4.1. Participant demographics and clinical details 
The PD–ICD and PD control groups were matched for medication intake. Both PD 
groups had similar BDI (II) scores and BSS scores, but these were significantly higher 
when compared to healthy volunteers. See Table 15. 
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Table 15. Clinical and behavioural details of participants in study investigating Internet 
use in Parkinson's disease. !
 PD ICD PD controls Healthy 
volunteers 
p value 
Frequency 29 (4F: 25M) 19 (6F: 13M)   20 (3F: 17M) - 
Age (yrs) 63.25 (9.28) 62.32 (9.06) 60.25 (10.33) 0.5802a 
Disease 
duration (yrs) 
12.44 (8.01) 10.37 (6.26) - 0.3637b 
UPDRS (III) 
OFF 
medication 
38.44 (11.34) 34.40 (11.13) - 0.2825b 
Total LEDD 
(mg/day) 
673.20 
(309.82) 
768.83 (321.67) - 0.5576b 
L-Dopa 
(mg/day) 
324.31 
(202.94) 
231.70 (84.72) - 0.1800b 
LEU DA 
(mg/day) 
348.89 
(307.72) 
537.13 (329.28) - 0.3702b 
Percentage of 
patients on DA 
(%) 
82 90 - - 
BDI (II) 15.48 (8.80)** 14.32 (9.76)** 6.35 (8.88) <0.0001 
BIS/BAS 56.89 (8.06) 55.37 (7.47) 55.80 (7.48) 0.0786a 
BSS 6.96 (3.12)  7.211 (3.38) 10.35 (3.96) 0.0033 
Values represent mean (standard deviation); § Kruskal-Wallis statistic; ns = non-significant; ** 
significant on PD ICD vs. HV and PD control vs. HV; a one way analysis of variance with Bonferroni 
correction; b unpaired t test with Welch’s correction. 
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6.4.2 Distribution of ICDs and types of websites frequented 
Of the 29 PD patients with ICD, 15 had a single ICD, eight had two ICDs, four had 
three ICDs and two patients had four ICDs. There were 19 patients with CSB, 10 
patients with binge eating, 13 patients with PG and nine patients with CB. All patients 
with binge eating had a coexisting ICD. All patients with CSB and/or PG use the 
Internet for sexual-related activities and online gambling, respectively, whilst only 
four out of nine patients with CB admitted to carrying out shopping-related activities 
online – two (50%) of these patients reported the use of online auction websites. See 
Table 16. 
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6.4.3  Yale-Brown Obsessive Compulsive Score, adapated for Internet (Y-BOCS-
Internet)  
PD–ICD patients scored significantly higher in the total score on the Y-BOCS-
Internet questionnaire compared to their PD counterparts (p<0.0001) and to healthy 
volunteers (p<0.0001) [PD–ICD mean (±SD) : 13.69 (±8.49); PD controls: 5.42 
(±3.56 ); HV: 4.70 (±1.12 )] (Figure 18). This was the case for both the obsessive and 
compulsive features [obsessive component subscores: PD–ICD: 6.17 (±4.34); PD 
controls: 2.16 (±1.83); HV: 1.85 (±2.60); p<0.0001 for both group comparisons, 
compulsive subscores PD–ICD: 7.55 (±4.62); PD controls: 3.26 (±1.99); HV: 2.90 
(±2.57); p<0.0001 for both group comparisons] (Figure 19). They scored significantly 
higher on seven out of a total of 10 questions within both the compulsive and the 
obsessive elements (Table 17).  This is particularly true for the following: the larger 
amounts of time they spent on the Internet (Q6); their effort to resist (Q4) and their 
drive to use the Internet (Q10); thoughts about Internet use (Q1) and its interference 
with participants’ social, work or role functioning (Q2); the increased amounts of 
effort to resist thoughts of Internet use (Q9) and the feeling of a lack of control over 
thoughts of Internet use (Q5).  
 
The Cronbach’s Alpha coefficient for the total Y-BOCS-Internet scale for the PD–
ICD group is 0.879, showing good internal consistency. 
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Figure 19. Total score for Y-BOCS-INternet for PD ICD, PD control and healthy 
volunteers groups."
!
 
Figure 20. Mean obsessive and compulsive sub-scores for the Y-BOCS-Internet for PD 
ICD, PD control and healthy volunteers groups. 
!
 
6.4.4. Correlation of clinical data 
I found that the PD–ICD subjects that scored high in obsessive features on the Y-
BOCS also scored high in the compulsive features (Spearman’s rank correlation 
coefficient=0.756, p<0.0001).  I did not find any statistically significant correlation 
between the Y-BOCS and number of ICDs present, BDI scores nor the BSS-4 
questionnaire.   
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6.4 Summary of findings 
Using Y-BOCS adapted for Internet use, I observed that PD patients (without ICDs) 
had similar scores to HV, but those with PD and ICD scored significantly higher 
compared to the other two groups. In the breakdown of questionnaires, PD patients 
with ICDs scored significantly higher regarding their time occupied by thoughts about 
Internet use (Q1) and time actually spent on the Internet, their drive to use the Internet 
and the amount of effort exerted to resist thoughts of the Internet. By comparing the 
ICD subtypes within the PD–ICD group, I found that those who utilise the Internet to 
facilitate activities related to their ICD are mainly patients with CSB and PG, and 
approximately half of the patients for CB.  The results suggest that Parkinson’s 
patients with impulsive-compulsive disorders have increased tendencies towards 
excessive, maladaptive Internet use, particularly those displaying pathological 
gambling or compulsive sexual behaviours.  
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Chapter 7 
Conclusions and reviews of major 
findings 
 
 
 
A range of impulse control disorders and related addictive behaviours such as punding 
and problematic Internet use have been reported in Parkinson’s disease.   The central 
role of dopaminergic drug therapy in these disorders (Weintraub, Koester, et al., 
2010) suggests that they may be different manifestations of the same underlying 
causal mechanism, but what this mechanism is remains unclear.  In this thesis project, 
I conducted studies investigating the role of dopamine underlying pathophysiology of 
impulse control disorders and related behaviours in Parkinson’s disease patients using 
clinical assessments, PET and fMRI neuroimaging techniques. 
 
7.1 Dopamine neurotransmission of impulse control 
disorders in Parkinson’s disease  
 
In Chapter 3, using PET with 11C-raclopride, I investigated dopamine 
neurotransmission in PD patients with a range of ICDs on exposure to reward-related 
and neutral visual cues.  I observed a greater reduction in RAC BPND in the ventral, 
but not dorsal striatum, of PD subjects with ICDs compared to PD controls following 
exposure to non-specific reward-related vs. neutral visual stimuli.  The radioligand 
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11C-racloride binds irreversibly to D2/3 post-synaptic receptors, and is sensitive to 
competition from endogenously released dopamine in response to drugs or tasks that 
induce dopamine release.  In this study, the observed decreases in binding potential 
are, therefore, likely to reflect dopamine release in response to viewing of reward-
related cues.    
 
Both comorbid and single ICD groups showed greater dopamine release in the ventral 
striatum to heterogenous reward-related images compared to the control group, but 
dopamine release was comparable between those with comorbid and those with a 
single ICD, and was not related to levels of depression.  Previous studies on PD 
patients focusing on a single ICD, such as pathological gambling, have shown a 
greater reduction in RAC BPND in response to gambling cues (Joutsa, Johansson, et 
al., 2012; Steeves et al., 2009).  However, this is the first study to compare PD 
subjects with comorbid ICDs to subjects diagnosed with only one ICD.  This study 
adds a further layer of evidence in suggesting that the magnitude of ventral striatal 
dopamine release is not directly related to the presence of comorbidity, nor to levels 
of depression severity (J. E. Grant & Kim, 2003; Joutsa, Johansson, et al., 2012; 
Voon, Sohr, et al., 2011). 
 
According to the Incentive Sensitisation Theory of Robinson and Berridge, repeated 
use of psychostimulant drugs produces progressive neuroadaptations in ventral striatal 
reward circuitry rendering it hypersensitive to drugs and their associated cues, enable 
these stimuli to elicit intense drug seeking (Berridge & Robinson, 1998).   It is 
therefore feasible that dopaminergic medication in vulnerable PD individuals causes a 
similar augmentation of striatal dopamine neurotransmission. An earlier PET study 
!!
189!
with 11C-Raclopride on PD patients with dopamine dysregulation (addiction-like 
excessive use of dopamine replacement therapy) revealed that they release more 
dopamine in ventral striatum in response to levodopa challenge compared to controls 
(Evans et al., 2006). 
 
Notably, animal models of incentive sensitization show that repeated exposure to 
psychostimulants, such as amphetamine, can increases the salience not just of drugs 
and their associated cues, but also for other ‘natural’ rewards such as food and sexual 
stimuli (Engber, Susel, Juncos, & Chase, 1989; Nocjar & Panksepp, 2002; Robinson 
& Berridge, 2003). Likewise, amphetamine has been shown to increase motivation for 
gambling in a manner that is predicted by the severity of the subject’s gambling (Zack 
& Poulos, 2004), and in our earlier study of DDS, elevated levels of levodopa evoked 
ventral striatal dopamine release were correlated with enhanced motivation for money 
in a simple card sorting task (Evans et al., 2006).  Taken together the evidence suggest 
that mechanisms for induction of ICD by dopaminergic medications could potentially 
operate on multiple levels: by preferentially activating dopamine receptor subtypes, 
sensitizing receptors or by providing excessive dopaminergic stimulation to circuits 
regulating individual components of the addiction process, including ‘wanting’ 
motivation, but also potentially other mechanisms such as reward learning; habit 
formation and stress regulation (A. D. Lawrence et al., 2003).     
 
This study also explored the range of chosen activities pursued for each impulse 
control disorder, and is found to be similar to that reported in the non-PD ICD 
population. Subjects with compulsive sexual behaviour admitted to watching 
pornography and pestering their partner or friend for sex; those with binge eating tend 
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to eat sweet, calorie-rich foods; those with pathological gambling preferred slot 
machines, horse and sports betting and bingo; and subjects with compulsive buying 
had a narrow range of focus in their purchase products.  The precise motivational 
mechanisms underpinning the various behavioural symptoms manifested in ICDs are 
important topics for future investigation. 
 
Subjects with comorbid ICDs had higher levels of depression and marginally 
increased sensation seeking scores compared to those with a single ICD and control 
group, despite having similar disease duration and motor disability. These 
observations are similar to those in larger populations of PD patients (Joutsa, 
Martikainen, Vahlberg, Voon, & Kaasinen, 2012; Voon, Sohr, et al., 2011) as well as 
from the general psychiatric populations where comorbidity is associated with more 
severe psychopathology, and greater psychosocial functioning impairments(Krueger 
& Bezdjian, 2009; Verhulst & van der Ende, 1993). Black and Moyer found a high 
rate of comorbid ICDs in a cohort of pathological gamblers, with a concurrent 
diagnosis of compulsive buying (23%), compulsive sexual behaviour (17%), and 
intermittent explosive disorder (13%)(Black & Moyer, 1998).  They also had higher 
rates of lifetime mood (60-76%), anxiety (16-40%), and substance use (33-63%) 
disorders (Black & Moyer, 1998; Bondolfi, Osiek, & Ferrero, 2000; el-Guebaly, 
1995; Ibanez et al., 2000). Similarly, binge eaters who display gambling behaviour 
have reduced self-esteem compared to those with binge eating alone (Yip, White, 
Grilo, & Potenza, 2011).     
 
Individuals with comorbid ICDs did not, however, show greater elevations of ventral 
striatal dopamine release during exposure to a broad range of reward-related stimuli 
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(e.g. food, sex, gambling cues) relative to those with a single ICD, and the magnitude 
of ventral striatal dopamine release was unrelated to levels of sensation seeking or 
depression.  In animal models, there is large individual variation in the ‘breadth’ of 
reward ‘wanting’ resulting from incentive sensitization (Berridge, 2012).  Thus, 
amphetamine sensitization in rats can amplify the incentive value of drug-associated 
stimuli (but not food or sex) in some individuals, but enhance ‘wanting’ of both food 
and sex rewards (but not drugs) in others (Nocjar & Panksepp, 2002).  Thus, 
individuals with comorbid (vs. single) ICDs might have a broader focus of ‘wanting’ 
across several types of incentive (e.g. food, sex, money), which, as demonstrated in 
this study, is not reflected in greater elevations of evoked ventral striatal release to 
heterogenous reward cues per se.  In animal models, the ‘focus’ of incentive salience 
wanting onto particular reward cues has been shown to be regulated by opioid 
mechanisms in central amygdala and neostriatum (Berridge, 2012). 
 
It was notable that binge eating and compulsive shopping, unlike pathological 
gambling and compulsive sexual behaviour, never occurred in isolation.  Whilst the 
high levels of comorbidity between different ICDs in PD suggest that they result from 
a shared vulnerability, it is also possible that the pathophysiology of binge eating and 
compulsive shopping is somewhat different to pathological gambling and compulsive 
sexual behaviour.  For example, it is now clear that there are multiple forms of 
impulsivity and compulsivity, some of which may be mediated by dopaminergic 
function, and others which may be mediated by serotonergic functioning (Dalley & 
Roiser, 2012).  It was also notable that all single ICD cases were men, and sex 
differences in ventral striatal dopamine release have been previously reported where 
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men show greater ventral striatal dopamine release following amphetamine (Munro et 
al., 2006). 
 
Overall, this study identified a number of new clinical and neuroimaging findings 
between Parkinson’s patients with comorbid ICDs compared to those with a single 
ICD and control PD subjects who were matched for age, disease severity and 
dopaminergic medication. Translated clinically, patient with comorbid ICDs can pose 
more challenges for their physicians and carers, in particular in managing mood 
disorders and sensation seeking behaviours.  
 
 
7.2 Dopaminergic basis of punding behaviour in 
Parkinson’s disease  
In Chapter 4, I compared basal striatal dopamine D2 binding in PD patients with 
punding behaviour and PD control patients using PET with 11C-raclopride.   Although 
dorsal striatal dopaminergic pathways have previously been implicated in punding 
behaviors in non-PD OCD subjects (Denys, van der Wee, Janssen, De Geus, & 
Westenberg, 2004), this study is the first to specifically study punding in Parkinson’s 
disease using 11C-raclopride PET. I found lower RAC BPND values in the dorsal 
striatum (caudate and putamen) of punders compared to controls when subjects were 
scanned under resting condition. This indicates that there are higher endogenous 
dopamine levels in punders at rest compared to controls.  The neuroimaging results 
from this study draw parallels to those seen in the OCD populations.  Denys and 
colleagues found low D2 receptor binding in the caudate of patients with OCD 
compared to healthy controls (Denys et al., 2004), whilst another study demonstrated 
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impairment in both the serotonergic system in the frontal regions and dopaminergic 
system in the striatum. Further, it is interesting that low D2 receptor binding in the 
striatum is linked to increased social withdrawal in OCD, which is a typical feature of 
punding and other forms of stereotypy (Schneier et al., 2008). 
 
One of the reasons that punder had lower levels of caudate D2 binding at baseline 
compared to controls, as reflected by RAC BPND, may be due to a higher level of 
endogenous dopamine as result of chronic exposure to dopaminergic medication. 
Dopamine, whose function is enhanced by cocaine and amphetamine, is a monoamine 
neurotransmitter with a central role in reward seeking behaviors.  Striatal dopamine is 
thought to play a determinant role in psychomotor induced stereotypies.  This has 
been argued to occur through incentive salience where punding may represent a form 
of psychomotor sensitization phenomenon with chronic dopaminergic medication use 
(Berridge, 2012; Berridge, Robinson, & Aldridge, 2009), as well as a process of habit 
formation through cue-conditioned learning (Everitt & Robbins, 2005).  Several lines 
of evidence from animal studies support these views.  Repeated dosing of 
amphetamines in rats results in behavioral sensitization, manifested as increased 
locomotion and stereotypic behavior with each subsequent dose of amphetamine 
(Lundh & Tunving, 1981; Rhee, Albertson, & Douglas, 1988).  Thus, the punding 
behaviors seen in PD individuals resembles some of the complex streotypies seem in 
these animal studies treated with chronic or large doses of amphetamines (Schiorring, 
1981) and levodopa (Randrup & Munkvad, 1966), with the underlying neurobiology 
has been linked to the dorsal striatum and its dopaminergic irrigation. 
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An alternative explanation for the difference in caudate D2 receptor binding may be a 
decreased level of dopamine D2 receptors in punders compared to controls.  Indeed, 
both genetic studies of mice with D2 receptor knockout genes and chronic studies 
suggest that reduced D2 receptors could be a contributing factor (either as a result of 
postsynaptic D2 receptors or presynaptic D2 autoreceptors).  Rosengarten and 
colleagues found that genetically based reductions in D2 receptors were linked to 
enhanced stimulant induced stereotypies in different strains of rodents (Rosengarten, 
Schweitzer, & Friedhoff, 1986).  Further, another study found increased stereotyped 
grooming in D2 knockout mice by administration of a D1 agonist, and concluded that 
cocaine intake result in an exaggerated striatal increase in extracellular dopamine 
levels due to the loss of D2 receptor-mediated presynaptic autoreceptor functions, in 
turn causing D1 receptor overstimulation in D2 receptor knockout mice (Welter et al., 
2007).   These studies support other models of stereotypy that emphasize greater D1 
relative to D2 stimulation in the dorsal striatum in the pathogenesis of stimulant-
induced stereotypy, for example, that of the ‘complex superstereotypy’ in rodents 
being linked to excessive D2 stimulation in the dorsal striatum (Berridge & Aldridge, 
2000a, 2000b).  Given that levodopa acts on both D1 and D2 receptors, lower D2 
receptors could lead to a relative increased D1 stimulation by levodopa in the 
striatum, possibly causing an increase in punding behavior.  Notably, 
hypodopaminergic DAT knockout mice display this superstereotypy characterized by 
excessively strong and rigid manifestations of complex and fixed action patterns 
(Berridge, Aldridge, Houchard, & Zhuang, 2005).  Interestingly, a recent 
neuroimaging study has shown reduced DAT binding in the striatum of patients with 
PD and a range of impulse control disorders, where the authors postulate that greater 
dopaminergic striatal activity in PD patients with ICDs (in comparison to PD patients 
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without ICDs) may be related to reduced uptake and clearance of dopamine from the 
synaptic cleft (Voon et al., 2013).   Punding in association with dopaminergic 
medication intake in Parkinson’s patients may therefore represent the culmination of a 
continuous process of psychomotor stimulation (mediated by ventral striatal 
structures) and behavioral competition (mediated by dorsal striatal structures). These 
findings lend parallels to the results of this study showing lower baseline dopamine 
D2 receptor binding, indirectly observed by lower RAC BPND in the dorsal striatum of 
punders with Parkinson’s disease.  
 
The frequent co-existence between punding behavior, impulse control disorders and 
addiction raises the broader notion of ‘impulsivity’ and ‘compulsivity’ as originating 
from the same neurobiological entity (Robbins, Gillan, Smith, de Wit, & Ersche, 
2012).  For example, reduced basal striatal D2 receptor binding on 11C-raclopride has 
been seen in both cocaine and amphetamine abusers (Martinez et al., 2004; Volkow et 
al., 2001), where these addicted populations have high levels of punding behaviors.  
In a monkey model, Groman and colleagues found that D2 receptors in caudate and 
putamen were reduced in methamphetamine treated moneys, and such reductions 
correlated with perseverative behavior of previously rewarded actions (Groman et al., 
2012).   In Parkinson’s disease, patients with punding have been observed to share 
similar traits with individuals with ICDs, such as male gender, young age, a history of 
psychiatric problems and depression, suggesting that these two clinical phenomena 
may share common neurobiological footing (Evans et al., 2004; A. J. Lawrence et al., 
2007; Voon & Fox, 2007; Voon et al., 2007).  Their frequent co-occurrence may also 
explain the increased presence of ICD and/or DDS in the cohort of patients in this 
study.  Further, recent neuroimaging studies using 11C-raclopride PET in patients with 
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PD and ICD showed enhanced ventral striatal dopamine release in response to 
reward-related cues (O'Sullivan et al., 2011; Steeves et al., 2009).  Another study of 
PD patients with addiction to dopaminergic medication demonstrated enhanced 
striatal dopamine release in response to levodopa challenge (Evans et al., 2006).  Such 
similar pathophysiological findings in individuals with different phenotypes beg the 
question whether these behaviors should be grouped together.  
 
The subjects of this study did not have any discernable pattern to the dopamine 
receptor stimulation profile of the medications used by the punders compared with the 
nonpunders.  More punders reported dyskinesias (n=7) than controls (n=4) but the 
difference was not statistically significant.  Evans and colleagues (2006) found that 
dyskinesias were present in all but one patient in the DDS group and most complained 
of distressing motor fluctuations, suggesting that dyskinesias were associated with 
medication overuse nature of DDS rather than punding (Evans et al., 2006).  Similar 
to previous reports (A. J. Lawrence et al., 2007), punders scored higher in the Padua 
inventory but the scores remain within the non-OCD range and did not differ 
significantly from PD controls, suggesting that punding behavior does not have the 
characteristics or driven by the anxiety of obsessions.   
 
In this study, I reported a higher percentage (100%) of co-morbid ICDs in the punding 
group than previously reported (59%) (Fasano & Petrovic, 2010).  This difference 
may be due to sampling techniques (face-to-face interview by trained neurologist) 
compared to other studies (postal questionnaires).  Furthermore, patients with punding 
are reported to have enhanced appetitive behaviors (Evans et al., 2004).  Similar to 
other reports of punding, I did not find any difference in depression scores between 
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punders and controls (Fasano et al), suggesting that punding does not correlate with 
mood or anxiety disorders. 
 
In summary, I showed that Parkinson’s disease with punding have increased basal 
dopamine level in the dorsal striatum compared to controls.   Increased basal dorsal 
striatal dopamine level may therefore contribute to the habit formation in stereotypic 
behaviours of punding. 
 
 
7.3 Neural response of reward-related visual cues in 
compulsive sexual behaviour 
Compulsive sexual behaviour is a relatively common unwanted effect of 
dopaminergic medication, which can result in devastating social consequences.  In 
Chapter 5, I explored the mechanisms underpinning dopaminergic medication linked 
CSB in patients with PD using behavioural assessments of sexual motivation and an 
fMRI paradigm.  I found that passive viewing of sex-related cues caused an increase 
in the sexual desire of PD CSB patients by activating brain regions linked to sexual 
motivation. 
 In! agreement! with! functional! imaging! studies! of! visual! sexual! stimulation! in!healthy!individuals!(Arnow!et!al.,!2002;!Redoute!et!al.,!2000;!Walter!et!al.,!2008),!
exposure to visual sexual cues activated parieto-temporal-occipital visual processing 
regions such as the MOG and MTG in the PD CSB group and PD controls. In PD 
CSB patients, exposure to sexual visual cues in both ON and OFF medication 
conditions showed increased activation in OFC, ACC, PCC, VS, aPFC, SPL, 
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amygdala and the hypothalamus compared to Parkinson’s disease controls. 
Parkinson’s disease CSB patients showed significantly increased sexual desire and 
liking of the sexual content following exposure to sexual cues. Their sexual desire 
was accentuated when they were ON L-Dopa compared to OFF medication after 
exposure to sexual content.  The crucial role of ACC, PCC, VS and OFC in sexual 
motivation was underscored by the fact that increased activation in these regions 
correlated with increased sexual desire.  
 
Animal studies have shown that dopamine is involved in sexual motivation and urge 
triggered by sexual cues in areas including VS, the hypothalamus, medial PFC, 
amygdala and ACC and that a sensitising regime of dopaminergic drugs can lead to 
exaggerated sexual pursuit and predation (Afonso et al., 2009; Fiorino & Phillips, 
1999b; Nocjar & Panksepp, 2002; Pfaus et al., 2010; Stolzenberg & Numan, 2011).   
Concurrent experience with dopaminergic drugs and sexual activity is required for 
development of compulsive sexual behaviour (Frohmader, Lehman, Laviolette, & 
Coolen, 2011), mirroring the delayed onset of CSB in Parkinson’s disease following 
treatment with dopaminergic drugs (Giladi, Weitzman, Schreiber, Shabtai, & Peretz, 
2007). Moreover, recent work has shown that drugs of abuse can activate the same 
neuronal systems as a sexual reward, with overlap occurring in regions including the 
hypothalamus and ACC (Frohmader et al., 2010).  These findings, taken together with 
those from previous studies conducted with animals, support the incentive 
sensitisation theory as a framework for understanding the mechanisms of 
dopaminergic drug-induced CSB in Parkinson’s disease. The incentive sensitisation 
theory holds that dopamine motivates the pursuit of rewards by attributing incentive 
salience to reward-related stimuli (such as sexual visual cues), triggering pursuit 
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(‘wanting’) of sex and, in the case of CSB, sex cues may be attributed with 
pathological incentive salience (Berridge et al., 2009). Incentive sensitisation theory 
further holds that the ‘wanting’ of rewards, mediated by VS dopamine-related 
neurocircuitry, may grow over time independently of reward ‘liking’ as an individual 
develops compulsive reward seeking (Berridge et al., 2009), and it is notable here that 
dopamine increased cue-evoked sexual desire (‘wanting’) but not rated ‘liking’ of the 
sexual images in PD CSB patients. 
 
Since the majority (8/12) of PD CSB patients had at least one additional ICD (e.g. 
pathological gambling, binge eating, etc), I wanted to test whether the changes in 
behavioral assessments and brain activation following reward cue exposure were 
specific to sex or extended to other rewards. Self-reported desire and liking for 
gambling, drugs and food were not different within or between the groups of PD CSB 
and PD controls before and after the ON and OFF scans. Similarly, there were no 
differences between PD CSB and PD controls in neural response to other rewarding 
visual cues in the fMRI analysis indicating that our imaging results were also specific 
to CSB. However, I also wanted to explore the specific brain activity related to sexual 
visual cues compared to other rewards. The findings revealed strong activation in both 
ON and OFF state scans in OFC, ACC, PCC, VS, aPFC, dorsolateral PFC, PHG and 
hypothalamus, confirming the specific importance of these regions in sexual 
motivation and desire, at least in the context of CSB. 
 
This selective enhancement for sexual cues is notable. Work in animal models by 
Berridge and colleagues has shown that stimulating opioid circuitry in the amygdala 
and striatum can focus cue-triggered ‘wanting’ very narrowly in a winner-take-all 
fashion. Under such conditions, a single favourite reward cue becomes a highly potent 
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‘motivational magnet’ that pulls all attraction to itself at the expense of other reward 
cues, even in animals that were also attracted to those other rewards (DiFeliceantonio 
& Berridge, 2012; Mahler & Berridge, 2009, 2012). Similarly, the sexual reward cues 
were associated with enhanced amygdala activity relative to other reward cues in CSB 
individuals and may have been selectively targeted with enhanced incentive salience 
in a ‘winner-take-all manner’, even in those individuals with comorbid ICDs. 
 
The increased activation in VS could be related to increased dopamine release in VS 
(Schott et al., 2008), consistent with PET data (O'Sullivan et al., 2011) and previous 
studies showing increased DA release related to sexual cues in the VS of sensitized 
animals (Fiorino & Phillips, 1999b). Lesions in hypothalamus and amygdala are 
known to impair sexual motivation in male and female rodents and hypothalamic and 
amygdala activation tracks sexual arousal in fMRI studies (Hamann, Herman, Nolan, 
& Wallen, 2004). The hypothalamus has been shown to play a central role in sexual 
behavior and is believed to be involved in the autonomic component of sexual arousal 
(Allen, Drabman, & Schleser, 1989; Kupfermann, 1991).  
 
The ACC is another paralimbic area connected to forebrain regions and controlling a 
number of autonomic and neuroendocrine functions (Stoleru et al., 1999). Previous 
studies have connected the activation of ACC with the degree of penile tumescence 
(Redoute et al., 2000) and with the motivational component of sexual arousal and 
desire (Arnow et al., 2002; Karama et al., 2002; Redoute et al., 2000; Walter et al., 
2008). Parietal areas and the PCC have also been linked to cue specificity in reward 
desire (Garavan et al., 2000). The OFC has been linked to explicit ratings of 
anticipated pleasure and desire and it is believed to have a role in mediating subjective 
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reward experience (Kringelbach, 2005). Furthermore, activation of OFC and PFC has 
been suggested to be associated with a pleasant bodily sensation being internally 
represented during sexual arousal (Stoleru et al., 2003).  In this study, the rated sexual 
desire was correlated with activity in cortical regions (including ACC and OFC) in 
addition to VS, which may be consistent with the notion that incentive salience 
‘wanting’ is not directly experienced in conscious awareness, and that explicit, 
conscious ‘wanting’ requires additional cortical processing of VS outputs (Berridge & 
Robinson, 1998). 
 
Results of my study showed enhanced brain activity after exposure to sexual cues was 
not influenced by the administration of L-DOPA as suggested by the similar BOLD 
signal increases in ON and OFF medication scans. However, the absence of acute L-
DOPA effect does not eliminate the effect of synergistic interaction of mesolimbic 
dopamine state and the presence of sexual cues in stimulating enhanced ‘wanting’ for 
sexual reward in the PD CSB group (Berridge, 2012; Oei et al., 2012). The PD CSB 
patients, even in the OFF state, are not entirely drug free and are presumably 
sensitized, and in animal studies, although acute amphetamine and sensitization 
effects can be additive (Tindell, Berridge, Zhang, Pecina, & Aldridge, 2005), 
sensitization caused by previous amphetamine administration causes reward cues to 
trigger excessive pursuit of their associated reward, even when sensitized rats are 
tested in a drug-free state (Wyvell & Berridge, 2001).  
 
Interestingly, in the PD CSB group of patients, after acute L-DOPA challenge, the 
decreases observed when OFF their drugs and in the OFF and ON state in PD controls 
(reduced BOLD signal during exposure to sexual vs. neutral visual cues in ICG, PHG, 
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cuneus, insula and claustrum) were eliminated (for a similar effect of dopaminergic 
drug challenge in cocaine addiction, see (Volkow et al., 2010). These results suggest 
that dopamine drugs could eliminate the deactivation of brain regions, which may be 
related to plastic changes in an effort to inhibit CSB stimulation. Although it is 
difficult to translate excitation or inhibition of neuronal firing into BOLD signal 
increases or decreases in activated voxels, dopamine drugs could release this 
inhibition through the activity of inhibitory interneurons acting within local neuronal 
circuits in the cerebral cortex. The release of neuronal inhibition in ICG, PHG, 
cuneus, insula and claustrum when patients are ON their dopaminergic drugs could be 
associated with concurrent behavioral changes, as in this study, was an associated 
increase in sexual desire scores. This theory is supported by the complete cessation of 
CSB after withdrawal from dopamine receptor agonist medications (Mamikonyan et 
al., 2008; Munhoz, Fabiani, Becker, & Teive, 2009).  
 
Inhibition of deactivation of insula through DA drugs could lead to the expression of 
pathological sexual behavior as this paralimbic area forms connections to regions 
involved in autonomic regulation (Oppenheimer, 1992), relates highly processed 
sensory information with motivational states (Stoleru et al., 1999) and in combination 
with the secondary somatosensory cortex has been reported to be involved in the 
perceived urge to express overt sexual behavior (Mouras et al., 2003). The claustrum 
has also been shown to be involved in emotional and motivational responses in 
animals (Hamamura & Ichimaru, 1997) and humans (Reiman, Fusselman, Fox, & 
Raichle, 1989) and is thought to be associated with sexual motivation (Rees & Noyes, 
2007). Deactivation in parahippocampal regions has been reported following 
presentation of sexually explicit video clips, however the potential role of these 
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deactivations are not well understood (Redoute et al., 2000).  
 
The findings of this study are novel in that it is the first to examine the mechanisms 
underlying CSB in Parkinson’s disease.  The ability to trigger increased neural 
response as a result of passive viewing of visual cues has potential implications for 
similar exposure via mass media to influence pathological sexual behaviour in 
Parkinson’s disease patients.  
 
7.4 Pathological Internet use in Parkinson’s disease 
patients 
Using the Y-BOCS-Internet scale, I found that PD patients (without ICDs) had similar 
scores to HV, but those with PD and ICD scored significantly higher compared to the 
other two groups. The differences in scores are most notable on items regarding time 
occupied by thoughts about Internet use (Q1), time actually spent on the Internet, the 
patients’ drive to use the Internet and the amount of effort exerted in resisting 
thoughts on Internet. By comparing the ICD subtypes within the PD–ICD group, I 
found that those who utilise the Internet to facilitate activities related to their ICD are 
mainly patients with CSB and PG, and approximately half of the patients for CB.  
  
Studies in the general population on subjects with PIU/Internet addiction (variously 
defined) found that they are most likely to engage in a range of activities, such as File 
Transfer Protocol, Internet gambling, online gaming, web surfing, use of remote 
support communication software, online shopping and online community activities. 
Results of this study on PD patients with ICDs, particularly CSB and PG, are similar 
to the above subjects in the general population with PIU / Internet addiction, where 
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individuals use the Internet for browsing sites of a sexual nature, engage in cybersex 
as part of online communities, and access Internet gambling sites; those with CB uses 
online shopping websites.   
 
In non-PD populations, PIU frequently co-occurs with other psychiatric conditions, 
PIU may preferentially occur with conditions related to the content browsed on the 
Internet (e.g. gambling, pornography).  For example, in a Canadian population-based 
study of non-PD pathological gamblers comparing 8,456 offline gamblers and 111 
online gamblers, a disproportionate number of men, young people and students 
participate in online gambling, and gambling behaviours were more excessive on the 
Internet. Comparing with offline gamblers, online gamblers report more co-occurring 
alcohol and cannabis use (Kairouz, Paradis, & Nadeau, 2012). Research conducted on 
non-PD men with sexual compulsivity found that the Internet use of these subjects 
played a role in facilitating their compulsions for problematic sexual thoughts and 
behaviours (Grov et al., 2008).  These evidence dovetail with the results of this study. 
A number of other studies have also found that subjects with CSB use the Internet to 
seek sexual partners and for cybersex, particularly if they are geographically isolated 
(Schnarrs et al., 2010) –these results also draw parallels with PD patients whom are 
socially isolated due to limited mobility.  
 
Although not included as a psychiatric diagnosis in the DSM, PIU/Internet addiction 
has often been modelled after impulse control disorders.  Interestingly, Shapira et al 
found that 55 per cent of subjects in the general population with PIU had a lifetime 
diagnosis of an ICD (Shapira et al., 2000). In another study, participants with PIU 
were noted to have neuropsychological and personality traits similar to sufferers with 
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other types of ICDs, such as increased levels of trait impulsivity comparable to 
subjects with PG (H. W. Lee et al., 2012). Further, a study of a random sample of 940 
university students found that those with a diagnosis of CB, or intermittent explosive 
disorder or pyromania are more likely to have PIU compared to students without the 
diagnosis. Cao and colleagues showed a specific relationship between impulse control 
and Internet addiction in a sample of Chinese adolescents (Cao, Sun, Wan, Hao, & 
Tao, 2011). Results of these and other studies suggest that Impulse-compulsive 
disorders are closely linked to PIU behaviour and that PIU share the multi-faceted 
characteristics of ICDs.  This also appears to be the case in the context of ICDs in PD. 
 
The association of PIU with well-established ICDs such as gambling disorder together 
with the finding that PIU may preferentially occur with those ICDs related to the 
content browsed on the Internet (such as gambling-related) raises the question as to 
whether PIU exists as a distinct entity, as opposed to the Internet serving as an outlet 
for other ICDs.  However, studies examining Internet-use behaviour in people with 
pathological gambling or compulsive sexual behaviour support the notion that PIU is 
a distinct entity.  Studies that examine gambling or compulsive sexual behaviour 
found only a proportion of subjects manifest them via the Internet (Grov et al., 2008; 
Kairouz et al., 2012), and in others Internet use only partially plays a role in 
facilitating their maladaptive behaviours (Schnarrs et al., 2010), i.e. people with 
compulsive sexual behaviour seek sexual partners online but meet to perform their act 
in person.  Further, there is general consensus that PIU is associated with material and 
psychological consequences (Mitchell, 2000) and that further research need to 
investigate the dimensional spectrum of PIU in different groups (Pomerantz, 1990; 
Redoute et al., 2000).  On this front, my study has reported an increased use of the 
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Internet in individuals with ICDs in PD, and assessed the obsessive-compulsive nature 
of Internet use in and its relation to the clinical features in PD. 
 
Although a number of screening scales for maladaptive Internet and computer use 
have already been published, these were primarily developed in young (student) 
populations and are therefore not ideal for use in an older age group consistent with 
the PD population (Meerkerk, Van Den Eijnden, Vermulst, & Garretsen, 2009; 
Nichols & Nicki, 2004; K. S. Young, 1998).  I believe that the Y-BOCS-Internet scale 
may serve as a more suitable assessment tool for an older adult population, having 
been validated in the context of ICDs in several different patient groups with a wide 
age range.  Also each question provides a measure of severity, which gives greater 
depth for assessment, and in the future may be useful for diagnosis as well as 
monitoring of progress during treatment. Furthermore, our results have shown that it 
discriminates PD ICD individuals from the PD and HV control groups, has good 
internal consistency and a strong correlation between the obsessive and compulsive 
elements.  More generally, despite an increasing literature, there are currently no 
standard diagnostic criteria and scales for PIU / Internet addiction (with the exception 
of Internet gaming disorder) and a key goal for future research should be to define the 
maladaptive features of Internet use and obtain data on the reliability and validity of 
specific diagnostic criteria in order to examine its associated biological features. 
 
7. 5 Clinical implications of the results from this 
thesis 
This thesis presents several novel findings in helping to understand the 
pathophysiology behind ICDs in Parkinson’s patients.  Firstly, that PD patients with 
!!
207!
ICD preferentially release dopamine in response to a varied range of passive exposure 
of reward-related cues compared to PD controls.  The observations that similar 
amount of dopamine is release in response to these cues despite subjects having 
different ‘disease load’ suggest similar degree of ventral sensitisation by the 
dopaminergic medication.   Secondly, using fMRI and a block design paradigm of 
passive exposure to sexual versus non-sexual cues, I found that PD individuals with 
CSB are able to display a motivational impetus for seeking sexual reward through 
increased and decreased activations of cerebral cortex. The results from both PET and 
fMRI study suggest an incentive sensitisation process of the dopaminergic reward 
system and raise the possibility that individuals with behavioural addictions are likely 
to undergo almost constant activations of their aberrant reward circuitry from the sort 
of reward-related cues that are typically employed in advertising (such as pop-up 
Internet advertisements), thus potentially maintaining the behaviour and making it 
more difficult for abstinence to occur.  These findings potentially have important 
implications for decision-making policies relating to advertising, which has a 
powerful impact and relies strongly on reward-related imagery.  Thirdly, I observed 
that, similar to sufferers of obsessive-compulsive disorder, patients with PD who 
exhibits stereotypical behaviours such as punding often lack insight and have 
associated social withdrawal.  They were also found to have D2/D3 downregulation in 
the dorsal, but not ventral, striatum compared to controls.  This neuroimaging finding 
is comparable to non-PD individuals with OCD (Denys et al., 2004) and lends support 
to the role of dopamine in the dorsal striatum, rather than ventral striatum, in 
mediating stereotypies through chronic dopaminergic medication use (Berridge & 
Aldridge, 2000b), as well as a role for habit formation through cue-conditioned 
learning (Everitt & Robbins, 2005).   
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Lastly, I found that PD ICD patients have increased tendencies towards excessive, 
maladaptive Internet use, particularly those displaying pathological gambling or 
compulsive sexual behaviours.  This shows similarities with evidence from studies in 
the general population showing non-PD individuals with ICDs are more likely to have 
problematic Internet use, suggesting that PIU should be viewed as a distinct impulse 
control disorder by both physicians and patients.  
 
Overall, this thesis has constructed a model for experimenting with the dopaminergic 
basis implicated in ICDs and related addictive behaviours in Parkinson’s disease 
patients. The results would be clinically useful to inform management of PD patients 
with impulse control and addictive behaviours and to benefit and facilitate further 
scientific research. 
 
7.6 Strengths and limitations 
Several strengths in this thesis project are notable.  The patients in these studies had a 
range of ICDs, unlike many other studies that focused only on a single ICD subtype.  
As such my studies are a better representative of the ‘real’ population of ICD patients.  
It also allowed for examination of the complex issue of comorbidity.  The use of 
passive reward-related visual cues in the PET and fMRI studies, as opposed to a 
hypothetical paradigm that models a specific ICD behaviour, to investigate dopamine 
neurotransmission in PD ICD patients is a ‘better fit’ of the stimuli from the ‘real 
world’, where visual stimuli were representative of that seen in the mass media.  As 
such the results are directly relevant and can be translated into the clinical setting to 
inform management.  This thesis not only explored the neurobiology of ICDs but also 
!!
209!
examined related behaviour such as punding and pathological Internet use, providing 
new knowledge into related fields of behavioural stereotypies and addiction in the 
context of Parkinson’s disease. 
  
However, the data need to be interpreted in light of several limitations.  Although 
sufficient to test statistical differences, the studies in this thesis project are limited by 
a relatively small sample size.  This was due to difficulties in recruiting PD patients 
who have ICDs, and whom were also willing to undergo quite a lengthy research 
protocol that involves exposure to relative increased amount of radiation and 
antiparkinsonian drug withdrawal on several occassions.  Patients in these studies 
were recruited from large academic tertiary movement disorder centres, with a higher 
proportion of male subjects, and may not be representative of the general PD 
population.  In addition, as I was involved in every aspect of the study (study 
conception and protocol design, recruitment, conducting the study, analysis and 
writing up), it was not possible to be blinded to the study groups.  Although this may 
have introduced bias into the interpretation of the answers during the face-to-face 
interviews, the presence or absence of any punding or impulse control disorders was 
usually very clear and without ambiguity.  All the studies in this thesis project are 
cross sectional in nature and cannot determine the longitudinal effect of medication as 
a risk factor.   
 
7.7 Future directions 
Impulse control disorders are a group of heterogenous entities separated by their 
distinct behaviours, but studies have suggested that they may be sub-grouped by 
similar features.  For example, food and sex are natural rewards, whereas gambling 
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and shopping are secondary or learned rewards.  Further studies are therefore 
warranted to explore whether there could be any overlap between these in terms of 
behavioural characteristics or underlying reward mechanisms.  The precise 
motivational mechanisms underpinning the various behavioural symptoms manifested 
in ICDs are also important topics for future investigations.  A larger number of 
subjects needs to be examined for their Internet behaviour to determine the precise 
role of Internet in the context of ICDs, and whether this behaviour should be classed 
as a distinct entity in its own right.   
 
In a wider context, impulse control can be due to dopaminergic pathways in the 
striatum as well as underactivity of the prefrontal cortex in inhibiting impulsivity 
behaviours.  Studies in drug addiction have suggested that impulsivity may in part be 
due to hypoactivation of frontal brain regions subserving response inhibition in the 
healthy brain – this would also be an area of interest for further research of ICDs in 
PD subjects. 
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Appendix 1. UK Parkinson’s Disease Society Brain Bank 
clinical diagnostic criteria for probable Parkinson’s disease  !
Reproduced from (Hughes et al., 1992) 
 
Step 1. Diagnosis of parkinsonian syndrome  
Bradykinesia and at least one of the following:  
• muscular rigidity  
• rest tremor (4–6 Hz)  
• postural instability unrelated to primary visual, cerebellar, vestibular or 
proprioceptive dysfunction 
 
Step 2. Exclusion criteria for Parkinson's disease (PD) 
History of : 
• repeated strokes with stepwise progression  
• repeated head injury  
• antipsychotic or dopamine-depleting drugs  
• definite encephalitis and/or oculogyric crises on no drug treatment  
• more than one affected relative  
• sustained remission  
• negative response to large doses of levodopa (if malabsorption is excluded)  
• strictly unilateral features after 3 years  
• other neurological features: supranuclear gaze palsy, cerebellar signs, early 
severe autonomic involvement, Babinski sign, early severe dementia with 
!!
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disturbances of language, memory or praxis  
• exposure to known neurotoxin  
• presence of cerebral tumour or communicating hydrocephalus on 
neuroimaging 
 
Step 3. Supportive criteria for PD 
Three or more of the following are required for diagnosis of definite PD: 
• unilateral onset 
• excellent response to levodopa 
• rest tremor present 
• severe levodopa-induced chorea 
• progressive disorder 
• levodopa response for over 5 years 
• persistent asymmetry affecting the side of onset most 
clinical course of over 10 years 
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Appendix 2. DSM-IV diagnostic criteria for 
pathological gambling 
 
Reproduced from DSM-IV manual (American_Psychiatric_Association, 2000) 
 
A.  Persistent and recurrent maladaptive gambling behaviour!is!indicated!by!five!(or!more)!of!the!following:!
• is preoccupied with gambling (e.g. is preoccupied with reliving past gambling 
experiences, handicapping or planning the next venture, or thinking of ways to 
get money with which to gamble) 
• needs to gamble with increasing amounts of money in order to achieve the 
desired excitement 
• has repeated unsuccessful efforts to control, cut back, or stop gambling 
• is restless or irritable when attempting to cut down or stop gambling 
• gambles as a way of escaping from problems or of relieving a dysphoric mood 
(e.g. feelings of helplessness, guilt, anxiety, depression) 
• after losing money gambling, often returns another day to get even (‘chasing’ 
one’s losses) 
• lies to family members, therapist, or others to conceal the extent of 
involvement with gambling 
• has committed illegal acts such as forgery, fraud, theft, or embezzlement to 
finance gambling 
• has jeopardised or lost a significant relationship, job, or educational or career 
opportunity because of gambling 
• relies on others to provide money to relieve a desperate financial situation 
caused by gambling 
B. The gambling behaviour is not better accounted for by a manic episode. 
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Appendix 3.  Diagnostic criteria for compulsive sexual 
behaviour 
 
Assessment of compulsive sexual behaviour was based on proposed operational 
diagnostic criteria as previously published (Voon et al., 2006): 
A. The sexual thoughts or behaviours are excessive or atypical from baseline marked 
by one or more of the following: 
1. Maladaptive preoccupation with sexual thoughts 
2. Inappropriately or excessively requesting sex from spouse or partner 
3. Habitual promiscuity 
4. Compulsive masturbation 
5. Telephone sex lines or pornography 
6. Paraphilias 
B. The behaviour must have persisted for at least 1 month. 
C. The behaviour causes at least one or more of the following: 
1. Marked distress 
2. Unsuccessful attempts to control thoughts or behaviour, and results in marked 
anxiety or distress 
3. Time-consumption 
4. Significant interference with social or occupational functioning 
D. These behaviours do not occur exclusively during periods of hypomania or mania. 
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Appendix 4. Diagnostic criteria for compulsive 
buying !!
Assessment of compulsive buying behaviour was based on McElroy’s criteria 
(McElroy, Keck, Pope, Smith, & Strakowski, 1994). 
A. Maladaptive preoccupation with buying or shopping, whether impulses or 
behaviour, that: 
1. are experienced as irresistable, intrusive and/or senseless 
2. results in frequent buying of more than can be afforded and items that are not 
needed or buying/shopping for longer periods of time than intended 
B. Causes marked distress, is time-consuming, significantly intereferes with social or 
occupational functioning, and/or results in financial problems 
C. The behaviours do not occur exclusively during periods of hypomania or mania. 
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Appendix 5. Diagnostic criteria for binge eating 
Assessment of binge eating behaviour was based on the DSM IV-TR research 
diagnostic criteria for binge eating (American_Psychiatric_Association, 2000). 
A. Recurrent binge eating characterised by eating large amounts in a discrete period 
along with loss of control. 
B. Three or more of the following: 
1. Rapid eating 
2. Feeling uncomfortably full 
3. Eating large amounts when not hungry 
4. Feeling disgusted or guilty after overeating 
5. Eating alone because of embarrassment of amount 
C. Marked distress 
D. Occurs at least 2 days per week for at least 6 months 
E. Does not occur with compensatory behaviours or during anorexia or bulimia 
nervosa 
!!
241!
Appendix 6. Diagnostic criteria for dopamine 
dysregulation syndrome (DDS) 
Diagnosis of DDS (also known as hedonistic homeostatic dysregulation syndrome) 
was based on the criteria set out by Giovannoni and colleagues  
(Giovannoni et al., 2000). 
A. Parkinson’s disease with documented levodopa responsiveness 
B. Need for increasing doses of DRT in excess of those normally required to relieve 
Parkinsonian symptoms and signs 
C. Pattern of pathological use: expressed need for increased DRT in the presence of 
excessive and significant dyskinesias despite being ‘on’, drug hoarding or drug 
seeking behaviour, unwillingness to reduce DRT, absence of painful dystonias 
D. Impairment in social or occupational functioning: fights, violent behaviour, loss of 
friends, absence from work, loss of job, legal difficulties, arguments or difficulties 
with family 
E. Development of hypomanic, manic, or cyclothymic affective syndrome in relation 
to DRT 
F. Development of a withdrawal state characterised by dysphoria, depression, 
irritability, and anxiety on reducing the level of dopaminergic medication. 
G. Duration of disturbance of at least 6 months 
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Appendix 7. Diagnostic guidelines of punding in 
Parkinson’s disease  
Reproduced from (Evans et al., 2004; A. J. Lawrence et al., 2007). 
A. Each participant is asked whether they spend any prolonged period of time on any particular tasks 
or their hobby-related activities, such as: 
Cleaning and tidying 
Gardening 
DIY 
Collecting and collections 
Repairing and/or dismantling things 
Sorting 
Computer use 
B. If a particular activity is identified, then this is followed up with further questions related to their 
activity, such as: 
When did you become interested in it (years)? 
How do you feel when you engage with your hobby, or, why do you do it? 
Do you find your hobby soothing? Calm? Fascinating? 
Are you driven to it in response to obsession? Fear? Anxiety? 
Do you sometimes spend excessive amounts of time on your hobby? 
Do you ever do it if you can’t sleep at night? 
Have you ever missed a whole night’s sleep because of it? 
Are you easily distracted when you are engaged with your hobby? 
How do you feel when you are interrupted when you are engaged with your hobby (i.e. do you ever 
get angry or upset? Do you ‘go off’?)? 
Are you interested in your hobby only when ‘on’ or when you are ‘on’ and ‘off’? 
Do you make much of a mess when you are pursuing your pastimes or hobbies? 
Do you have difficulties in finishing projects? 
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Appendix 8. Yale-Brown Obsessive Compulsive Scale, 
adapted for Internet use 
 
INSTRUCTIONS: 
The following questionnaire asks about your use of the Internet in the last 12 months.  
‘Internet use’ in this questionnaire relates to non-essential Internet usage (non-business or 
non-academic use) and includes access to the Internet via any electronic medium, such as 
laptop and desktop computers, tablet computers, smart phones and any other media through 
which Internet can be accessed. 
 
Please circle the number corresponding to the statement that best describes how you feel. 
 
1. How much of your time is occupied by thoughts about using the Internet, whether it 
be for a specific task or generally browsing on the Internet?  
0- None 
1- Mild (less than 1 hour per day or occasional intrusion) 
2- Moderate (1 to 3 hours per day, or frequent intrusion) 
3- Severe (3 to 8 hours per day, or very frequent intrusion) 
4- Extreme (more than 8 hours per day, or near constant intrusion) 
 
2. How much do your thoughts about Internet use interfere with your social, work or 
role functioning? 
0- None  
1- Mild, slight interference with social or occupational activities but overall 
performance is not impaired 
2- Moderate, definite interference with social or occupational performance, but still 
manageable 
3- Severe, causes substantial impairment in social or occupational performance 
4- Extreme, incapacitating 
 
3. How much distress do your thoughts about Internet use cause you? 
0- None 
1- Mild, not too disturbing 
2- Moderate, disturbing but still manageable 
3- Severe, very disturbing 
4- Extreme, near constant and disabling distress 
 
4. How much effort do you make to resist thoughts about Internet use? How often do 
you try to disregard these thoughts as they enter your mind?   
0- Always make an effort to resist, or symptoms so minimal that active resistance is 
not needed 
1- Try to resist most of the time 
2- Make some effort to resist 
3- Yield to all thoughts without attempting to control them, but do so with some 
resistance 
4- Completely and willingly yield to all thoughts about the use of Internet 
 
5. How much control do you have over your thoughts about Internet use?  How 
successful are you in stopping or diverting these thoughts?  Can you dismiss them? 
0- Complete control 
1- Much control, usually able to divert thoughts with some effort and concentration 
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2- Moderate control, sometimes able to stop or divert thinking 
3- Little control, rarely successful in stopping or dismissing thinking, can only 
divert attention with difficulty 
4- No control, experience is completely involuntary, rarely able even momentarily 
to alter thoughts about Internet use 
 
6. How much time do you spend on the Internet? 
0- None 
1- Mild (less than an hour per day) 
2- Moderate (1 to 3 hours per day) 
3- Severe (3 to 8 hours per day) 
4- Extreme (more than 8 hours per day) 
 
7. How much does your Internet use interfere with your social, work or role 
functioning?  Is there anything you don’t do because of this? 
0- None 
1- Mild, slight interference with social or occupational activities but overall 
performance is not impaired 
2- Moderate, definite interference with social or occupational performance but still 
manageable 
3- Severe, causes substantial impairment in social or occupational performance 
4- Extreme, incapacitating 
 
8. How would you feel if you were prevented from using the Internet?  How anxious 
would you be? 
0- None 
1- Mild, only slightly anxious if prevented from activity 
2- Moderate, anxiety would mount but would remain manageable 
3- Severe, prominent, and very disturbing increase in anxiety 
4- Extreme, incapacitating anxiety 
 
9. How much of an effort do you make to resist using the Internet? 
0- Always make an effort to resist, or symptoms so minimal that active resistance is 
not needed 
1- Try to resist most of the time 
2- Make some effort to resist 
3- Yield to all thoughts without attempting to control them, but do so with some 
resistance 
4- Completely and utterly yield to all thoughts about using the Internet 
 
10. How strong is your drive to use the Internet?  How much control do you have over 
it? 
0- Complete control 
1- Much control, usually able to control 
2- Moderate control, strong pressure to use the Internet but can control it with 
difficulty 
3- Little control, strong pressure to use the Internet 
4- No control, experience is completely involuntary 
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Appendix 9. Unified Parkinson’s disease rating scale 
(UPDRS) – Part III 
  
Speech 
 
0 – normal 
1 – slight loss of expression, diction, volume 
2 – monotone, slurred but understandable, moderate impaired 
3 – marked impairment, difficult to understand 
4 – unintelligible 
 
 
Facial Expression 
 
0 – Normal 
1 – slight hypomymia, could be poker face 
2 – slight but definite abnormal diminution in expression 
3 – mod. hypomimia, lips parted some of time 
4 – masked or fixed face, lips parted 1/4 of inch or more with complete loss of expression 
 
 
Tremor at Rest 
 
Face  
0 – absent 
1 – slight and infrequent 
2 – mild and present most of time 
3 – moderate and present most of time 
4 – marked and present most of time 
 
Right Upper Extremity (RUE) 
0 – absent 
1 – slight and infrequent 
2 – mild and present most of time 
3 – moderate and present most of time 
4 – marked and present most of time 
 
Left Upper Extremity (LUE) 
0 – absent 
1 – slight and infrequent 
2 – mild and present most of time 
3 – moderate and present most of time 
4 – marked and present most of time 
 
Right Lower Extremity (RLE) 
0 – absent 
1 – slight and infrequent 
2 – mild and present most of time 
3 – moderate and present most of time 
4 – marked and present most of time 
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Left Lower Extremity (LLE) 
0 – absent 
1 – slight and infrequent 
2 – mild and present most of time 
3 – moderate and present most of time 
4 – marked and present most of time  
 
 
Action or Postural Tremor 
 
RUE 
0 – absent 
1 – slight, present with action 
2 – moderate, present with action 
3 – moderate present with action and posture holding 
4 – marked, interferes with feeding 
 
LUE 
0 – absent 
1 – slight, present with action 
2 – moderate, present with action 
3 – moderate present with action and posture holding 
4 – marked, interferes with feeding 
 
 
Rigidity 
 
Neck 
0 – absent 
1 – slight or only with activation 
2 – mild/moderate 
3 – marked, full range of motion 
4 – severe 
 
RUE 
0 – absent 
1 – slight or only with activation 
2 – mild/moderate 
3 – marked, full range of motion 
4 – severe 
 
 
LUE 
0 – absent 
1 – slight or only with activation 
2 – mild/moderate 
3 – marked, full range of motion 
4 – severe 
 
 
RLE 
0 – absent 
1 – slight or only with activation 
2 – mild/moderate 
3 – marked, full range of motion 
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4 – severe 
 
 
LLE 
0 – absent 
1 – slight or only with activation 
2 – mild/moderate 
3 – marked, full range of motion 
4 – severe 
 
 
Finger taps 
 
Right 
0 – normal 
1 – mild slowing, and/or reduction in amplitude 
2 – moderately impaired; definite and early fatiguing, may have occasional 
arrests 
3 – severely impaired; frequent hesitations and arrests 
4 – can barely perform 
 
Left 
0 – normal 
1 – mild slowing, and/or reduction in amplitude 
2 – moderately impaired; definite and early fatiguing, may have occasional 
arrests 
3 – severely impaired; frequent hesitations and arrests 
4 – can barely perform 
 
 
Hand Movements (open and close hands in rapid succession) 
 
Right 
0 – normal 
1 – mild slowing, and/or reduction in amplitude 
2 – moderately impaired; definite and early fatiguing, may have occasional 
arrests 
3 – severely impaired, frequent hesitations and arrests 
4 – can barely perform 
 
 
Left 
0 – normal 
1 – mild slowing, and/or reduction in amplitude 
2 – moderately impaired; definite and early fatiguing, may have occasional 
arrests 
3 – severely impaired; frequent hesitations and arrests 
4 – can barely perform 
 
 
Rapid Alternating Movements (pronate and supinate hands) 
 
Right 
0 – normal 
1 – mild slowing, and or reduction in amplitude 
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2 – moderately impaired; definite and early fatiguing, may have occasional 
arrests 
3 – severely impaired; frequent hesitations and arrests 
4 – can barely perform 
 
Left 
0 – normal 
1 – mild slowing, and/or reduction in amplitude 
2 – moderately impaired; definite and early fatiguing, may have occasional 
arrests 
3 – severely impaired; frequent hesitations and arrests 
4 – can barely perform 
 
 
Leg Agility (tap heel on ground, amplitude should be 3 inches) 
 
Right 
0 – normal 
1 – mild slowing, and/or reduction in amplitude 
2 – moderately impaired; definite and early fatiguing, may have occasional 
arrests 
3 – severely impaired; frequent hesitations and arrests 
4 – can barely perform 
 
Left 
0 – normal 
1 – mild slowing, and/or reduction in amplitude 
2 – moderately impaired; definite and early fatiguing, may have occasional 
arrests 
3 – severely impaired; frequent hesitations and arrests 
4 – can barely perform 
 
 
 
 
Arising From Chair (patient arises with arms folded across chest) 
 
0 – normal 
1 – slow, may need more than one attempt 
2 – pushes self up from arms or seat 
3 – tends to fall back, may need multiple tries but can arise without 
assistance 
4 – unable to arise without help 
 
 
Posture 
 
0 – normal erect 
1 – slightly stooped, could be normal for older person 
2 – definitely abnormal, moderately stooped, may lean to one side 
3 – severely stooped with kyphosis 
4 – marked flexion with extreme abnormality of posture 
 
 
Gait 
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0 – normal 
1 – walks slowly, may shuffle with short steps, no festination or propulsion 
2 – walks with difficulty, little or no assistance, some festination, short 
steps or propulsion 
3 – severe disturbance, frequent assistance 
4 – cannot walk 
 
 
Postural Stability (retropulsion test) 
 
0 – normal 
1 – recovers unaided 
2 – would fall if not caught 
3 – falls spontaneously 
4 – unable to stand 
 
 
Body Bradykinesia/ Hypokinesia 
 
0 – none 
1 – minimal slowness, could be normal, deliberate character 
2 – mild slowness and poverty of movement, definitely abnormal, or decreased amplitude 
of movement 
3 – moderate slowness, poverty, or small amplitude 
4 – marked slowness, poverty, or amplitude 
 
  
 
